[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 975
1. Dourmashkin JT, Chang GQ, Gayles EC, Hill JO, Fried SK, Julien C, Leibowitz SF: Different forms of obesity as a function of diet composition. Int J Obes (Lond); 2005 Nov;29(11):1368-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To characterize the phenotype of obesity on a high-carbohydrate diet (HCD) as compared to a high-fat diet (HFD) or moderate-fat diet (MFD).
  • (2) balanced MFD with 25% fat; or (3) HCD with 10% fat/65% carbohydrate.
  • Characteristics common to the obese rats on the HFD or MFD, but not seen on the HCD, were hyperphagia, elevated circulating levels of triglycerides (TG), nonesterified fatty acids (NEFA) and glucose, and a significant increase in beta-hydroxyacyl-CoA dehydrogenase (HADH) activity in muscle, reflecting its greater capacity to metabolize fat.
  • In contrast to these fat-associated changes, rats that became obese on an HCD maintained normal caloric intake and levels of TG, NEFA, and glucose.
  • Whereas obesity on an HFD is associated with hyperphagia and elevated lipids, fat metabolism in muscle, and fat-stimulated peptides such as GAL, obesity on an HCD with a similar increase in body fat shows none of these characteristics and instead exhibits a metabolic pattern in muscle that favors carbohydrate over fat oxidation.

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088331.001).
  • [ISSN] 0307-0565
  • [Journal-full-title] International journal of obesity (2005)
  • [ISO-abbreviation] Int J Obes (Lond)
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / MH43422
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Dietary Carbohydrates; 0 / Dietary Fats; 0 / Fatty Acids, Nonesterified; 0 / Insulin; 0 / Leptin; 0 / RNA, Messenger; 0 / Triglycerides; 88813-36-9 / Galanin; EC 1.1.1.- / 3-Hydroxyacyl CoA Dehydrogenases; EC 2.7.1.11 / Phosphofructokinase-1; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


2. Hayashi T, Matsui-Hirai H, Fukatsu A, Sumi D, Kano-Hayashi H, Rani P JA, Iguchi A: Selective iNOS inhibitor, ONO1714 successfully retards the development of high-cholesterol diet induced atherosclerosis by novel mechanism. Atherosclerosis; 2006 Aug;187(2):316-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Seven groups of male rabbits were fed a 0.5% high-cholesterol diet (HCD) for 8 weeks.
  • Gp1-HCD was fed HCD only; Gp2-O17 was fed HCD with ONO1714, an iNOS inhibitor; Gp3-AG was fed HCD with amino-guanidine (AG), an iNOS inhibitor; Gp4-AR was fed HCD with l-arginine; Gp5-AR-O17 was fed HCD with l-arginine with ONO1714; Gp6-LNA was fed HCD with l-NAME (a NOS inhibitor); and Gp7-LN-O17 was fed HCD with l-NAME plus ONO1714.
  • ONO1714 decreased atherosclerosis by about 70% (area occupied by lesions: 3.0+/-0.4% in Gp2-O17 versus 10.3+/-1.6% in Gp1-HCD) and also decreased atherosclerosis in Gp7-LN-O17.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325187.001).
  • [ISSN] 0021-9150
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 7-chloro-3-imino-5-methyl-2-azabicyclo(4.1.0)heptane; 0 / Amidines; 0 / Cholesterol, Dietary; 0 / Enzyme Inhibitors; 0 / Heterocyclic Compounds, 2-Ring; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 31C4KY9ESH / Nitric Oxide; 94ZLA3W45F / Arginine; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III; H2D2X058MU / Cyclic GMP; V55S2QJN2X / NG-Nitroarginine Methyl Ester
  •  go-up   go-down


3. Stroubini T, Perelas A, Liapi C, Perrea D, Dontas I, Tzavara Ch, Galanopoulou P: Serum adiponectin and resistin in rats under three isocaloric diets: The effect of sibutramine. Cytokine; 2009 May;46(2):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three groups of male Wistar rats (n=63) were fed with high fat diet (HFD), high carbohydrate diet (HCD) or high protein diet (HPD) for 13weeks.
  • S at 10mg/Kg decreased fat/lean ratio in the HCD and HPD and adiponectin in the HFD group.
  • Adiponectin was paradoxically elevated in the HFDS10 compared to the HCD or HPD S10 groups.
  • Resistin was lower in the HCD compared to the HPD and HFD groups.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIBUTRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251435.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Appetite Depressants; 0 / Cyclobutanes; 0 / Dietary Carbohydrates; 0 / Dietary Fats; 0 / Dietary Proteins; 0 / Resistin; WV5EC51866 / sibutramine
  •  go-up   go-down


Advertisement
4. Ronneburger A, Basarab J, Howland HC: Growth of the cornea from infancy to adolescence. Ophthalmic Physiol Opt; 2006 Jan;26(1):80-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An equation was derived from the optics of the Gullstrand model eye to calculate horizontal corneal diameter (HCD) from HVID.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390486.001).
  • [ISSN] 0275-5408
  • [Journal-full-title] Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
  • [ISO-abbreviation] Ophthalmic Physiol Opt
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY 02994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


5. Pravenec M, Kazdova L, Landa V, Zidek V, Mlejnek P, Simakova M, Jansa P, Forejt J, Kren V, Krenova D, Qi N, Wang JM, Chan D, Aitman TJ, Kurtz TW: Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat. Hypertension; 2008 Jan;51(1):148-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat.
  • Approximately 30% of patients with hypertension have hepatic steatosis, and it has recently been proposed that fatty liver be considered a feature of the metabolic syndrome.
  • Obesity, diet, and level of physical activity are likely factors modulating risk for hepatic steatosis, however genetic factors could also influence susceptibility or resistance to fatty liver in hypertensive or normotensive subjects.
  • In genetic studies in spontaneously hypertensive rats (SHRs) and Brown Norway (BN) rats, we discovered that a variant form of sterol regulatory element binding transcription factor 1 (Srebf1 gene, SREBP-1 protein) underlies a quantitative trait locus (QTL) influencing hepatic cholesterol levels in response to a high cholesterol diet.
  • Compared with the BN allele of Srebf1, the SHR allele of Srebf1 includes variants in the promoter and coding regions that are linked to hepatic deficiency of SREBP-1 mRNA and protein, reduced expression of the SREBP-1 target gene stearoyl-CoA desaturase 1, reduced promoter activity for SREBP-1c, and relative protection from dietary induced accumulation of liver cholesterol.
  • Genetic correction of reduced SREBP-1 activity by derivation of congenic and transgenic strains of SHR increased hepatic cholesterol levels, thereby confirming Srebf1 as a QTL influencing hepatic lipid metabolism in the rat.
  • The Srebf1 variant regulating hepatic cholesterol did not appear to affect blood pressure.
  • These findings (1) are consistent with the results of association studies indicating that common polymorphisms affecting SREBP-1 may influence cholesterol synthesis in humans and (2) indicate that variation in Srebf1 may influence risk for hepatic steatosis.
  • [MeSH-major] Fatty Liver / genetics. Hypertension / genetics. Mutation / genetics. Quantitative Trait Loci / genetics. Sterol Regulatory Element Binding Protein 1 / genetics
  • [MeSH-minor] Alleles. Animals. Animals, Genetically Modified. Blood Pressure / physiology. Cholesterol / metabolism. Female. Liver / metabolism. Male. Rats. Rats, Inbred BN. Rats, Inbred SHR. Risk Factors. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • SciCrunch. RGD: Data: Animal Model .
  • SciCrunch. RGD: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071061.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U120061454; United States / NHLBI NIH HHS / HL / HL63709; United States / NHLBI NIH HHS / HL / HL56028; United States / FIC NIH HHS / TW / TW01236; United States / NHLBI NIH HHS / HL / HL35018
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Srebf1 protein, rat; 0 / Sterol Regulatory Element Binding Protein 1; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


6. Martanová H, Krepelová A, Baxová A, Hansíková H, Cánský Z, Kvapil M, Gregor V, Magner M, Zeman J: X-linked dominant chondrodysplasia punctata (CDPX2): multisystemic impact of the defect in cholesterol biosynthesis. Prague Med Rep; 2007;108(3):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present clinical course of the disease and the results of metabolic, X-ray and molecular analyses in 19-months old girl with X-linked dominant chondrodysplasia punctata with intrauterine growth retardation, craniofacial dysmorphy, cataracts, cutaneous anomalies including ichthyosis, asymmetric rhizomesomelic shortness of the limbs, deformity of the spine, club foot, polydactyly, syndactyly, epiphyseal stippling and low cholesterol (2.29 mmol/l).
  • The diagnosis of X-linked dominant chondrodysplasia punctata (CDPX2) was confirmed by the molecular analysis.
  • Sequencing of the EBP gene encoding for 3beta-hydroxysteroid-delta8,delta7-isomerase revealed the presence of "de novo" heterozygous mutation c.327C>T (p.Arg110Stop).
  • High cholesterol diet normalized cholesterol level (3.28 mmol/l) but it had no influence on the unfavourable prognosis of the disease.
  • [MeSH-major] Cholesterol / biosynthesis. Chondrodysplasia Punctata / genetics. Genetic Diseases, X-Linked. Lipid Metabolism, Inborn Errors / genetics

  • Genetic Alliance. consumer health - Chondrodysplasia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Lipid Metabolism Disorders.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399064.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


7. Tapson VF, Hyers TM, Waldo AL, Ballard DJ, Becker RC, Caprini JA, Khetan R, Wittkowsky AK, Colgan KJ, Shillington AC, NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee: Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med; 2005 Jul 11;165(13):1458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Antithrombotic therapy is efficacious for the prevention of thromboembolic disease, but it necessitates careful risk-benefit assessment.
  • CONCLUSIONS: A significant percentage of hospitalized patients do not receive adequate antithrombotic therapy for the primary and secondary prevention of thromboembolic disease.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Intern Med. 2005 Jul 11;165(13):1455-6 [16009859.001]
  • [CommentIn] Arch Intern Med. 2006 Jan 9;166(1):126 [16401824.001]
  • (PMID = 16009860.001).
  • [ISSN] 0003-9926
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fibrinolytic Agents; 5Q7ZVV76EI / Warfarin; R16CO5Y76E / Aspirin
  •  go-up   go-down


8. Stein S, Lohmann C, Handschin C, Stenfeldt E, Borén J, Lüscher TF, Matter CM: ApoE-/- PGC-1α-/- mice display reduced IL-18 levels and do not develop enhanced atherosclerosis. PLoS One; 2010;5(10):e13539
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atherosclerosis is a chronic inflammatory disease that evolves from the interaction of activated endothelial cells, macrophages, lymphocytes and modified lipoproteins (LDLs).

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Nov;5(11):1313-6 [10546000.001]
  • [Cites] Eur Heart J. 2010 Sep;31(18):2301-9 [20418343.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):523-31 [10953027.001]
  • [Cites] J Biol Chem. 2000 Dec 29;275(52):40663-6 [11060282.001]
  • [Cites] Mol Cell. 2001 Jan;7(1):161-71 [11172721.001]
  • [Cites] Cell. 2001 Feb 23;104(4):503-16 [11239408.001]
  • [Cites] Nat Immunol. 2000 Oct;1(4):298-304 [11017100.001]
  • [Cites] Ann N Y Acad Sci. 2001;936:466-8 [11460504.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):131-8 [11557972.001]
  • [Cites] Circ Res. 2001 Sep 28;89(7):E41-5 [11577031.001]
  • [Cites] Circ Res. 2002 Feb 8;90(2):E34-8 [11834721.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2607-19 [11909955.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13918-25 [11854298.001]
  • [Cites] Eur Heart J. 2002 May;23(9):706-13 [11977996.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):78-90 [12588810.001]
  • [Cites] Biochem J. 2003 Apr 1;371(Pt 1):89-96 [12470296.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Nature. 2003 May 29;423(6939):550-5 [12754525.001]
  • [Cites] Cardiovasc Res. 2003 Jul 1;59(1):234-40 [12829194.001]
  • [Cites] J Exp Med. 2003 Oct 6;198(7):977-85 [14530373.001]
  • [Cites] J Leukoc Biol. 2004 Feb;75(2):267-74 [14634054.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3678-85 [15004171.001]
  • [Cites] J Immunol. 2004 May 15;172(10):6362-72 [15128827.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26807-10 [15128749.001]
  • [Cites] Physiol Genomics. 2004 Sep 16;19(1):131-42 [15238619.001]
  • [Cites] Cell. 2004 Oct 1;119(1):121-35 [15454086.001]
  • [Cites] Nucleic Acids Res. 1986 Nov 25;14(22):8879-92 [3024123.001]
  • [Cites] Science. 1987 Jul 24;237(4813):402-5 [3299705.001]
  • [Cites] Science. 1987 Jul 24;237(4813):405-8 [3299706.001]
  • [Cites] J Biol Chem. 1992 May 5;267(13):9210-3 [1374388.001]
  • [Cites] Cell. 1992 Oct 16;71(2):343-53 [1423598.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2246-57 [7738190.001]
  • [Cites] Cell. 1998 Mar 20;92(6):829-39 [9529258.001]
  • [Cites] Endocr Rev. 1999 Oct;20(5):649-88 [10529898.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):791-6 [15604417.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1685-95 [15843671.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):361-70 [16054085.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1879-83 [16102055.001]
  • [Cites] Eur Cytokine Netw. 2005 Sep;16(3):177-85 [16266856.001]
  • [Cites] Atherosclerosis. 2006 Oct;188(2):450-4 [16405895.001]
  • [Cites] Antioxid Redox Signal. 2007 Mar;9(3):301-7 [17184171.001]
  • [Cites] J Am Coll Cardiol. 2007 Aug 21;50(8):752-9 [17707180.001]
  • [Cites] BMC Cardiovasc Disord. 2007;7:33 [17971240.001]
  • [Cites] Gene Ther. 2008 Feb;15(3):224-32 [18033310.001]
  • [Cites] Circulation. 2008 Feb 12;117(6):798-805 [18212290.001]
  • [Cites] Annu Rev Biochem. 2008;77:289-312 [18518822.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1172-7 [18565194.001]
  • [Cites] Metabolism. 2009 Apr;58(4):519-24 [19303973.001]
  • [Cites] Eur J Endocrinol. 2009 Aug;161(2):339-44 [19497986.001]
  • [Cites] J Atheroscler Thromb. 2009 Oct;16(5):586-93 [19729872.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):290-7 [19965780.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1868-76 [10669761.001]
  • (PMID = 21042583.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Interleukin-18; 0 / Peroxisome Proliferator-Activated Receptors; 0 / Ppargc1a protein, mouse; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC2962638
  •  go-up   go-down


9. Holm S, Voshol PJ, Gustafsson JA, Nebb HI: LXRbeta deficient mice have reduced hepatic insulin clearance during hyperinsulinemic euglucemic clamp. Biochem Biophys Res Commun; 2010 Feb 12;392(3):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LXRbeta deficient mice have reduced hepatic insulin clearance during hyperinsulinemic euglucemic clamp.
  • The present study addresses the insulin sensitivity in mice deficient in LXRbeta (LXRbeta(-/-)) as well as in wild type (wt) mice assessed by hyperinsulinemic euglycemic clamp.
  • Wt and LXRbeta(-/-) mice were fed either a normal chow diet or a high fat and high cholesterol diet (HFCD), and insulin sensitivity was assessed by hyperinsulinemic euglycemic clamps.
  • We show that LXRbeta(-/-) mice have reduced insulin clearance during hyperinsulinemic clamps upon feeding both HFCD and a regular chow diet.
  • Moreover we also observed reduced hepatic inflammation in LXRbeta(-/-) mice compared to wt mice upon feeding an HFCD, despite equal levels of hepatic steatosis.
  • In summary, our results indicate that LXRbeta(-/-) mice have reduced insulin clearance during hyperinsulinemic euglycemic clamps and also reduced hepatic inflammation upon feeding an HFCD for 26weeks.
  • [MeSH-major] Hepatitis / genetics. Insulin / metabolism. Insulin Resistance / genetics. Liver / metabolism. Orphan Nuclear Receptors / physiology
  • [MeSH-minor] Animals. Cholesterol, Dietary / administration & dosage. Cholesterol, Dietary / adverse effects. Diet / adverse effects. Dietary Fats / administration & dosage. Dietary Fats / adverse effects. Fatty Liver / genetics. Glucose Clamp Technique. Male. Mice. Mice, Knockout. Triglycerides / metabolism

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079709.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, Dietary; 0 / Dietary Fats; 0 / Insulin; 0 / Orphan Nuclear Receptors; 0 / Triglycerides; 0 / liver X receptor
  •  go-up   go-down


10. Ohshima S, Fujimoto S, Petrov A, Nakagami H, Haider N, Zhou J, Tahara N, Osako MK, Fujimoto A, Zhu J, Murohara T, Edwards DS, Narula N, Wong ND, Chandrashekhar Y, Morishita R, Narula J: Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging. J Am Coll Cardiol; 2010 Mar 23;55(12):1240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Atherosclerotic lesions were produced in 38 rabbits with a high cholesterol diet for 4 months; 5 groups of rabbits, in the fourth month, received fluvastatin (FS) (n = 6), low-dose MC (n = 7), high-dose MC (n = 7), a combination of low-dose MC and FS (n = 6), or no intervention (n = 12); 8 unmanipulated rabbits were used as disease controls.
  • A cell culture study evaluated the effect of MC on MMP production by activated human monocytes.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20298932.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL 078681
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Fatty Acids, Monounsaturated; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Indoles; 4L066368AS / fluvastatin; EC 3.4.- / Metalloproteases; FYY3R43WGO / Minocycline
  •  go-up   go-down


11. Takahashi K, Kunishiro K, Kasai M, Miike T, Kurahashi K, Shirahase H: Relationships between lipophilicity and biological activities in a series of indoline-based anti-oxidative acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors. Arzneimittelforschung; 2008;58(12):666-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipophilicity (logP) increased and water solubility decreased with dependence on the number of carbons in the 1-alkyl chain.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202739.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Antioxidants; 0 / Enzyme Inhibitors; 0 / Indicators and Reagents; 0 / Indoles; 0 / Lipids; 059QF0KO0R / Water; EC 2.3.1.26 / Sterol O-Acyltransferase
  •  go-up   go-down


12. Yoshida Y, Yokoi W, Ohishi K, Ito M, Naito E, Sawada H: Effects of the cell wall of Kluyveromyces marxianus YIT 8292 on the plasma cholesterol and fecal sterol excretion in rats fed on a high-cholesterol diet. Biosci Biotechnol Biochem; 2005 Apr;69(4):714-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Feeding KM-CW and KM-W increased the fecal sterol excretion and concentration of short-chain fatty acids (SCFA) in the cecum.

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849409.001).
  • [ISSN] 0916-8451
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cell Extracts; 0 / Cholesterol, Dietary; 0 / Fatty Acids; 0 / Polysaccharides; 0 / Sterols; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


13. He XH, Wu GF, Zhang Y, Chen XL, Zhang ZS, Zhan CY, Liu J, He JG, Xiong Y, Fang DQ, Liang LG, Qian YT, Lin GF, Dai G, Feng MZ, Wang KJ, Zhu ZY, Ma H: [Effect of chronic enhanced external counterpulastion on gene expression profiles of arterial endothelial cells of pigs fed with high-cholesterol diet]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul;28(7):1195-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of chronic enhanced external counterpulastion on gene expression profiles of arterial endothelial cells of pigs fed with high-cholesterol diet].
  • OBJECTIVE: To investigate the effect of chronic enhanced external counterpulastion (EECP) on gene expression profiles of arterial endothelial cells (ECs) of pigs fed with high-cholesterol diet.
  • METHODS: Eight male pigs were fed with high-cholesterol diet for 12 weeks to induce arteriosclerosis and subjected to EECP for accumulative 36 h (2 h every other day for 18 sessions).
  • Another 8 pigs on cholesterol-enriched diet and 6 normally fed pigs served as the arteriosclerosis model group and normal control group, respectively, and the high-cholesterol diet was maintained until the end of EECP treatment.
  • The coronary artery was then isolated for transmission electro microscopy, and the abdominal aorta was observed using Sudan III staining.
  • The gene expression profiles in ECs from the thoracic aorta using cDNA microarrays.
  • RESULTS: Macrophages and foam cells were detected beneath the ECs in the coronary artery of pigs in the model group, but not in the other two groups.
  • The ratios of Sudan III-positive area in the celiac aorta were significantly lower in normal control and EECP groups than in the model control group (P<0.05).
  • Compared with the normal control group, the gene expressions of integrins-beta1 and CTGF were up-regulated in the model group.
  • Compared with the model group, the expressions of integrins-beta1, CTGF and VCAM-1 were down-regulated and eNOS up-regulated in EECP group.
  • CONCLUSION: Chronic EECP may reduce endothelial injury, down-regulate the gene expression level of integrin-beta1, CTGF and VCAM-1, lower cholesterol uptake and attenuate arterial endothelial inflammation to protect the pigs fed with high-cholesterol diet from arteriosclerosis.
  • [MeSH-major] Arteriosclerosis / genetics. Counterpulsation / methods. Endothelial Cells / metabolism. Gene Expression Profiling
  • [MeSH-minor] Animals. Aorta, Abdominal / metabolism. Aorta, Abdominal / pathology. Coronary Vessels / metabolism. Coronary Vessels / pathology. Diet, Atherogenic. Male. Oligonucleotide Array Sequence Analysis / methods. Swine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676261.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Tang FT, Chen SR, Wu XQ, Wang TQ, Chen JW, Li J, Bao LP, Huang HQ, Liu PQ: Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress. Calcif Tissue Int; 2006 Nov;79(5):326-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypercholesterolemia plays an important role in the initiation and progression of atherosclerosis and has a positive correlation with cardiovascular disease.
  • Models of vascular calcification were established by administering vitamin D2 (VD) to rats alone or combined with a high-cholesterol diet (HCD) and by treating rat aorta smooth muscle cells (RASMCs) with beta-glycerophosphate (GP) alone or combined with oxidized low-density lipoprotein (oxLDL) in vitro.
  • In rats, the combination of VD with HCD significantly enhanced vessel calcium deposition and the activity and mRNA expression of vessel alkaline phosphatase (ALP) compared to treatment with VD alone.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17120185.001).
  • [ISSN] 0171-967X
  • [Journal-full-title] Calcified tissue international
  • [ISO-abbreviation] Calcif. Tissue Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipoproteins, LDL; 0 / oxidized low density lipoprotein; 1406-16-2 / Vitamin D
  •  go-up   go-down


15. Brinkworth GD, Noakes M, Clifton PM, Bird AR: Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. Br J Nutr; 2009 May;101(10):1493-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Obesity.
  • Hazardous Substances Data Bank. p-CRESOL .
  • Hazardous Substances Data Bank. SODIUM P-METHYLPHENOLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224658.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cresols; 0 / Dietary Carbohydrates; 0 / Dietary Fats; 0 / Fatty Acids, Volatile; 0 / Phenols; 1MXY2UM8NV / 4-cresol
  •  go-up   go-down


16. Ballard J, Turenne CY, Wolfe JN, Reller LB, Kabani A: Molecular characterization of nontuberculous mycobacteria isolated from human cases of disseminated disease in the USA, Thailand, Malawi, and Tanzania. J Gen Appl Microbiol; 2007 Apr;53(2):153-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of nontuberculous mycobacteria isolated from human cases of disseminated disease in the USA, Thailand, Malawi, and Tanzania.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575455.001).
  • [ISSN] 0022-1260
  • [Journal-full-title] The Journal of general and applied microbiology
  • [ISO-abbreviation] J. Gen. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Ribosomal Spacer; 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


17. Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, Denson LA: Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis; 2008 Apr;14(4):446-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease.
  • BACKGROUND: While activation of the IL-6-dependent transcription factor signal transducer and activator of transcription 3 (STAT3) has been implicated in the pathogenesis of inflammatory bowel disease (IBD), a direct effect on mucosal gene expression and inflammation has not been shown.
  • METHODS: Patients with pediatric-onset IBD were enrolled at diagnosis and during therapy.
  • RESULTS: Circulating IL-6 was upregulated in active IBD patients at diagnosis and during therapy.
  • CONCLUSIONS: A proinflammatory IL6:STAT3 biologic network is upregulated in active pediatric IBD patients at diagnosis and during therapy.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 May;6(5):583-8 [10802717.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):423-32 [17681163.001]
  • [Cites] Clin Exp Immunol. 2003 Oct;134(1):127-37 [12974765.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):451-9 [14762782.001]
  • [Cites] Cytokine. 2004 Apr 21;26(2):45-56 [15050604.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):989-96; discussion 947 [15057738.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1991 May;12(4):439-47 [1678008.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1996 Aug;23(2):164-71 [8856584.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):262-7 [9453485.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4652-60 [9794394.001]
  • [Cites] Scand J Gastroenterol Suppl. 1998;228:47-50 [9867112.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):64-72 [15654782.001]
  • [Cites] Inflamm Bowel Dis. 2005 Feb;11(2):91-8 [15677901.001]
  • [Cites] Immunology. 2005 Mar;114(3):301-12 [15720432.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1386-93 [15746037.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):185-203 [16012947.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2357-65 [16081806.001]
  • [Cites] PLoS Med. 2005 Aug;2(8):e199 [16107186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13260-5 [16150725.001]
  • [Cites] Gut. 2006 Jun;55(6):749-53 [16698746.001]
  • [Cites] Circulation. 2006 May 16;113(19):2301-12 [16682613.001]
  • [Cites] Gut. 2006 Sep;55(9):1263-9 [16682432.001]
  • [Cites] Inflamm Bowel Dis. 2007 Jan;13(1):42-50 [17206638.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16777-81 [12615922.001]
  • (PMID = 18069684.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068164-02; United States / NIDDK NIH HHS / DK / DK068164-03; United States / NIDDK NIH HHS / DK / R01 DK068164; United States / NIDDK NIH HHS / DK / DK068164-02; United States / NCRR NIH HHS / RR / M01 RR 08084; United States / NIDDK NIH HHS / DK / DK02700; United States / NIDDK NIH HHS / DK / DK068164-01A2; United States / NCRR NIH HHS / RR / M01 RR008084; United States / NIDDK NIH HHS / DK / R01 DK068164-01A2; United States / NIDDK NIH HHS / DK / DK63956; United States / NIDDK NIH HHS / DK / R01 DK002700; United States / NIDDK NIH HHS / DK / R24 DK64403; United States / NIDDK NIH HHS / DK / K08 DK002700; United States / NIDDK NIH HHS / DK / R24 DK064403; United States / NIDDK NIH HHS / DK / R01 DK068164-03; United States / NIDDK NIH HHS / DK / R03 DK063956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL10; 0 / Chemokine CXCL11; 0 / Interleukin-6; 0 / Receptors, Interleukin-6; 0 / STAT3 Transcription Factor
  • [Other-IDs] NLM/ NIHMS76393; NLM/ PMC2581837
  •  go-up   go-down


18. Bieswal F, Ahn MT, Reusens B, Holvoet P, Raes M, Rees WD, Remacle C: The importance of catch-up growth after early malnutrition for the programming of obesity in male rat. Obesity (Silver Spring); 2006 Aug;14(8):1330-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At weaning, rats were transferred to chow or to a hypercaloric diet (HCD) known to induce obesity.
  • Body weight, food intake, blood parameters, glucose tolerance, adipocyte cellularity, and adipose factors contributing to cardiovascular disease development were measured.
  • Feeding an HCD postnatally amplified the effect of calorie restriction, and offspring that underwent catch-up growth became more obese than Cs.
  • The HCD was associated with hyperphagia, hyperglycemia, hyperinsulinemia, glucose intolerance, insulin resistance, and adipocyte hypertrophy.
  • The expression of genes encoding factors implicated in cardiovascular disease was also modulated differently by early malnutrition and adult obesity.
  • [MeSH-minor] Adipocytes / cytology. Adipocytes / metabolism. Adiponectin / genetics. Adipose Tissue / cytology. Adipose Tissue / metabolism. Angiotensinogen / genetics. Animals. Animals, Newborn. Diet. Eating / physiology. Female. Leptin / blood. Litter Size. Male. Plasminogen Activator Inhibitor 1 / genetics. Pregnancy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988075.001).
  • [ISSN] 1930-7381
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Leptin; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / Triglycerides; 11002-13-4 / Angiotensinogen
  •  go-up   go-down


19. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM: Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst; 2005 May 18;97(10):715-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / epidemiology. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Confidence Intervals. Coronary Disease / epidemiology. Coronary Disease / etiology. Cost-Benefit Analysis. Decision Making. Evaluation Studies as Topic. Female. Genetic Predisposition to Disease. Humans. Mass Screening. Mutation. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / genetics. Predictive Value of Tests. Reproducibility of Results. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900041.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Terao J, Kawai Y, Murota K: Vegetable flavonoids and cardiovascular disease. Asia Pac J Clin Nutr; 2008;17 Suppl 1:291-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vegetable flavonoids and cardiovascular disease.
  • Studies have suggested that dietary flavonoids are helpful in the prevention of atherosclerosis and cardiovascular disease.
  • We found that these metabolites circulating in the human blood stream were mostly localized in plasma albumin fraction, but not LDL fraction.
  • Furthermore, quercetin metabolites were detected in human atherosclerotic aorta exclusively.
  • [MeSH-major] Cardiovascular Diseases / prevention & control. Flavonoids / analysis. Flavonoids / pharmacology. Vegetables / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. QUERCETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18296359.001).
  • [ISSN] 0964-7058
  • [Journal-full-title] Asia Pacific journal of clinical nutrition
  • [ISO-abbreviation] Asia Pac J Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Flavonoids; 0 / Serum Albumin; 9IKM0I5T1E / Quercetin
  • [Number-of-references] 12
  •  go-up   go-down


21. Thingholm TE, Palmisano G, Kjeldsen F, Larsen MR: Undesirable charge-enhancement of isobaric tagged phosphopeptides leads to reduced identification efficiency. J Proteome Res; 2010 Aug 6;9(8):4045-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This reduces phosphopeptide identification efficiency with multistage activation and HCD MS/MS by more than 50% and may contribute to the discrepancy observed between identifications observed for large cell- or tissue-based data sets from labeled and nonlabeled peptide mixtures.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. Ammonia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515019.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphopeptides; 15FIX9V2JP / titanium dioxide; 7664-41-7 / Ammonia; D1JT611TNE / Titanium
  •  go-up   go-down


22. Amrani S, Harnafi H, Gadi D, Mekhfi H, Legssyer A, Aziz M, Martin-Nizard F, Bosca L: Vasorelaxant and anti-platelet aggregation effects of aqueous Ocimum basilicum extract. J Ethnopharmacol; 2009 Aug 17;125(1):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The vasorelaxant effect was undertaken in thoracic aorta from three experimental groups of rats: one of them (NCG) fed with standard diet, the second (HCG) with hypercholesterolemic diet (HCD) and the third (BTG) with hypercholesterolemic diet together with an intragastric administration of Ocimum basilicum extract at a dose of 0.5 g/kg body weight for a period of 10 weeks.
  • RESULTS: The results show that the HCD statistically decreases vascular relaxation in HCG compared to NCG (p<0.001) and increases the vascular responses to phenylephrine (p<0.02).
  • The plant extract also tends to suppress the elevated contractions induced by HCD (p=0.05).

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505553.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Platelet Aggregation Inhibitors; 0 / Vasodilator Agents; 059QF0KO0R / Water
  •  go-up   go-down


23. Hayashi T, Esaki T, Sumi D, Mukherjee T, Iguchi A, Chaudhuri G: Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism. Proc Natl Acad Sci U S A; 2006 Jul 5;103(27):10485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the effects of a 0.5% cholesterol-enriched diet (HCD) on nitric-oxide synthase (NOS) and arginase expression and the modulating role of 17beta-estradiol (E(2)) on this phenomenon.
  • Group I received normal chow; group II, HCD; and group III, HCD plus E(2) pellets.
  • There was significant expression of inducible NOS and increased staining of nitrotyrosine-positive areas.
  • In group III animals, E(2) supplementation led to a decrease in atheromatous lesions and BrdU-positive cells and reduced expression of both inducible NOS and arginase I and II accompanied by a decrease in nitrotyrosine staining.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Jun;17(7):358-63 [11593962.001]
  • [Cites] N Engl J Med. 1986 Oct 2;315(14):841-6 [3748103.001]
  • [Cites] Lancet. 1990 Oct 13;336(8720):897-900 [1699098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8612-6 [2236071.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):1168-72 [1522225.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11259-63 [1454805.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):2002-12 [7504210.001]
  • [Cites] Arterioscler Thromb. 1994 May;14(5):746-52 [8172852.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):5212-6 [7515189.001]
  • [Cites] Circ Res. 1995 Jun;76(6):980-6 [7758169.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:165-94 [7541188.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):60-8 [7542286.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1613-21 [10845880.001]
  • [Cites] Circ Res. 2000 Jul 7;87(1):19-25 [10884367.001]
  • [Cites] Cardiovasc Drugs Ther. 2000 Jun;14(3):309-16 [10935153.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 May;121(5):971-80 [11326242.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Sep 25;214(3):847-55 [7575554.001]
  • [Cites] Prog Cardiovasc Dis. 1995 Nov-Dec;38(3):189-98 [7494881.001]
  • [Cites] Adv Pharmacol. 1995;34:187-206 [8562434.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):44-50 [8548425.001]
  • [Cites] J Cardiovasc Pharmacol. 1995 Nov;26(5):792-802 [8637195.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1996 May;114(1):107-32 [8759304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9114-9 [8799163.001]
  • [Cites] Am J Physiol. 1996 Nov;271(5 Pt 1):C1424-37 [8944624.001]
  • [Cites] Atherosclerosis. 1997 Jan 3;128(1):39-46 [9051196.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1575-82 [9763529.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] J Cell Biol. 1999 Feb 8;144(3):427-34 [9971738.001]
  • [Cites] Circ Res. 1999 Aug 20;85(4):377-85 [10455066.001]
  • [Cites] Circulation. 2004 Dec 14;110(24):3708-14 [15569838.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1747-55 [7706483.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R64-9 [11742824.001]
  • [Cites] Circulation. 2002 Apr 9;105(14):1686-92 [11940548.001]
  • [Cites] J Rheumatol. 2002 Nov;29(11):2261-5 [12415579.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11746-52 [12547825.001]
  • [Cites] Hum Reprod. 2003 Jul;18(7):1395-403 [12832362.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2433-40 [14633615.001]
  • [Cites] Clin Chem. 1974 Apr;20(4):470-5 [4818200.001]
  • [Cites] Endocrinol Jpn. 1975 Aug;22(4):297-302 [1201739.001]
  • [Cites] Biomed Mass Spectrom. 1980 Nov;7(11-12):500-4 [6452916.001]
  • [Cites] Am J Physiol. 1982 Nov;243(5):C212-21 [6814260.001]
  • [Cites] Int J Cardiol. 2001 Nov;81(1):43-50 [11690664.001]
  • (PMID = 16801563.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG015857; United States / NIA NIH HHS / AG / AG-15857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 4TI98Z838E / Estradiol; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 3.5.3.1 / Arginase; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC1502484
  •  go-up   go-down


24. Lee JH, Son CW, Kim MY, Kim MH, Kim HR, Kwak ES, Kim S, Kim MR: Red beet (Beta vulgaris L.) leaf supplementation improves antioxidant status in C57BL/6J mice fed high fat high cholesterol diet. Nutr Res Pract; 2009;3(2):114-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red beet (Beta vulgaris L.) leaf supplementation improves antioxidant status in C57BL/6J mice fed high fat high cholesterol diet.
  • The effect of diet supplemented with red beet (Beta vulgaris L.) leaf on antioxidant status of plasma and tissue was investigated in C57BL/6J mice.
  • The mice were randomly divided into two groups after one-week acclimation, and fed a high fat (20%) and high cholesterol (1%) diet without (control group) or with 8% freeze-dried red beet leaf (RBL group) for 4 weeks.
  • In RBL mice, lipid peroxidation determined as 2-thiobarbituric acid-reactive substances (TBARS value) was significantly reduced in the plasma and selected organs (liver, heart, and kidney).
  • Levels of antioxidants (glutathione and beta-carotene) and the activities of antioxidant enzyme (glutathione peroxidase) in plasma and liver were considerably increased, suggesting that antioxidant defenses were improved by RBL diet.
  • Comet parameters such as tail DNA (%), tail extent moment, olive tail moment and tail length were significantly reduced by 25.1%, 49.4%, 35.4%, and 23.7%, respectively, in plasma lymphocyte DNA of RBL mice compared with control mice, and indicated the increased resistance of lymphocyte DNA to oxidative damage.
  • In addition, the RBL diet controlled body weight together with a significant reduction of fat pad (retroperitoneal, epididymal, inguinal fat, and total fat).
  • Therefore, the present study suggested that the supplementation of 8% red beet leaf in high fat high cholesterol diet could prevent lipid peroxidation and improve antioxidant defense system in the plasma and tissue of C57BL/6J mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Nutr. 2009 Apr;101(8):1246-54 [19243638.001]
  • [Cites] Neurochem Res. 2001 Jan;26(1):31-6 [11358279.001]
  • [Cites] J Agric Food Chem. 2006 Jul 26;54(15):5416-21 [16848526.001]
  • [Cites] J Agric Food Chem. 2005 Jan 12;53(1):103-10 [15631516.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Am J Clin Nutr. 1999 Apr;69(4):712-8 [10197573.001]
  • [Cites] Free Radic Res. 1997 May;26(5):449-55 [9179590.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1291-5 [8640816.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5258-65 [7777494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12808-12 [7809125.001]
  • [Cites] Biochim Biophys Acta. 1991 Oct 15;1086(1):134-8 [1954240.001]
  • [Cites] Drug Metab Dispos. 1991 Jan-Feb;19(1):100-6 [1673382.001]
  • [Cites] Exp Cell Res. 1988 Mar;175(1):184-91 [3345800.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):473-80 [11304460.001]
  • [Cites] Biosci Biotechnol Biochem. 2000 Dec;64(12):2543-51 [11210115.001]
  • [Cites] Free Radic Res. 2000 Nov;33 Suppl:S85-97 [11191279.001]
  • [Cites] Curr Opin Cardiol. 2000 Sep;15(5):355-63 [11128189.001]
  • [Cites] Med Hypotheses. 1999 Dec;53(6):507-15 [10687893.001]
  • [Cites] J Lipid Res. 1999 Dec;40(12):2143-57 [10588940.001]
  • [Cites] Br Med Bull. 1999;55(3):568-77 [10746347.001]
  • [Cites] Arch Biochem Biophys. 1984 Jan;228(1):1-12 [6364985.001]
  • [Cites] Methods Enzymol. 1978;52:506-13 [672654.001]
  • [Cites] Lipids. 1973 Apr;8(4):177-82 [4348615.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] J Biol Chem. 1969 Nov 25;244(22):6049-55 [5389100.001]
  • [Cites] Eur J Nutr. 2004 Aug;43(4):237-45 [15338249.001]
  • [Cites] J Nutr. 2004 Mar;134(3):489-92 [14988435.001]
  • [Cites] Free Radic Res. 2003 Jun;37(6):689-96 [12868496.001]
  • [Cites] Toxicology. 2003 Jul 15;189(1-2):41-54 [12821281.001]
  • [Cites] Nutrition. 2002 Oct;18(10):872-9 [12361782.001]
  • [Cites] J Agric Food Chem. 2001 Nov;49(11):5178-85 [11714300.001]
  • [Cites] Neurol Sci. 2001 Feb;22(1):83-4 [11487213.001]
  • [Cites] J Nutr. 2006 Oct;136(10):2588-93 [16988131.001]
  • (PMID = 20016711.001).
  • [ISSN] 2005-6168
  • [Journal-full-title] Nutrition research and practice
  • [ISO-abbreviation] Nutr Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2788172
  • [Keywords] NOTNLM ; Antioxidant / DNA / TBARS value / mice / red beet leaf
  •  go-up   go-down


25. McKean-Cowdin R, Li X, Bernstein L, McTiernan A, Ballard-Barbash R, Gauderman WJ, Gilliland F: The ADRB3 Trp64Arg variant and obesity in African-American breast cancer cases. Int J Obes (Lond); 2007 Jul;31(7):1110-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several observational studies have found that women, who are overweight or obese at the time of diagnosis, as well as those who gain weight after diagnosis, are at greater risk for breast cancer recurrence and death than non-overweight women.
  • MEASURES: ADRB3 Trp64Arg genotype, measures of weight including body mass index (BMI), weight gain (weight 5 years before diagnosis compared with weight at 30 months after diagnosis), obesity (BMI> or =30 kg/m(2)), waist/hip circumference and visceral or subcutaneous fat were determined by magnetic resonance imaging.
  • RESULTS: African-American women who were homozygous for the ADRB3 wild-type allele had significantly higher mean visceral fat levels than women who carried the variant (P=0.04), and were significantly more likely to be obese (odd ratios (OR)=2.1, 95% confidence interval (CI)=1.1-4.2).
  • The association with obesity was most pronounced among women who were premenopausal (OR=4.8, 95% CI=1.3-18), who received chemotherapy for their breast cancer (OR=6.1, 95% CI=1.8-20), or who were not physically active (OR=3.9, 95% CI=1.5-9.7).

  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1121-7 [15247122.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):352-8 [16410350.001]
  • [Cites] Breast Cancer Res Treat. 1985;5(2):195-200 [4016284.001]
  • [Cites] Science. 1989 Sep 8;245(4922):1118-21 [2570461.001]
  • [Cites] Am J Clin Nutr. 1991 Jun;53(6):1378-83 [2035465.001]
  • [Cites] Am J Clin Nutr. 1992 May;55(5):950-4 [1570802.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1418-29 [8315439.001]
  • [Cites] Annu Rev Nutr. 1993;13:337-54 [8369150.001]
  • [Cites] Trends Pharmacol Sci. 1994 Jan;15(1):3-7 [8140656.001]
  • [Cites] J Natl Cancer Inst. 1994 Sep 21;86(18):1403-8 [8072034.001]
  • [Cites] Int J Obes Relat Metab Disord. 1994 Sep;18(9):614-21 [7812415.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1109-16 [7883959.001]
  • [Cites] N Engl J Med. 1995 Aug 10;333(6):343-7 [7609750.001]
  • [Cites] N Engl J Med. 1995 Aug 10;333(6):348-51 [7609751.001]
  • [Cites] N Engl J Med. 1995 Aug 10;333(6):352-4 [7609752.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 13;215(2):555-60 [7487991.001]
  • [Cites] Obes Res. 1995 Sep;3(5):447-57 [8521164.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2638-41 [8641219.001]
  • [Cites] Breast Cancer Res Treat. 1999 Oct;57(3):285-90 [10617305.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Jan;25(1):54-60 [11244458.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2381-9 [11331316.001]
  • [Cites] Breast Cancer Res. 2001;3(4):264-9 [11434877.001]
  • [Cites] Diabetes Care. 2001 Sep;24(9):1579-83 [11522702.001]
  • [Cites] Am J Epidemiol. 2001 Sep 1;154(5):442-50 [11532786.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):720-9 [11550140.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1128-43 [11844838.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1728-32 [12365956.001]
  • [Cites] Diabetes Obes Metab. 2002 Nov;4(6):428-30 [12406043.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2086-93 [8903328.001]
  • [Cites] Diabetologia. 1997 Feb;40(2):200-4 [9049481.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1284-7 [9100608.001]
  • [Cites] JAMA. 2003 Jan 15;289(3):323-30 [12525233.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1746-57 [12655532.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1961-6 [12743149.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26 [12928347.001]
  • [Cites] J Endocrinol Invest. 2003 Sep;26(9):937-40 [14964449.001]
  • [Cites] J Am Diet Assoc. 1997 May;97(5):519-26, 529; quiz 527-8 [9145091.001]
  • [Cites] Int J Epidemiol. 1997 Jun;26(3):484-90 [9222771.001]
  • [Cites] Eur J Biochem. 1997 Aug 1;247(3):1174-9 [9288945.001]
  • [Cites] J Clin Invest. 1998 Feb 1;101(3):584-7 [9449691.001]
  • [Cites] Behav Genet. 1997 Jul;27(4):325-51 [9519560.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(1):53-64 [9541189.001]
  • [Cites] Metabolism. 1998 May;47(5):617-21 [9591756.001]
  • [Cites] Diabetes. 1999 Jan;48(1):203-5 [9892244.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):143-9 [10084106.001]
  • [Cites] J Intern Med. 1999 Jun;245(6):667-72 [10395196.001]
  • [Cites] JAMA. 2005 May 25;293(20):2479-86 [15914748.001]
  • [Cites] Int J Obes (Lond). 2005 Jul;29(7):746-54 [15917856.001]
  • [Cites] J Appl Physiol (1985). 2005 Oct;99(4):1613-8 [16002776.001]
  • [Cites] Med Sci Sports Exerc. 2004 Sep;36(9):1484-91 [15354027.001]
  • (PMID = 17264845.001).
  • [ISSN] 0307-0565
  • [Journal-full-title] International journal of obesity (2005)
  • [ISO-abbreviation] Int J Obes (Lond)
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / N01 HD3-3175; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC035138-22; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / PC-67010; United States / NCI NIH HHS / PC / N01 PC035138-22; United States / NCI NIH HHS / CA / N01PC35139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Adrenergic, beta-3
  • [Other-IDs] NLM/ NIHMS250945; NLM/ PMC3063149
  •  go-up   go-down


26. Metzner J, Popp L, Marian C, Schmidt R, Manderscheid C, Renne C, Fisslthaler B, Fleming I, Busse R, Geisslinger G, Niederberger E: The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J Mol Med (Berl); 2007 Jun;85(6):623-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Disease Progression. Epoprostenol / blood. Female. Inflammation Mediators / metabolism. Lipids / blood. Mice. Thromboxane A2 / blood

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2003 Dec 16;108(24):3017-23 [14638539.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Glia. 2004 Oct;48(1):76-84 [15326617.001]
  • [Cites] Pain. 2004 Jul;110(1-2):409-18 [15275793.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2000 Aug;20(2):146-52 [10942685.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7 [9874808.001]
  • [Cites] Arterioscler Thromb. 1994 Jan;14(1):133-40 [8274468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12764-9 [11027305.001]
  • [Cites] Nat Rev Drug Discov. 2003 Nov;2(11):879-90 [14668809.001]
  • [Cites] Nat Biotechnol. 2006 Oct;24(10):1270-8 [17013374.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1302-8 [16740558.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1724-8 [10894809.001]
  • [Cites] Am Heart J. 1999 Nov;138(5 Pt 2):S419-20 [10539839.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3358-63 [11248083.001]
  • [Cites] FASEB J. 2001 Oct;15(12):2057-72 [11641233.001]
  • [Cites] Scand Cardiovasc J. 2002 Dec;36(6):362-7 [12626204.001]
  • [Cites] J Med Chem. 2005 Apr 7;48(7):2251-7 [15801815.001]
  • [Cites] PLoS Clin Trials. 2006 Nov 17;1(7):e33 [17111043.001]
  • [Cites] Arch Intern Med. 2005 May 9;165(9):978-84 [15883235.001]
  • [Cites] Clin Pharmacokinet. 2000 Mar;38(3):225-42 [10749518.001]
  • [Cites] Circulation. 2002 Apr 16;105(15):1816-23 [11956125.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):862-73 [11953961.001]
  • [Cites] Life Sci. 2000 Dec 15;68(4):457-65 [11205894.001]
  • [Cites] Am J Cardiol. 2002 Mar 21;89(6A):26D-32D [11909558.001]
  • [Cites] Curr Opin Pharmacol. 2004 Apr;4(2):116-23 [15063354.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1281-91 [10514410.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):405-9 [12551863.001]
  • [Cites] J Am Coll Cardiol. 2003 May 21;41(10):1812-9 [12767669.001]
  • [Cites] J Mol Cell Cardiol. 2005 Sep;39(3):443-52 [16040051.001]
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):198-204 [14522423.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):954-9 [11509060.001]
  • [Cites] J Histochem Cytochem. 1999 Jun;47(6):719-30 [10330448.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 7;98(11):736-47 [16757698.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 2000 Feb 11;738(2):377-85 [10718655.001]
  • [Cites] CMAJ. 2006 May 23;174(11):1563-9 [16670396.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):129-31 [15626595.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2003;83:189-209 [12934931.001]
  • (PMID = 17318614.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Apolipoproteins E; 0 / Inflammation Mediators; 0 / Lipids; 57576-52-0 / Thromboxane A2; DCR9Z582X0 / Epoprostenol; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


27. Johnson NA, Stannard SR, Chapman PG, Thompson MW: Effect of altered pre-exercise carbohydrate availability on selection and perception of effort during prolonged cycling. Eur J Appl Physiol; 2006 Sep;98(1):62-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This finding suggests that reduced work rate during exercise following lowered CHO intake may, in part, be a consequence of the subject's awareness of dietary CHO restriction rather than solely a physiologically mediated action.

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Physiol Scand. 1979 Sep;107(1):19-32 [525365.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jul;281(1):R187-96 [11404293.001]
  • [Cites] Int J Sport Nutr Exerc Metab. 2005 Apr;15(2):97-116 [28589767.001]
  • [Cites] Int J Sports Med. 1989 May;10 Suppl 1:S63-7 [2744928.001]
  • [Cites] Med Sci Sports Exerc. 1982;14(5):377-81 [7154893.001]
  • [Cites] Br J Sports Med. 2004 Aug;38(4):511-4 [15273198.001]
  • [Cites] Med Sci Sports Exerc. 1981;13(3):150-63 [7019620.001]
  • [Cites] Sports Med. 1989 Aug;8(2):80-100 [2675259.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1997;75(5):407-12 [9189727.001]
  • [Cites] Med Sci Sports Exerc. 2004 Oct;36(10):1819-25 [15595306.001]
  • [Cites] J Appl Physiol (1985). 2000 Apr;88(4):1284-90 [10749820.001]
  • [Cites] Experientia. 1996 May 15;52(5):416-20 [8641377.001]
  • [Cites] J Appl Physiol (1985). 1993 Jun;74(6):2998-3005 [8365999.001]
  • [Cites] Scand J Clin Lab Invest. 1967;19(3):218-28 [6048626.001]
  • [Cites] J Appl Physiol (1985). 1988 Jun;64(6):2622-30 [3403447.001]
  • [Cites] Pflugers Arch. 1973 Nov 15;344(1):1-12 [4272644.001]
  • [Cites] J Appl Physiol (1985). 1987 Dec;63(6):2388-95 [3325488.001]
  • [Cites] Acta Physiol Scand. 1967 Oct-Nov;71(2):140-50 [5584523.001]
  • [Cites] J Appl Physiol (1985). 1997 Apr;82(4):1185-9 [9104855.001]
  • [Cites] Med Sci Sports Exerc. 2004 Dec;36(12):2107-11 [15570147.001]
  • [Cites] J Appl Physiol. 1972 Oct;33(4):421-5 [4263085.001]
  • [Cites] Sports Med. 1994 Feb;17(2):77-85 [8171225.001]
  • [Cites] Med Sci Sports Exerc. 2005 Mar;37(3):461-8 [15741846.001]
  • [Cites] Br J Sports Med. 2005 Jan;39(1):34-8 [15618337.001]
  • [Cites] Med Sci Sports. 1973 Summer;5(2):97-103 [4721014.001]
  • [Cites] Ergonomics. 1979 Oct;22(10):1141-6 [540641.001]
  • [Cites] J Appl Physiol (1985). 1986 Jul;61(1):165-72 [3525502.001]
  • [Cites] Eur J Appl Physiol. 2003 Oct;90(3-4):270-4 [14523564.001]
  • (PMID = 16799816.001).
  • [ISSN] 1439-6319
  • [Journal-full-title] European journal of applied physiology
  • [ISO-abbreviation] Eur. J. Appl. Physiol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dietary Carbohydrates
  •  go-up   go-down


28. Yu C, Wang F, Jin C, Huang X, McKeehan WL: Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem; 2005 May 6;280(18):17707-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To prove that hepatocyte FGFR4 was a negative regulator of cholesterol metabolism and bile acid synthesis independent of background, we generated transgenic mice overexpressing a constitutively active human FGFR4 (CahR4) in hepatocytes and crossed them with the FGFR4-deficient mice to generate CahR4/mR4(-/-) mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750181.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA59971; United States / NIDDK NIH HHS / DK / DK35310
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Receptors, Fibroblast Growth Factor; EC 2.7.10.1 / FGFR4 protein, human; EC 2.7.10.1 / Fgfr4 protein, mouse; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


29. Allan LM, Ballard CG, Burn DJ, Kenny RA: Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. J Am Geriatr Soc; 2005 Oct;53(10):1681-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To compare the prevalence, severity, and type of gait and balance disorders in Alzheimer's disease (AD), vascular dementia (VaD), Parkinson's disease with dementia (PDD), dementia with Lewy bodies (DLB), Parkinson's disease without dementia (PD), and age-matched controls.
  • The types of gait disorders in each diagnostic group were classified using the Nutt et al. classification.
  • The risk of gait and balance disorder was higher in the non-Alzheimer's dementia groups (VaD, PDD, and DLB) than in the AD group (odds ratio=15 (95% confidence interval=6-37).
  • If a gait disorder was present in mild dementia (Cambridge Examination for Mental Disorders of the Elderly cognitive subsection score >65), this was diagnostic of non-Alzheimer's dementia, with sensitivity of 78% and specificity of 100%.
  • [MeSH-major] Alzheimer Disease / epidemiology. Dementia, Vascular / epidemiology. Gait Disorders, Neurologic / epidemiology. Lewy Body Disease / epidemiology
  • [MeSH-minor] Aged. Aged, 80 and over. Comorbidity. Cross-Sectional Studies. Female. Geriatric Assessment. Health Status Indicators. Humans. Incidence. Male. Neurologic Examination. Parkinson Disease / diagnosis. Parkinson Disease / epidemiology. Postural Balance


30. Choi UK, Lee OH, Yim JH, Cho CW, Rhee YK, Lim SI, Kim YC: Hypolipidemic and antioxidant effects of dandelion (Taraxacum officinale) root and leaf on cholesterol-fed rabbits. Int J Mol Sci; 2010;11(1):67-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypolipidemic and antioxidant effects of dandelion (Taraxacum officinale) root and leaf on cholesterol-fed rabbits.
  • Dandelion (Taraxacum officinale), an oriental herbal medicine, has been shown to favorably affect choleretic, antirheumatic and diuretin properties.
  • Recent reports have indicated that excessive oxidative stress contributes to the development of atherosclerosis-linked metabolic syndrome.
  • The objective of this current study was to investigate the possible hypolipidemic and antioxidative effects of dandelion root and leaf in rabbits fed with a high-cholesterol diet.
  • A group of twenty eight male rabbits was divided into four subgroups; a normal diet group, a high-cholesterol diet group, a high-cholesterol diet with 1% (w/w) dandelion leaf group, and a high-cholesterol diet with 1% (w/w) dandelion root group.
  • After the treatment period, the plasma antioxidant enzymes and lipid profiles were determined.
  • Our results show that treatment with dandelion root and leaf positively changed plasma antioxidant enzyme activities and lipid profiles in cholesterol-fed rabbits, and thus may have potential hypolipidemic and antioxidant effects.
  • Dandelion root and leaf could protect against oxidative stress linked atherosclerosis and decrease the atherogenic index.
  • [MeSH-major] Antioxidants / pharmacology. Hypolipidemic Agents / pharmacology. Plant Extracts / pharmacology. Plant Leaves / chemistry. Plant Roots / chemistry. Taraxacum / chemistry
  • [MeSH-minor] Administration, Oral. Animals. Aorta / drug effects. Aorta / pathology. Body Weight / drug effects. Diet. Lipid Peroxidation / drug effects. Lipids / blood. Liver / anatomy & histology. Liver / drug effects. Liver / metabolism. Male. Organ Size. Rabbits

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Cardiovasc Med. 2001 Apr-May;11(3-4):93-102 [11686009.001]
  • [Cites] Free Radic Res. 2009 Mar;43(3):241-9 [19184760.001]
  • [Cites] Metabolism. 2002 Aug;51(8):1071-6 [12145784.001]
  • [Cites] Phytomedicine. 2003 Jan;10(1):17-22 [12622459.001]
  • [Cites] Obes Rev. 2004 Feb;5(1):27-42 [14969505.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] Anal Biochem. 1976 Jul;74(1):214-26 [962076.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Medicine (Baltimore). 1981 Mar;60(2):110-23 [7012540.001]
  • [Cites] Arch Biochem Biophys. 1981 Sep;210(2):505-16 [7305340.001]
  • [Cites] Methods Enzymol. 1981;77:325-33 [7329310.001]
  • [Cites] Am J Med Sci. 1986 Aug;292(2):97-103 [3728559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7725-9 [3478721.001]
  • [Cites] Toxicology. 1990 Dec 3;64(3):271-9 [2267665.001]
  • [Cites] Br Med Bull. 1990 Oct;46(4):1075-87 [2100688.001]
  • [Cites] Mol Chem Neuropathol. 1991 Jun;14(3):213-26 [1958264.001]
  • [Cites] Biochem Pharmacol. 1992 Dec 1;44(11):2185-9 [1472083.001]
  • [Cites] Am Heart J. 1993 Apr;125(4):958-73 [8465768.001]
  • [Cites] Phytochemistry. 1996 May;42(1):121-7 [8728061.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] Circulation. 1999 Mar 16;99(10):1355-62 [10077521.001]
  • [Cites] J Nutr. 1999 Jul;129(7 Suppl):1457S-66S [10395621.001]
  • [Cites] J Endocrinol Invest. 2005 Apr;28(4):333-9 [15966506.001]
  • [Cites] Bioorg Med Chem. 2005 Sep 15;13(18):5362-70 [15993081.001]
  • [Cites] Diabetes. 2005 Nov;54(11):3140-7 [16249437.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2006 Apr;16(3):174-85 [16580585.001]
  • [Cites] Atherosclerosis. 2002 Mar;161(1):1-16 [11882312.001]
  • (PMID = 20162002.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Hypolipidemic Agents; 0 / Lipids; 0 / Plant Extracts
  • [Other-IDs] NLM/ PMC2820990
  • [Keywords] NOTNLM ; Taraxacum officinale / antioxidant activity / atherosclerosis / dandelion / hypolipidemic effects
  • [General-notes] NLM/ Original DateCompleted: 20100630
  •  go-up   go-down


31. Sasaguri Y, Wang KY, Tanimoto A, Tsutsui M, Ueno H, Murata Y, Kohno Y, Yamada S, Ohtsu H: Role of histamine produced by bone marrow-derived vascular cells in pathogenesis of atherosclerosis. Circ Res; 2005 May 13;96(9):974-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of histamine produced by bone marrow-derived vascular cells in pathogenesis of atherosclerosis.
  • To clarify the role of histamine-producing cells and its origin in atherosclerosis, we investigated histidine decarboxylase (HDC; histamine-producing enzyme) expression in murine arteries with vascular injuries after the animal had received transplanted bone marrow (BM) from green fluorescent protein (GFP)-transgenic mice.
  • The neointima in the ligated carotid arteries contained BM-derived HDC+ cells that expressed macrophage (Mac-3) or smooth muscle cell antigen (alpha-SMA).
  • In contrast, the HDC+ BM-derived cells, which were positive for Mac-3, were mainly located in the adventitia in the cuff replacement model.
  • In apolipoprotein E-knockout mice on a high cholesterol diet, BM-derived cells expressing Mac-3 in the atheromatous plaques were also positive for HDC.
  • In comparison with wild-type mice, HDC-/- mice showed reduced neointimal thickening and a decreased intima-to-media ratio after ligation and cuff replacement.
  • These results indicate that histamine produced from BM-derived progenitor cells, which could transdifferentiate into SMC- or macrophage-like cells, are important for the formation of neointima and atheromatous plaques.
  • [MeSH-major] Arteries / cytology. Arteriosclerosis / etiology. Bone Marrow Cells / enzymology. Histamine / physiology. Histidine Decarboxylase / metabolism. Stem Cells / enzymology
  • [MeSH-minor] Animals. Apolipoproteins E / genetics. Carotid Arteries / pathology. Carotid Arteries / surgery. Green Fluorescent Proteins / genetics. Hyperlipidemias / complications. Ligation. Macrophages / metabolism. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Muscle, Smooth, Vascular / cytology. Muscle, Smooth, Vascular / metabolism. Tunica Intima / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HISTAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15831815.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 147336-22-9 / Green Fluorescent Proteins; 820484N8I3 / Histamine; EC 4.1.1.22 / Histidine Decarboxylase
  •  go-up   go-down


32. George SM, Neuhouser ML, Mayne ST, Irwin ML, Albanes D, Gail MH, Alfano CM, Bernstein L, McTiernan A, Reedy J, Smith AW, Ulrich CM, Ballard-Barbash R: Postdiagnosis diet quality is inversely related to a biomarker of inflammation among breast cancer survivors. Cancer Epidemiol Biomarkers Prev; 2010 Sep;19(9):2220-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty months after diagnosis, the women completed food frequency questionnaires.
  • Among women not engaging in recreational physical activity after diagnosis, better diet quality was associated with lower CRP concentrations (2.5 mg/L versus 5.0 mg/L), but no association was observed among women engaging in any recreational physical activity (1.4 mg/L versus 1.6 mg/L; P heterogeneity = 0.03).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] JAMA. 1999 Dec 8;282(22):2131-5 [10591334.001]
  • [Cites] J Clin Oncol. 2011 Jan 1;29(1):32-9 [21115858.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Dec;279(6):E1374-82 [11093926.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):499-511 [12551878.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1961-6 [12743149.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):508S-513S [12936941.001]
  • [Cites] Circulation. 2004 May 4;109(17):2046-9 [15096450.001]
  • [Cites] Med Sci Sports Exerc. 2004 Sep;36(9):1484-91 [15354027.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):630-5 [15369797.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] J Am Diet Assoc. 1988 Oct;88(10):1268-71 [3171020.001]
  • [Cites] Semin Arthritis Rheum. 1990 Dec;20(3):129-47 [1705051.001]
  • [Cites] Ann Clin Biochem. 1998 Nov;35 ( Pt 6):745-53 [9838988.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920 [15867843.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9295-303 [16361628.001]
  • [Cites] Breast Cancer Res Treat. 2006 Apr;96(3):227-32 [16538543.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E83-90 [17356008.001]
  • [Cites] Am J Clin Nutr. 2007 Nov;86(5):1445-55 [17991658.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3958-64 [18711185.001]
  • [Cites] J Am Diet Assoc. 2008 Nov;108(11):1854-64 [18954575.001]
  • [Cites] J Am Diet Assoc. 2008 Nov;108(11):1896-901 [18954580.001]
  • [Cites] J Nutr. 2008 Dec;138(12):2293-6 [19022947.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):919-26 [19114692.001]
  • [Cites] J Natl Cancer Inst. 2009 May 6;101(9):630-43 [19401543.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3437-44 [19470939.001]
  • [Cites] Med Sci Sports Exerc. 2009 Aug;41(8):1533-9 [19568208.001]
  • [Cites] Adv Med Sci. 2009;54(2):150-7 [19875356.001]
  • [Cites] J Womens Health (Larchmt). 2010 Jan;19(1):139-45 [20088670.001]
  • [Cites] Inflamm Res. 2010 May;59(5):399-405 [19916070.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • (PMID = 20716617.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / CA / T32 CA105666; United States / NCI NIH HHS / CA / T32 CA09661; United States / NCRR NIH HHS / RR / M01-RR-00037; United States / NCI NIH HHS / CN / N01-CN-75036-20; United States / NCRR NIH HHS / RR / M01 RR000037; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CN / N01 CN005228; United States / NCRR NIH HHS / RR / M01 RR000997; United States / NCI NIH HHS / CA / T32 CA105666-08; United States / NCI NIH HHS / CA / CA105666-08; United States / NCI NIH HHS / CN / N01-CN-05228; United States / NCRR NIH HHS / RR / M01-RR-0997; United States / NICHD NIH HHS / HD / N01-HD-3-3175; United States / NCI NIH HHS / CA / T32 CA009661
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Biomarkers, Tumor; 0 / Leptin; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS231477; NLM/ PMC3077799
  •  go-up   go-down


33. Chung IM, Kim MY, Park WH, Moon HI: Antiatherogenic activity of Dendropanax morbifera essential oil in rats. Pharmazie; 2009 Aug;64(8):547-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Korea, Dendropanax morbifera Leveille (Araliaceae) is commonly used in traditional medicines for various diseases.
  • The DMEO yield was 3.5%, and GC/MS analysis revealed that its major constituents were gamma-elemene (18.59%), tetramethyltricyclo hydrocarbons (10.82%), beta-zingiberene (10.52%), and beta-selinene (10.41%).

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746846.001).
  • [ISSN] 0031-7144
  • [Journal-full-title] Die Pharmazie
  • [ISO-abbreviation] Pharmazie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hypolipidemic Agents; 0 / Lipids; 0 / Oils, Volatile
  •  go-up   go-down


34. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW: Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther; 2005 May;313(2):502-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased superoxide and tumor necrosis factor-alpha (TNF-alpha) production were significantly lowered by cilostazol in situ as well as in cultured human umbilical vein endothelial cells (HUVECs).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734902.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, Dietary; 0 / Receptors, LDL; 0 / Tetrazoles; 0 / Tumor Necrosis Factor-alpha; 11062-77-4 / Superoxides; N7Z035406B / cilostazol
  •  go-up   go-down


35. Setorki M, Asgary S, Eidi A, Rohani AH, Khazaei M: Acute effects of vinegar intake on some biochemical risk factors of atherosclerosis in hypercholesterolemic rabbits. Lipids Health Dis; 2010;9:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute effects of vinegar intake on some biochemical risk factors of atherosclerosis in hypercholesterolemic rabbits.
  • BACKGROUND: Exaggerated postprandial spikes in blood glucose and lipids induce proportional increases in oxidative stress, which acutely trigger impairment endothelial, inflammation and increased risk of future cardiovascular events.
  • In this research, we have investigated acute effects of vinegar intake on some of the biochemical atherosclerosis risk factors in high cholesterol fed rabbits to see if we can find a probable protective value for it.
  • METHODS: The rabbits were randomly divided into four groups: normal diet, high cholesterol diet (%1 cholesterol), %1 cholesterol with 5 ml vinegar (low dose), %1 cholesterol with 10 ml vinegar (high dose).
  • After fasting for 12-15 hours, blood samples were taken to determine baseline values.
  • Three hours after feeding, blood samples were collected again to investigate acute effects of vinegar intake on the measured factors.
  • RESULTS: Using high-dose vinegar with cholesterolemic diet caused significant reduce in LDL-cholesterol (LDL-C), oxidized-LDL (ox-LDL), malondialdehyde (MDA), total cholesterol (TC) and apolipoprotein B (ApoB) in comparison with hypercholesterolemic diet.
  • Consumption low-dose vinegar with cholesterolemic diet induced a significant decrease in fibrinogen and glucose compared to hypercholesterolemic diet.
  • Level of serum nitrite, nitrate, triacylglycerol (TAG), HDL-cholesterol (HDL-C), apolipoprotein A (ApoA), serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetate transaminase (SGOT) and C-reactive protein (CRP) were not significantly difference in low and high doses vinegar with cholesterolemic diet compared to hypercholesterolemic diet.
  • A significant difference was observed for LDL-C, ApoB100 and TC between low and high doses vinegar.
  • CONCLUSION: This study suggest that vinegar, might have some acute effects on biochemical risk factors of atherosclerosis and a probable protective value can be considered for its postprandial use.
  • [MeSH-major] Acetic Acid / pharmacology. Atherosclerosis / prevention & control. Hypercholesterolemia / drug therapy
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Apolipoproteins / blood. Blood Glucose / metabolism. Lipids / chemistry. Male. Oxaloacetic Acid / chemistry. Plant Extracts / pharmacology. Postprandial Period. Rabbits. Risk Factors. Transaminases / blood

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2000 Mar;130(3):507-13 [10702577.001]
  • [Cites] Clin Nutr. 2008 Aug;27(4):594-600 [18295937.001]
  • [Cites] J Nutr. 2001 Jul;131(7):1973-7 [11435516.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2001;109(4):S533-47 [11453041.001]
  • [Cites] Curr Opin Lipidol. 2002 Feb;13(1):19-24 [11790959.001]
  • [Cites] Biosci Biotechnol Biochem. 2001 Dec;65(12):2690-4 [11826965.001]
  • [Cites] Circulation. 2002 Sep 3;106(10):1211-8 [12208795.001]
  • [Cites] J Agric Food Chem. 2002 Dec 18;50(26):7720-5 [12475295.001]
  • [Cites] Clin Chim Acta. 2003 Jan;327(1-2):129-37 [12482628.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2003 Jul;30(7):504-6 [12823267.001]
  • [Cites] Curr Atheroscler Rep. 2003 Nov;5(6):452-8 [14525678.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):65-70 [14619957.001]
  • [Cites] Drugs Exp Clin Res. 2003;29(5-6):217-23 [15134377.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):228-34 [2195060.001]
  • [Cites] Lancet. 1992 Aug 1;340(8814):289-91 [1353203.001]
  • [Cites] Am Heart J. 1993 Apr;125(4):958-73 [8465768.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):801-9 [8479518.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jul 17;212(2):360-6 [7626049.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Free Radic Biol Med. 1996;20(3):331-42 [8720903.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1514 [8942794.001]
  • [Cites] Free Radic Biol Med. 1997;22(5):749-60 [9119242.001]
  • [Cites] Am J Cardiol. 1997 Feb 1;79(3):350-4 [9036757.001]
  • [Cites] Cardiovasc Res. 1997 Dec;36(3):330-6 [9534853.001]
  • [Cites] Eur J Clin Nutr. 1998 May;52(5):368-71 [9630389.001]
  • [Cites] Free Radic Biol Med. 1998 Jun;24(9):1355-63 [9641252.001]
  • [Cites] Free Radic Biol Med. 1998 Jul 15;25(2):250-2 [9667503.001]
  • [Cites] Arch Biochem Biophys. 1998 Aug 15;356(2):133-41 [9705203.001]
  • [Cites] Life Sci. 1999;64(21):1913-20 [10353589.001]
  • [Cites] Biosci Biotechnol Biochem. 1999 May;63(5):905-10 [10380633.001]
  • [Cites] Circulation. 1999 Sep 7;100(10):1050-5 [10477529.001]
  • [Cites] Atherosclerosis. 2004 Dec;177(2):401-8 [15530916.001]
  • [Cites] J Agric Food Chem. 2005 Apr 6;53(7):2462-6 [15796580.001]
  • [Cites] Eur J Clin Nutr. 2005 Sep;59(9):983-8 [16015276.001]
  • [Cites] Br J Nutr. 2005 Nov;94(5):714-9 [16277773.001]
  • [Cites] J Am Diet Assoc. 2005 Dec;105(12):1939-42 [16321601.001]
  • [Cites] Med Sci Monit. 2005 Dec;11(12):BR465-72 [16319784.001]
  • [Cites] Br J Nutr. 2006 May;95(5):916-24 [16611381.001]
  • [Cites] QJM. 2006 May;99(5):277-87 [16504986.001]
  • [Cites] Nitric Oxide. 2006 Aug;15(1):30-9 [16517190.001]
  • [Cites] MedGenMed. 2006;8(2):61 [16926800.001]
  • [Cites] J Am Coll Cardiol. 2006 Oct 17;48(8):1666-71 [17045905.001]
  • [Cites] Diabetes Metab. 2006 Sep;32 Spec No2:2S28-33 [17375404.001]
  • [Cites] Liver Int. 2007 Sep;27(7):895-900 [17696927.001]
  • [Cites] FASEB J. 2008 Jan;22(1):41-6 [17712060.001]
  • [Cites] Asia Pac J Clin Nutr. 2008;17 Suppl 1:380-2 [18296384.001]
  • [Cites] Mol Nutr Food Res. 2008 Apr;52(4):400-7 [18214852.001]
  • [Cites] Eur J Cardiovasc Prev Rehabil. 2008 Jun;15(3):300-5 [18525384.001]
  • [Cites] J Lipid Res. 2001 May;42(5):725-34 [11352979.001]
  • (PMID = 20109192.001).
  • [ISSN] 1476-511X
  • [Journal-full-title] Lipids in health and disease
  • [ISO-abbreviation] Lipids Health Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoproteins; 0 / Blood Glucose; 0 / Lipids; 0 / Plant Extracts; 2F399MM81J / Oxaloacetic Acid; EC 2.6.1.- / Transaminases; EC 2.6.1.2 / Alanine Transaminase; Q40Q9N063P / Acetic Acid
  • [Other-IDs] NLM/ PMC2837006
  •  go-up   go-down


36. Daghini E, Chade AR, Krier JD, Versari D, Lerman A, Lerman LO: Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol; 2006 Mar;290(3):R609-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypercholesterolemia (HC), a major risk factor for onset and progression of renal disease, is associated with increased oxidative stress, potentially causing endothelial dysfunction.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284087.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL095638; United States / NHLBI NIH HHS / HL / HL-63282; United States / NHLBI NIH HHS / HL / HL-77131
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, Dietary; EC 1.17.3.2 / Xanthine Oxidase; G97OZE5068 / Oxypurinol
  •  go-up   go-down


37. Amran AA, Zaiton Z, Faizah O, Morat P: Effects of Garcinia atroviridis on serum profiles and atherosclerotic lesions in the aorta of guinea pigs fed a high cholesterol diet. Singapore Med J; 2009 Mar;50(3):295-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Garcinia atroviridis on serum profiles and atherosclerotic lesions in the aorta of guinea pigs fed a high cholesterol diet.
  • INTRODUCTION: The fruit extract of Garcinia atroviridis (G. atroviridis) contains hydroxycitric acid and flavonoids, which have been reported to have a hypolipidaemic property.
  • This extract with solvent methanol was used to investigate its effects on serum lipid profiles of guinea pigs fed a high cholesterol diet.
  • METHODS: 24 male Dunkin Hartley guinea pigs were randomly divided into four groups.
  • The first group served as controls and was fed with commercial rabbit chow.
  • The second group was given only G. atroviridis by oral gavage (50 mg/body weight).
  • The third group was fed a one percent cholesterol diet in food pellets in order to induce atherosclerosis.
  • The fourth group was administered G. atroviridis with cholesterol.
  • All the treatments were given daily for eight weeks, after which the animals were sacrificed, and the blood and aorta were taken for biochemical analysis and histological studies.
  • RESULTS: The supplementation of G. atroviridis with a cholesterol diet decreased the level of lipid profile in the serum.
  • Histological studies showed a reduction in fat deposition in the aorta of high cholesterol diet animals given G. atroviridis as compared to the high cholesterol diet group.
  • CONCLUSION: This study has shown that dietary intake of G. atroviridis has a tendency to decrease lipid composition levels in the serum and reduce fat deposition in the aorta of high cholesterol diet animals.
  • [MeSH-major] Aorta / drug effects. Arteriosclerosis / blood. Dietary Fats / blood. Fruit. Garcinia. Nutritional Status. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Guinea Pigs. Humans. Male. Plant Preparations / pharmacology

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352574.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Plant Extracts; 0 / Plant Preparations
  •  go-up   go-down


38. Jones EL, Margallo-Lana M, Prasher VP, Ballard CG: The extended tau haplotype and the age of onset of dementia in Down syndrome. Dement Geriatr Cogn Disord; 2008;26(3):199-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Most people with Down syndrome (DS) develop Alzheimer's disease (AD).
  • H1/H2 individuals are more likely to develop dementia before 45 than H1/H1 individuals (OR = 3, 95% CI = 1.01-8.91).
  • [MeSH-major] Alzheimer Disease / genetics. Down Syndrome / genetics. tau Proteins / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Female. Genetic Predisposition to Disease / epidemiology. Haplotypes. Humans. Male. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Down Syndrome.
  • Genetic Alliance. consumer health - TAU syndrome.
  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18765933.001).
  • [ISSN] 1421-9824
  • [Journal-full-title] Dementia and geriatric cognitive disorders
  • [ISO-abbreviation] Dement Geriatr Cogn Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MAPT protein, human; 0 / tau Proteins
  •  go-up   go-down


39. Elliott MS, Ballard CG, Kalaria RN, Perry R, Hortobágyi T, Francis PT: Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain; 2009 Jul;132(Pt 7):1858-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, a significant subset of people with Alzheimer's disease have concurrent cerebrovascular disease.
  • We have determined, using saturation radioligand binding, the binding parameters (affinity and maximal binding) of ((3)H)-WAY 100635 binding to 5-HT(1A) receptors and ((3)H)-ketanserin binding to 5-HT(2A) receptors in post-mortem tissue from the frontal and temporal cortices of patients with either multi-infarct vascular dementia, sub-cortical ischaemic vascular dementia, mixed Alzheimer's disease/vascular dementia or stroke no dementia (SND).
  • [MeSH-minor] Aged. Aged, 80 and over. Alzheimer Disease / metabolism. Dementia, Multi-Infarct / metabolism. Dementia, Multi-Infarct / pathology. Dementia, Multi-Infarct / psychology. Female. Humans. Male. Prefrontal Cortex / metabolism. Prospective Studies. Stroke / metabolism. Temporal Lobe / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433439.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400074; United Kingdom / Medical Research Council / / G0500247; United Kingdom / Medical Research Council / / G0502157; United Kingdom / Medical Research Council / / G0600676
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptor, Serotonin, 5-HT2A; 112692-38-3 / Receptor, Serotonin, 5-HT1A
  •  go-up   go-down


40. Korou LM, Agrogiannis G, Pantopoulou A, Vlachos IS, Iliopoulos D, Karatzas T, Perrea DN: Comparative antilipidemic effect of N-acetylcysteine and sesame oil administration in diet-induced hypercholesterolemic mice. Lipids Health Dis; 2010;9:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Male C57bl/6 mice were assigned to the following groups: (NC) control group, (HC) group receiving test diet supplemented with 2% cholesterol and 0.5% cholic acid for 8 weeks, (HCN) group receiving the test diet with NAC supplementation (230 mg/kg p.o.) and (HCS) group fed the test diet enriched with 10% sesame oil.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • Hazardous Substances Data Bank. SESAME OIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Metab Cardiovasc Dis. 2006 Apr;16(3):174-85 [16580585.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):242-9 [16373607.001]
  • [Cites] J Med Food. 2006 Winter;9(4):487-90 [17201634.001]
  • [Cites] Neurotoxicology. 2007 Jan;28(1):83-92 [16973216.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1832-7 [17498222.001]
  • [Cites] Br J Nutr. 2008 Jan;99(1):37-43 [17651528.001]
  • [Cites] J Vasc Res. 2008;45(3):205-10 [18063868.001]
  • [Cites] Food Chem Toxicol. 2008 Jun;46(6):1889-95 [18353516.001]
  • [Cites] Hepatology. 2008 Aug;48(2):474-86 [18666236.001]
  • [Cites] Nutrition. 2008 Oct;24(10):1030-8 [18585898.001]
  • [Cites] Atherosclerosis. 2000 Jun;150(2):285-93 [10856520.001]
  • [Cites] J Clin Invest. 2002 Jul;110(1):29-31 [12093884.001]
  • [Cites] Clin Chem Lab Med. 2003 Jan;41(1):56-60 [12636050.001]
  • [Cites] Curr Opin Lipidol. 2003 Jun;14(3):281-7 [12840659.001]
  • [Cites] Life Sci. 2004 Feb 27;74(15):1889-98 [14761670.001]
  • [Cites] J Pineal Res. 2004 Apr;36(3):212-6 [15009513.001]
  • [Cites] Am Heart J. 1993 Apr;125(4):958-73 [8465768.001]
  • [Cites] Am J Clin Nutr. 1995 Aug;62(2):458S-462S [7625360.001]
  • [Cites] Int J Vitam Nutr Res. 1996;66(4):386-92 [8979168.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3230-5 [9409316.001]
  • [Cites] Indian J Exp Biol. 1997 Nov;35(11):1218-23 [9567754.001]
  • [Cites] J Nutr. 1999 Oct;129(10):1885-90 [10498763.001]
  • [Cites] Lipids. 2004 Sep;39(9):843-8 [15669759.001]
  • [Cites] Kidney Int. 2005 Jun;67(6):2288-94 [15882270.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Atherosclerosis. 2005 Sep;182(1):17-28 [16115471.001]
  • [Cites] Nitric Oxide. 2006 Feb;14(1):12-20 [16198610.001]
  • [Cites] Eur J Pharmacol. 2006 Aug 14;543(1-3):151-7 [16814277.001]
  • (PMID = 20205925.001).
  • [ISSN] 1476-511X
  • [Journal-full-title] Lipids in health and disease
  • [ISO-abbreviation] Lipids Health Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Triglycerides; 31C4KY9ESH / Nitric Oxide; 8008-74-0 / Sesame Oil; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2848040
  •  go-up   go-down


41. El Aoufi S, Gendre P, Sennoune SR, Rigoard P, Maixent JM, Griene L: A high calorie diet induces type 2 diabetes in the desert sand rat (Psammomys obesus). Cell Mol Biol (Noisy-le-grand); 2007;53 Suppl:OL943-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diabetes mellitus type 2 is a major factor for cardiovascular diseases.
  • Studies have shown that obesity and high calorie diet (HCD) are associated with the development of DS-II, however the lack of naturally occurring experimental models of DS-II have impaired to directly address these issues.
  • We hypothesize that a HCD induces DS-II.
  • This study (15 months duration) is designed to determine if HCD induces DS-II in the desert sand rat (Psammomys obesus; P. obesus).
  • This study demonstrates that 40% of the animals in HCD develop DS-II at 3 months.
  • [MeSH-minor] Albuminuria / urine. Animal Nutritional Physiological Phenomena. Animals. Aorta, Thoracic / pathology. Aorta, Thoracic / ultrastructure. Atherosclerosis / etiology. Atherosclerosis / pathology. Blood Glucose / analysis. Blood Glucose / metabolism. Energy Intake. Female. Glycosuria / urine. Histocytochemistry. Insulin / blood. Ketone Bodies / urine. Lipids / blood. Male. Rodent Diseases / metabolism. Tunica Media / pathology. Tunica Media / ultrastructure

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666165.001).
  • [ISSN] 1165-158X
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Ketone Bodies; 0 / Lipids
  •  go-up   go-down


42. Guillory B, Sakwe AM, Saria M, Thompson P, Adhiambo C, Koumangoye R, Ballard B, Binhazim A, Cone C, Jahanen-Dechent W, Ochieng J: Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer. Am J Pathol; 2010 Nov;177(5):2635-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer.
  • The present analyses were done to define the role of fetuin-A (Fet) in mammary tumorigenesis using the polyoma middle T antigen (PyMT) transgenic mouse model.
  • We crossed Fet-null mice in the C57BL/6 background with PyMT mice in the same background and after a controlled breeding protocol obtained PyMT/Fet+/+, PyMT/Fet+/-, and PyMT/Fet-/- mice that were placed in control and experimental groups.
  • Whereas the control group (PyMT/Fet+/+) formed mammary tumors 90 days after birth, tumor latency was prolonged in the PyMT/Fet-/- and PyMT/Fet+/- mice.
  • The majority of the PyMT/Fet-/- mice were tumor-free at the end of the study, at approximately 40 weeks.
  • The pathology of the mammary tumors in the Fet-null mice showed extensive fibrosis, necrosis, and squamous metaplasia.
  • The preneoplastic mammary tissues of the PyMT/Fet-/- mice showed intense phopho-Smad2/3 staining relative to control tissues, indicating that transforming growth factor-β signaling is enhanced in these tissues in the absence of Fet.
  • Likewise, p19ARF and p53 were highly expressed in tumor tissues of PyMT/Fet-/- mice relative to the controls in the absence of Fet.
  • The phosphatidylinositol 3-kinase/Akt signaling pathway that we previously showed to be activated by Fet, on the other hand, was unaffected by the absence of Fet.
  • The data indicate that Fet is a powerful modulator of breast tumorigenesis in this model system and has the potential to modulate breast cancer progression in humans.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6402-9 [15374947.001]
  • [Cites] Biochem J. 1970 Apr;117(2):377-84 [5420053.001]
  • [Cites] J Biol Chem. 1974 Sep 25;249(18):5704-17 [4137945.001]
  • [Cites] Crit Rev Oncog. 1999;10(4):303-60 [10654929.001]
  • [Cites] Mol Cell Endocrinol. 2000 Jun;164(1-2):87-98 [11026561.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4951-60 [11526480.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4972-83 [11526482.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Immunol Lett. 2002 Jun 3;82(1-2):85-91 [12008039.001]
  • [Cites] Cell. 2003 May 2;113(3):301-14 [12732139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5 [12808151.001]
  • [Cites] J Clin Invest. 2003 Aug;112(3):357-66 [12897203.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Biochim Biophys Acta. 2003 Dec 1;1652(2):91-102 [14644044.001]
  • [Cites] Am J Clin Oncol. 2003 Dec;26(6):571-3 [14663374.001]
  • [Cites] Cancer Lett. 2004 Sep 30;213(2):129-38 [15327827.001]
  • [Cites] Nature. 1976 JUL 15;262(5565):226-7 [934340.001]
  • [Cites] J Biol Chem. 1990 Apr 5;265(10):5883-8 [1690716.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):C551-62 [1384344.001]
  • [Cites] Eur J Biochem. 1994 Nov 15;226(1):59-69 [7525288.001]
  • [Cites] Bioessays. 1992 Nov;14(11):749-55 [1285422.001]
  • [Cites] Prog Clin Biol Res. 1995;391:133-48 [8532712.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12755-61 [8662721.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20789-96 [8702833.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31496-503 [9395485.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):554-61 [10091729.001]
  • [Cites] J Cell Biochem. 2004 Nov 15;93(5):1020-32 [15389876.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):499-506 [15695392.001]
  • [Cites] Clin Chem. 2006 Feb;52(2):227-34 [16384891.001]
  • [Cites] Cancer Biol Ther. 2006 Feb;5(2):218-24 [16418571.001]
  • [Cites] Science. 2007 Feb 9;315(5813):840-3 [17234915.001]
  • [Cites] Nephrol Dial Transplant. 2007 Jun;22(6):1537-46 [17389622.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1809-19 [18339861.001]
  • [Cites] Exp Oncol. 2008 Jun;30(2):96-101 [18566570.001]
  • [Cites] J Clin Invest. 2009 Feb;119(2):252-66 [19147981.001]
  • [Cites] Development. 2009 Jun;136(12):2081-9 [19465598.001]
  • [Cites] Breast Cancer Res. 2009;11(1):202 [19291273.001]
  • [Cites] BMC Cancer. 2009;9:188 [19531263.001]
  • [Cites] Microbiol Mol Biol Rev. 2009 Sep;73(3):542-63, Table of Contents [19721090.001]
  • [Cites] Histol Histopathol. 2010 Apr;25(4):515-26 [20183804.001]
  • [Cites] Cell Cycle. 2006 Dec;5(23):2787-95 [17172861.001]
  • (PMID = 20847285.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / SC1 CA134018
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AHSG protein, human; 0 / Ahsg protein, mouse; 0 / Antigens, Polyomavirus Transforming; 0 / Blood Proteins; 0 / Transforming Growth Factor beta; 0 / alpha-2-HS-Glycoprotein; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase
  • [Other-IDs] NLM/ PMC2966818
  •  go-up   go-down


43. Kim SK, Park IK, Park BH, Park W, Lee HS, Kim TH, Jun JB, Bae SC, Yoo DH, Uhm WS: A case report: isolated a heavy chain monoclonal gammopathy in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin change syndrome. Int J Clin Pract Suppl; 2005 Apr;(147):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report: isolated a heavy chain monoclonal gammopathy in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin change syndrome.
  • In this case, the M-band on serum protein electrophoresis and isolated IgA heavy chain on serum immunofixation electrophoresis were demonstrated, but there was no abnormal light chain.
  • We suggest that this case may be associated with a pattern of abnormal secretion of monoclonal protein or a coincidence of a heavy chain disease in POEMS syndrome, even though the latter possibility may be very rare.
  • [MeSH-major] Heavy Chain Disease / diagnosis. POEMS Syndrome / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875614.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin alpha-Chains
  •  go-up   go-down


44. Klass DM, Bührmann K, Sauter G, Del Puppo M, Scheibner J, Fuchs M, Stange EF: Biliary lipids, cholesterol and bile synthesis: different adaptive mechanisms to dietary cholesterol in lean and obese subjects. Aliment Pharmacol Ther; 2006 Apr 1;23(7):895-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary lipids, cholesterol and bile synthesis: different adaptive mechanisms to dietary cholesterol in lean and obese subjects.
  • BACKGROUND: Increased biliary cholesterol secretion together with elevated cholesterol synthesis may predispose obese subjects to cholesterol gallstone formation.
  • AIM: To investigate whether processing of dietary cholesterol is altered in obesity, we enrolled eight lean and seven obese subjects in a double-blind crossover study.
  • METHODS: Cholesterol consumption was 300 mg/day on low and 1300 mg/day on high cholesterol diet.
  • After 3 weeks on either diet, hepatic bile was collected to determine biliary lipid secretion, and bile salt composition by high-performance liquid chromatography and cholesterol saturation index was calculated.
  • Cholesterol synthesis was measured employing mass isotopomer distribution analysis.
  • Bile acid synthesis via neutral and acidic pathway was assessed by serum levels of 7alpha-hydroxy-4-cholesten-3-one and 27-hydroxycholesterol.
  • RESULTS: Cholesterol synthesis was increased in obese compared with lean and feedback inhibited only in obese.
  • On low cholesterol diet, cholesterol secretion was doubled in obese but bile acid composition and synthesis was similar between the two groups.
  • After high cholesterol diet, cholesterol saturation index and bile secretion were unchanged.
  • In contrast to obese, lean increased bile acid synthesis only via the acidic pathway.
  • CONCLUSIONS: Dietary cholesterol appears to preferentially induce bile acid synthesis via the acidic pathway in lean, whereas cholesterol synthesis was inhibited in obese.
  • Thus, stable cholesterol saturation index may be achieved by different mechanisms.
  • [MeSH-major] Cholesterol, Dietary / administration & dosage. Obesity / metabolism
  • [MeSH-minor] Adult. Bile / chemistry. Bile Acids and Salts / analysis. Bile Acids and Salts / biosynthesis. Cholestenones / blood. Cholesterol / biosynthesis. Cholesterol / blood. Cross-Over Studies. Double-Blind Method. Energy Intake / physiology. Female. Gallbladder / physiopathology. Humans. Hydroxycholesterols / blood. Lipids / analysis. Lipids / blood. Male

  • MedlinePlus Health Information. consumer health - Obesity.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573792.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Cholestenones; 0 / Cholesterol, Dietary; 0 / Hydroxycholesterols; 0 / Lipids; 20380-11-4 / 27-hydroxycholesterol; 3862-25-7 / 7 alpha-hydroxy-4-cholesten-3-one; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


45. Yaffe K, Ackerson L, Kurella Tamura M, Le Blanc P, Kusek JW, Sehgal AR, Cohen D, Anderson C, Appel L, Desalvo K, Ojo A, Seliger S, Robinson N, Makos G, Go AS, Chronic Renal Insufficiency Cohort Investigators: Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc; 2010 Feb;58(2):338-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study.
  • OBJECTIVES: To investigate cognitive impairment in older, ethnically diverse individuals with a broad range of kidney function, to evaluate a spectrum of cognitive domains, and to determine whether the relationship between chronic kidney disease (CKD) and cognitive function is independent of demographic and clinical factors.
  • MEASUREMENTS: Estimated glomerular filtration rate (eGFR, mL/min per 1.73 m(2)) was estimated using the four-variable Modification of Diet in Renal Disease equation.
  • In addition, participants with advanced CKD (eGFR<30) were more likely to have clinically significant cognitive impairment on global cognition (adjusted odds ratio (AOR) 2.0, 95% CI=1.1-3.9), naming (AOR=1.9, 95% CI=1.0-3.3), attention (AOR=2.4, 95% CI=1.3-4.5), executive function (AOR=2.5, 95% CI=1.9-4.4), and delayed memory (AOR=1.5, 95% CI=0.9-2.6) but not on category fluency (AOR=1.1, 95% CI=0.6-2.0) than those with mild to moderate CKD (eGFR 45-59).

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroepidemiology. 2000 Nov-Dec;19(6):312-9 [11060505.001]
  • [Cites] J Clin Exp Neuropsychol. 1990 Aug;12(4):529-38 [2211975.001]
  • [Cites] N Engl J Med. 2002 Feb 14;346(7):476-83 [11844848.001]
  • [Cites] Arch Neurol. 2002 Mar;59(3):378-84 [11890840.001]
  • [Cites] Am J Kidney Dis. 2002 May;39(5):920-9 [11979335.001]
  • [Cites] Ageing Res Rev. 2002 Feb;1(1):61-77 [12039449.001]
  • [Cites] Circulation. 2003 Jan 7;107(1):87-92 [12515748.001]
  • [Cites] J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53 [12819321.001]
  • [Cites] Kidney Int. 2003 Aug;64(2):603-9 [12846756.001]
  • [Cites] Kidney Int. 2003 Aug;64(2):610-5 [12846757.001]
  • [Cites] Neurology. 2003 Jul 8;61(1):76-80 [12847160.001]
  • [Cites] Ann Intern Med. 2003 Jul 15;139(2):137-47 [12859163.001]
  • [Cites] J Am Soc Nephrol. 2004 Jul;15(7):1904-11 [15213280.001]
  • [Cites] Neurobiol Aging. 2004 Sep;25(8):1033-43 [15212828.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1863-9 [15507063.001]
  • [Cites] Neurology. 1974 Nov;24(11):1019-25 [4473151.001]
  • [Cites] J Clin Psychiatry. 1987 Aug;48(8):314-8 [3611032.001]
  • [Cites] Neurology. 1994 Apr;44(4):609-14 [8164812.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Dec;65(6):810-21 [9854955.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] J Am Geriatr Soc. 2004 Dec;52(12):2120-7 [15571554.001]
  • [Cites] Am J Kidney Dis. 2005 Jan;45(1):66-76 [15696445.001]
  • [Cites] J Am Soc Nephrol. 2005 Jul;16(7):2127-33 [15888561.001]
  • [Cites] J Am Soc Nephrol. 2005 Dec;16(12):3721-7 [16236809.001]
  • [Cites] Am J Med. 2006 Apr;119(4):327-34 [16564775.001]
  • [Cites] Dement Geriatr Cogn Disord. 2006;22(1):42-7 [16682792.001]
  • [Cites] J Int Neuropsychol Soc. 2007 Mar;13(2):344-53 [17286891.001]
  • [Cites] Neuroepidemiology. 2007;29(1-2):125-32 [17975326.001]
  • [Cites] Ann Neurol. 2008 Jun;63(6):798-802 [18496846.001]
  • [Cites] Am J Kidney Dis. 2008 Aug;52(2):227-34 [18585836.001]
  • [Cites] J Am Geriatr Soc. 2008 Aug;56(8):1449-58 [18637980.001]
  • [Cites] J Am Geriatr Soc. 2008 Nov;56(11):2082-8 [18795984.001]
  • [Cites] Nephrol Dial Transplant. 2009 Aug;24(8):2446-52 [19297357.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1061-8 [11549598.001]
  • (PMID = 20374407.001).
  • [ISSN] 1532-5415
  • [Journal-full-title] Journal of the American Geriatrics Society
  • [ISO-abbreviation] J Am Geriatr Soc
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK069406; United States / NIDDK NIH HHS / DK / DK069406-04; United States / NIDDK NIH HHS / DK / U01 DK060984; United States / NIDDK NIH HHS / DK / U01 DK061021; United States / NIMHD NIH HHS / MD / P60 MD002265; United States / NIDDK NIH HHS / DK / R01 DK069406-04; United States / NIDDK NIH HHS / DK / U01 DK060980; United States / NIA NIH HHS / AG / K24 AG031155-01; United States / NIDDK NIH HHS / DK / U01 DK60984; United States / NIDDK NIH HHS / DK / U01 DK60980; United States / NIDDK NIH HHS / DK / U01-DK060990; United States / NIA NIH HHS / AG / K24 AG031155; United States / NIA NIH HHS / AG / K24 AG 031155; United States / NIDDK NIH HHS / DK / K24 DK062234; United States / NIDDK NIH HHS / DK / U01 DK060902; United States / NIDDK NIH HHS / DK / U01 DK060990; United States / NIDDK NIH HHS / DK / U01 DK61021; United States / NIDDK NIH HHS / DK / U01 DK 60902
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS149754; NLM/ PMC2852884
  • [Investigator] Feldman HI; Landis JR; Ballard S; Chen Z; Cifelli D; Curley RM; Dattilo J; Durborow M; Durborow S; Eachus S; Fargo J; Glenn M; Hanish A; Helker C; Herlim M; Anderson AH; Joffe M; Kim H; Kimmel SE; Kumanyika S; Mohler ER 3rd; Nessel L; Parikh G; Praestgard A; Robinson N; Rosen L; Schwartz JS; Smith S; Stahl J; Teal VL; Xie D; Yang P; Townsend RR; Capolla T; Cohen D; Cuevas M; Duckworth MJ; Ford V; Gorman CM; Grunwald J; Kibe L; Leonard MB; Maguire M; McDowell S; Murphy J; Reilly M; Rosas SE; Seamon WM; Sheridan A; Teff K; Appel LJ; Anderson C; Astor B; Charleston J; Jaar B; Miller EP; Ngoh P; Venkatesh H; Young JH; Fink J; Fink W; Parsa A; Scism B; Seliger S; Weir M; Rahman M; Brooks R; Corrigan V; Kisin G; Kanthety R; Strauss L; Wright JT Jr; Schelling J; Kao P; Horowitz E; Bjaloncik J; Fallon T; Sedor JR; Shella MA; Theurer J; Thornton JD; Schreiber MJ; Coleman M; Fatica R; Frey D; Greenwald D; Halliburton S; Horner C; Markle T; Pangonis S; Paradis C; Rafey MA; Russo A; Slattery S; Soos J; Spirko R; Stelmach K; Stephens V; Ojo A; Attili A; Briesmiester J; Corbin TL; Cornish-Zirker D; Gadegbeku C; Hill N; Jamerson K; Whelton P; Go AS; Ackerson LM; Dorin P; Fernandez D; Fox R; Jensvold NG; Lo JC; Ordonez JD; Perloff R; Tan T; Thompson D; Valladares GM; Wiggins A; Wong DB; Yang JM; Hsu CY; Chertow GM; Bansal N; Gorodetskaya I; Grubbs V; Kurella M; Lo L; Shlipak MG; Yaffe K; Kusek JW; Narva AS; Faber-Langendoen K; Kiberd BA; Lee ET; Lewis J; McClellan W; Meyer T; Nathan D; Stokes JB; Taylor H; Wilson PW; Raj D; Shah V; Ridker PM; Rader DJ; DiFlorio A; Mifflin T; Morrell L; Wolfe ML; Hall P; Saunders S; Budoff M; Dailing C; Prineas R; Soliman E; Zhang ZM
  •  go-up   go-down


46. Kim H, Moody MR, Laing ST, Kee PH, Huang SL, Klegerman ME, McPherson DD: In vivo volumetric intravascular ultrasound visualization of early/inflammatory arterial atheroma using targeted echogenic immunoliposomes. Invest Radiol; 2010 Oct;45(10):685-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo volumetric intravascular ultrasound visualization of early/inflammatory arterial atheroma using targeted echogenic immunoliposomes.
  • OBJECTIVES: This study aimed to demonstrate three-dimensional (3D) visualization of early/inflammatory arterial atheroma using intravascular ultrasound (IVUS) and targeted echogenic immunoliposomes (ELIP).
  • IVUS can be used as a molecular imaging modality with the use of targeted contrast agents for atheroma detection.
  • Three-dimensional reconstruction of 2-dimensional IVUS images may provide improved atheroma visualization.
  • MATERIALS AND METHODS: Atheroma were induced in arteries of Yucatan miniswine (n = 5) by endothelial cell denudation followed by a 4-week high cholesterol diet.
  • The contralateral arteries were left intact and served as controls.
  • Anti-intercellular adhesion molecule-1 (ICAM-1) and generic gammaglobulin (IgG) conjugated ELIP were prepared.
  • Arteries were imaged using IVUS before and after ELIP injection.
  • Images were digitized, manually traced, segmented, and placed in tomographic sequence for 3D visualization.
  • Atheroma brightness enhancement was compared and reported as mean gray scale values.
  • Plaque volume was quantified both from IVUS and histologic images.
  • RESULTS: Anti-ICAM-1 ELIP highlighting of the atheroma in all arterial segments was different compared with baseline (P < 0.05).
  • There was no difference in the mean gray scale values with IgG-ELIP.
  • Arterial 3D IVUS images allowed visualization of the entire plaque distribution.
  • The highlighted plaque/atheroma volume with anti-ICAM-1 ELIP was greater than baseline (P < 0.01).
  • CONCLUSION: This study demonstrates specific highlighting of early/inflammatory atheroma in vivo using anti-ICAM-1 ELIP.
  • Three-dimensional IVUS reconstruction provides good visualization of plaque distribution in the arterial wall.
  • This novel methodology may help to detect and diagnose pathophysiologic development of all stages of atheroma formation in vivo and quantitate plaque volume for serial and long-term atherosclerotic treatment studies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2001 Jan 30;103(4):604-16 [11157729.001]
  • [Cites] J Pharm Sci. 2008 Jun;97(6):2242-9 [17894368.001]
  • [Cites] Acta Physiol Scand. 2001 Sep;173(1):35-43 [11678724.001]
  • [Cites] Anal Biochem. 2002 Jan 1;300(1):46-52 [11743691.001]
  • [Cites] J Pharm Sci. 2001 Dec;90(12):1917-26 [11745750.001]
  • [Cites] Invest Radiol. 1983 Jan-Feb;18(1):63-7 [6219966.001]
  • [Cites] Circulation. 2002 May 28;105(21):2504-11 [12034657.001]
  • [Cites] Circulation. 2002 Jun 11;105(23):2772-8 [12057993.001]
  • [Cites] Eur Heart J. 2003 Feb;24(4):329-36 [12581680.001]
  • [Cites] Invest Radiol. 2004 Feb;39(2):104-10 [14734925.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 4;43(3):453-60 [15013130.001]
  • [Cites] Br Heart J. 1982 Sep;48(3):265-71 [7104120.001]
  • [Cites] Circulation. 1985 Apr;71(4):709-16 [3971540.001]
  • [Cites] Int J Card Imaging. 1989;4(2-4):135-43 [2671166.001]
  • [Cites] J Am Coll Cardiol. 1991 Jan;17(1):79-86 [1987244.001]
  • [Cites] Arterioscler Thromb. 1992 Jan;12(1):1-5 [1731852.001]
  • [Cites] Curr Opin Oncol. 1991 Dec;3(6):1096-104 [1843112.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):801-9 [8479518.001]
  • [Cites] J Surg Res. 1996 Mar;61(2):413-5 [8656617.001]
  • [Cites] Thromb Haemost. 1996 Apr;75(4):595-9 [8743185.001]
  • [Cites] J Pharm Sci. 1996 May;85(5):486-90 [8742939.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):289-94 [8780927.001]
  • [Cites] J Drug Target. 1998;5(6):507-18 [9783681.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] J Am Coll Cardiol. 1999 Mar;33(3):867-75 [10080492.001]
  • [Cites] J Control Release. 1999 Nov 1;62(1-2):269-77 [10518660.001]
  • [Cites] J Biomech. 2007;40(2):445-50 [16488423.001]
  • [Cites] Comput Med Imaging Graph. 2007 Mar;31(2):71-80 [17215103.001]
  • [Cites] J Drug Target. 2007 Feb;15(2):109-14 [17365281.001]
  • [Cites] Ultrasound Med Biol. 2007 May;33(5):797-809 [17412486.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1768(7):1703-16 [17509522.001]
  • [Cites] J Am Coll Cardiol. 2001 Apr;37(5):1478-92 [11300468.001]
  • (PMID = 20733507.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL074002-07; United States / NCRR NIH HHS / RR / UL1 RR024148-05W1; United States / NINDS NIH HHS / NS / R01 NS047603; United States / NHLBI NIH HHS / HL / R01 HL059586; United States / NHLBI NIH HHS / HL / R01 HL059586-10; United States / NINDS NIH HHS / NS / NS-047603; United States / NHLBI NIH HHS / HL / R01 HL-059586; United States / NHLBI NIH HHS / HL / HL-074002; United States / NHLBI NIH HHS / HL / R56 HL059586; United States / NCRR NIH HHS / RR / RR024148-05W1; United States / NHLBI NIH HHS / HL / R56 HL059586-08; United States / NHLBI NIH HHS / HL / R01 HL074002; United States / NCRR NIH HHS / RR / UL1 RR024148; None / None / / R01 HL059586-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Liposomes; 126547-89-5 / Intercellular Adhesion Molecule-1
  • [Other-IDs] NLM/ NIHMS296378; NLM/ PMC3119511
  •  go-up   go-down


47. Rezen T, Juvan P, Fon Tacer K, Kuzman D, Roth A, Pompon D, Aggerbeck LP, Meyer UA, Rozman D: The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolism. BMC Genomics; 2008;9:76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deciphering complex regulation and response of these two processes to different factors is crucial also for understanding of disease development.
  • [MeSH-minor] Animals. DNA, Complementary / genetics. Gene Expression / drug effects. Homeostasis / drug effects. Liver / drug effects. Liver / metabolism. Male. Mice. Mice, Inbred C57BL. Phenobarbital / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / pharmacology


48. Shi ZS, Feng L, He X, Ishii A, Goldstine J, Vinters HV, Viñuela F: Vulnerable plaque in a Swine model of carotid atherosclerosis. AJNR Am J Neuroradiol; 2009 Mar;30(3):469-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Distal embolism and acute thrombosis due to rupture of a vulnerable atherosclerotic plaque are the common mechanisms of stroke in patients with carotid disease.
  • [MeSH-major] Carotid Artery Diseases / complications. Carotid Stenosis / etiology. Disease Models, Animal. Stroke / etiology. Swine, Miniature

  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • MedlinePlus Health Information. consumer health - Stroke.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147719.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS044378
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Wu M, Li YG: The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats. Mol Cell Biochem; 2006 Jan;282(1-2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats.
  • This study investigated the expression of CD40, CD40 ligand (CD40L) and matrix metalloproteinases (MMPs) in dietary-induced atherosclerosis in rats.
  • Wister rats were fed with high cholesterol diet (As group, n = 6) or with normal diet (N group, n = 6).
  • Blood cells that express CD40 and CD40L were sorted by flow cytometry, the MMP-2 and MMP-9 were measured by zymography method.
  • The morphological locations of MMP-2 and MMP-9 in the aorta were studied with immunohistochemistry and by microscopy.
  • The results showed that the expression of CD40, CD40L and matrix metalloproteinase were higher in As group than those in control group.
  • The MMP-2 and MMP-9 were positive in As group but negative in control group by immunohistochemistry study.
  • Our results suggest that the expression of CD40 and CD40L in the blood cells and the activities of MMP-2 and MMP-9 in plasma were higher in As group than those in Normal group, indicating that they may contribute to the formation of atherosclerosis.
  • [MeSH-major] Antigens, CD40 / metabolism. Atherosclerosis / metabolism. CD40 Ligand / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism
  • [MeSH-minor] Animals. Aorta / metabolism. Aorta / pathology. Cholesterol / blood. Cholesterol, Dietary. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Haemost. 1999 Aug;82(2):736-41 [10605776.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1828-35 [10206300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1931-6 [9050882.001]
  • [Cites] Ann Vasc Surg. 2005 Jan;19(1):130-8 [15714382.001]
  • [Cites] Stroke. 2002 Dec;33(12 ):2929-35 [12468793.001]
  • [Cites] J Interv Cardiol. 2004 Feb;17(1):27-31 [15009768.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):816-21 [12637341.001]
  • [Cites] Science. 1996 Sep 27;273(5283):1864-7 [8791592.001]
  • [Cites] Thromb J. 2004 Dec 01;2(1):12 [15574198.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):843-53 [10049948.001]
  • [Cites] Chin Med J (Engl). 2004 Dec;117(12):1825-9 [15603712.001]
  • [Cites] Am J Cardiol. 2005 Feb 15;95(4):452-6 [15695127.001]
  • [Cites] J Investig Med. 2003 Sep;51(5):295-300 [14577520.001]
  • [Cites] Toxicology. 2000 Aug 7;148(2-3):111-8 [10962129.001]
  • [Cites] Circulation. 1998 Jun 23;97(24):2382-3 [9641687.001]
  • [Cites] Circulation. 2004 May 25;109(20):2405-10 [15123527.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7458-63 [10861012.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Circ Res. 1997 Sep;81(3):448-54 [9285647.001]
  • [Cites] J Vasc Surg. 2005 Feb;41(2):321-31 [15768016.001]
  • [Cites] Blood. 2005 Jan 1;105(1):219-25 [15315967.001]
  • [Cites] Circulation. 1993 Aug;88(2):358-63 [8101771.001]
  • [Cites] Atherosclerosis. 2004 Jul;175(1):145-50 [15186959.001]
  • (PMID = 16317521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Cholesterol, Dietary; 147205-72-9 / CD40 Ligand; 97C5T2UQ7J / Cholesterol; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


51. Diniz Lde F, Caldas IS, Guedes PM, Crepalde G, de Lana M, Carneiro CM, Talvani A, Urbina JA, Bahia MT: Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother; 2010 Jul;54(7):2979-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite being unable to induce a parasitological cure, ravuconazole treatment led to significant reductions in the levels of gamma interferon expression and lesions in cardiac tissues in animals infected with the Y strain, while the level of interleukin-10 mRNA expression increased.
  • We conclude that ravuconazole has potent suppressive but not curative activity in the canine model of acute Chagas' disease, probably due to its unfavorable pharmacokinetic properties (half-life, 8.8 h).
  • The longer half-life of ravuconazole in humans (4 to 8 days) makes it a promising drug for assessment for use as chemotherapy in human Chagas' disease.
  • [MeSH-major] Chagas Disease / drug therapy. Chagas Disease / immunology. Thiazoles / therapeutic use. Triazoles / therapeutic use. Trypanocidal Agents / therapeutic use. Trypanosoma cruzi / immunology. Trypanosoma cruzi / pathogenicity
  • [MeSH-minor] Animals. Dogs. Enzyme-Linked Immunosorbent Assay. Immunoglobulin G / blood. Interferon-gamma / genetics. Interleukin-10 / genetics. Myocardium / metabolism. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Chagas Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Inst Med Trop Sao Paulo. 2002 Jan-Feb;44(1):29-37 [11896410.001]
  • [Cites] Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):111-8 [11388500.001]
  • [Cites] Acta Trop. 2002 Oct;84(1):9-17 [12387906.001]
  • [Cites] Int J Antimicrob Agents. 2003 Jan;21(1):27-38 [12507835.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Apr;47(4):1193-9 [12654646.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2003 Jul;98(5):577-91 [12973523.001]
  • [Cites] Trends Parasitol. 2003 Nov;19(11):495-501 [14580960.001]
  • [Cites] Arch Oral Biol. 2004 Jun;49(6):443-50 [15099801.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jul;48(7):2379-87 [15215084.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Nov;48(11):4286-92 [15504854.001]
  • [Cites] Bull World Health Organ. 1976;53(1):55-65 [1085667.001]
  • [Cites] Rev Soc Bras Med Trop. 1989 Jan-Mar;22(1):19-23 [2517801.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Mar;37(3):580-91 [8460926.001]
  • [Cites] Mem Inst Oswaldo Cruz. 1993 Jan-Mar;88(1):171-2 [8246754.001]
  • [Cites] Am Heart J. 1994 Jan;127(1):151-62 [8273735.001]
  • [Cites] Exp Parasitol. 1998 Jan;88(1):28-33 [9571142.001]
  • [Cites] Life Sci. 2004 Dec 24;76(6):685-97 [15567193.001]
  • [Cites] Cad Saude Publica. 2007;23 Suppl 1:S13-22 [17308713.001]
  • [Cites] Circulation. 2007 Mar 6;115(9):1109-23 [17339569.001]
  • [Cites] Rev Soc Bras Med Trop. 2006;39 Suppl 3:59-62 [17605209.001]
  • [Cites] Parasitol Res. 2008 Jul;103(2):413-21 [18454349.001]
  • [Cites] Vet Immunol Immunopathol. 2008 Jul 15;124(1-2):163-8 [18439688.001]
  • [Cites] Vet Immunol Immunopathol. 2009 Jul 15;130(1-2):43-52 [19211152.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:311-8 [19753490.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2000 May-Jun;42(3):157-61 [10887376.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Apr;45(4):1210-5 [11257036.001]
  • [Cites] Int J Parasitol. 2001 May 1;31(5-6):550-4 [11334941.001]
  • [Cites] Chemotherapy. 2002 Mar;48(1):7-9 [11901249.001]
  • (PMID = 20404124.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ER 30346; 0 / Immunoglobulin G; 0 / Thiazoles; 0 / Triazoles; 0 / Trypanocidal Agents; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2897273
  •  go-up   go-down


52. Garelnabi M, Selvarajan K, Litvinov D, Santanam N, Parthasarathy S: Dietary oxidized linoleic acid lowers triglycerides via APOA5/APOClll dependent mechanisms. Atherosclerosis; 2008 Aug;199(2):304-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary oxidized linoleic acid lowers triglycerides via APOA5/APOClll dependent mechanisms.
  • Previously we have shown that intestinal cells efficiently take up oxidized fatty acids (OxFAs) and that atherosclerosis is increased when animals are fed a high cholesterol diet in the presence of oxidized linoleic acid.
  • Interestingly, we found that in the absence of dietary cholesterol, the oxidized fatty acid fed low-density lipoprotein (LDL) receptor negative mice appeared to have lower plasma triglyceride (TG) levels as compared to animals fed oleic acid.
  • In the present study, we fed C57BL6 mice a normal mice diet supplemented with oleic acid or oxidized linoleic acid (at 18 mg/animal/day) for 2 weeks.
  • After the mice were sacrificed, we measured the plasma lipids and collected livers for the isolation of RNA.
  • The results showed that while there were no significant changes in the levels of total cholesterol and high-density lipoprotein cholesterol (HDLc), there was a significant decrease (41.14%) in the levels of plasma TG in the mice that were fed oxidized fatty acids.
  • The decreases in plasma TG levels were accompanied by significant increases (P<0.001) in the expressions of APOA5 and acetyl-CoA oxidase genes as well as a significant (P<0.04) decrease in APOClll gene expression.
  • Oxidized lipids have been suggested to be ligands for peroxisome proliferator-activated receptor (PPAR*).
  • However, there were no increases in the mRNA or protein levels of PPAR* in the oxidized linoleic acid fed animals.
  • These results suggest that oxidized fatty acids may act through an APOA5/APOClll mechanism that contributes to lowering of TG levels other than PPAR* induction.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Lipid Res. 1999 Dec;40(12):2143-57 [10588940.001]
  • [Cites] Diab Vasc Dis Res. 2006 Dec;3(3):166-71 [17160911.001]
  • [Cites] FEBS Lett. 2000 Apr 7;471(1):34-8 [10760508.001]
  • [Cites] J Lipid Res. 2000 Aug;41(8):1205-13 [10946007.001]
  • [Cites] Curr Med Res Opin. 2001;17(1):60-73 [11464448.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):44512-20 [11577099.001]
  • [Cites] J Lipid Res. 2002 Apr;43(4):557-64 [11907138.001]
  • [Cites] Hum Mol Genet. 2002 Nov 15;11(24):3031-8 [12417524.001]
  • [Cites] Hum Mol Genet. 2002 Nov 15;11(24):3039-46 [12417525.001]
  • [Cites] J Nutr. 2002 Nov;132(11):3256-62 [12421837.001]
  • [Cites] Curr Opin Lipidol. 2002 Dec;13(6):605-16 [12441884.001]
  • [Cites] Curr Opin Lipidol. 2004 Jun;15(3):239-46 [15166778.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27941-7 [15090553.001]
  • [Cites] J Am Diet Assoc. 1967 Dec;51(6):508-16 [4862187.001]
  • [Cites] Lipids. 1971 Jun;6(6):369-77 [4940501.001]
  • [Cites] J Nutr. 2007 Jan;137(1):77-83 [17182804.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):705-12 [7860752.001]
  • [Cites] Hum Genet. 1995 Apr;95(4):371-5 [7705829.001]
  • [Cites] J Atheroscler Thromb. 1996;3(2):81-9 [9226459.001]
  • [Cites] J Lipid Res. 1998 Feb;39(2):268-76 [9507987.001]
  • [Cites] Curr Opin Lipidol. 1998 Jun;9(3):211-9 [9645503.001]
  • [Cites] Ann Endocrinol (Paris). 1998 Nov;59(4):335-43 [9864555.001]
  • [Cites] J Diabetes Complications. 2005 Jan-Feb;19(1):18-25 [15642486.001]
  • [Cites] Nutrition. 2005 Apr;21(4):512-9 [15811773.001]
  • [Cites] Life Sci. 2005 Aug 5;77(12):1293-306 [15894339.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2862-9 [16200213.001]
  • [Cites] Mol Nutr Food Res. 2005 Nov;49(11):1075-82 [16270280.001]
  • [Cites] Drugs Today (Barc). 2006 Jan;42(1):39-64 [16511610.001]
  • [Cites] Curr Opin Lipidol. 2006 Apr;17(2):122-7 [16531747.001]
  • [Cites] Eur J Biochem. 1994 Jun 15;222(3):803-11 [7913034.001]
  • (PMID = 18243209.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL074239; United States / NIDDK NIH HHS / DK / DK056353; United States / NIDDK NIH HHS / DK / R01 DK056353-07; United States / NHLBI NIH HHS / HL / HL69038; United States / NIDDK NIH HHS / DK / R01 DK056353; United States / NIDDK NIH HHS / DK / DK056353-07; United States / NHLBI NIH HHS / HL / R01 HL069038-07; United States / NHLBI NIH HHS / HL / HL069038-07; United States / NHLBI NIH HHS / HL / R01 HL069038
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apoa5 protein, mouse; 0 / Apolipoprotein C-III; 0 / Apolipoproteins; 0 / Fatty Acids; 0 / PPAR alpha; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; 9KJL21T0QJ / Linoleic Acid; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS45032; NLM/ PMC2562931
  •  go-up   go-down


53. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, Mehta JL: Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis; 2008 Aug;199(2):288-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression.
  • Atherogenesis is associated with inflammation and oxidative stress.
  • Activation of renin-angiotensin system with generation of angiotensin II and type 1 receptor (AT1R) stimulation has been amply reported in atherosclerosis.
  • Since angiotensin II type 2 receptor (AT2R) activity is purported to oppose the effects of AT1R, we hypothesized that AT2R (agtr2) over-expression would inhibit atherogenesis.
  • We prepared recombinant adeno-associated virus type-2 (AAV) carrying AT2R cDNA (AAV/AT2R), and homozygous LDLR-deficient (KO) mice were given AAV/AT2R, AAV/Neo or saline.
  • All mice were placed on a high cholesterol diet.
  • After 18 weeks, AT2R was found to be over-expressed systemically in AAV/AT2R-treated mice.
  • Atherogenesis in aorta was reduced in the AAV/AT2R group by approximately 50% compared to other LDLR KO mice groups.
  • Expression of NADPH oxidase, nitrotyrosine and NF-kappaB was increased in aortic tissues of the LDLR KO mice given saline or AAV/Neo, but not in mice with AT2R upregulation.
  • Expression of endothelial nitric oxide synthase (eNOS) and heme-oxygenase-1 (HO-1) was decreased and that of the lectin-like oxidized-LDL receptor (LOX-1) increased in the LDLR KO mice, but not in the mice with AT2R over-expression.
  • Further, Akt-1 phosphorylation was reduced in the LDLR KO mice, but not in the mice with AT2R over-expression.
  • Thus, AT2R upregulation can reduce atherogenesis, possibly by modulating oxidative stress and the pro-inflammatory cascade, mediated via Akt-1.
  • Over-expression of AT2R may be an important therapeutic approach in atherosclerosis.
  • [MeSH-major] Gene Expression Regulation. Gene Expression Regulation, Neoplastic. Heme Oxygenase-1 / metabolism. Receptor, Angiotensin, Type 2 / biosynthesis. Receptor, Angiotensin, Type 2 / genetics. Scavenger Receptors, Class E / metabolism
  • [MeSH-minor] Angiotensins / metabolism. Animals. Atherosclerosis / metabolism. Mice. Mice, Inbred C57BL. Mice, Knockout. Models, Biological. Nitric Oxide Synthase Type III / metabolism. Oxidative Stress. Receptors, LDL / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096165.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Angiotensins; 0 / Olr1 protein, mouse; 0 / Receptor, Angiotensin, Type 2; 0 / Receptors, LDL; 0 / Scavenger Receptors, Class E; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.99.3 / Heme Oxygenase-1
  •  go-up   go-down


54. Hashimoto M, Hossain S, Shido O: Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity. Mol Cell Biochem; 2006 Dec;293(1-2):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity.
  • To determine the differential effects of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acid on platelet membrane fluidity under hypercholesterolemic conditions.
  • DHA and EPA were orally administered (300 mg/kg body weight(.)day) to hypercholesterolemic rats for 12 weeks.
  • Membrane fluidity, evaluated by fluorescence polarization of nonpolar 1,6-diphenyl-1,3,5-hexatriene (DPH), of the platelets of high cholesterol (HC; 1%)-fed rats decreased significantly compared with that of the platelets of normocholesterolemic rats.
  • In HC-fed rats, dietary administration of DHA, unlike that of EPA, significantly increased platelet membrane fluidity.
  • A high cholesterol diet significantly increased platelet aggregation, compared with the platelet aggregation of normocholesterolemic rats.
  • DHA administration significantly decreased the aggregation, whereas EPA had no effect.
  • Levels of EPA in the platelets of the EPA-fed HC rats and those of DHA in the platelets of the DHA-fed HC rats increased by 482 and 174%, respectively, compared with those in the platelets of the HC-fed rats.
  • The unsaturation index and the ratio of saturated to (poly)unsaturated fatty acid of the platelet membrane increased only in the DHA-fed rats.
  • The phospholipid content in platelet membranes remained unaltered in all groups, whereas the cholesterol content decreased significantly in DHA-fed rats, resulting in a significant decrease in the cholesterol/phospholipid molar ratio only in the platelet membranes of DHA-fed rats.
  • These results suggest that DHA is a more potent membrane-fluidizer than EPA in withstanding cholesterol-induced decreases in platelet membrane fluidity and a stronger ameliorative modulator of platelet hyperaggregation.
  • [MeSH-major] Blood Platelets / metabolism. Cholesterol, Dietary / metabolism. Docosahexaenoic Acids / pharmacology. Eicosapentaenoic Acid / pharmacology. Membrane Fluidity / drug effects
  • [MeSH-minor] Animals. Diphenylhexatriene / chemistry. Diphenylhexatriene / metabolism. Female. Fluorescence Polarization. Rats. Rats, Wistar. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lipids. 1994 Dec;29(12):825-9 [7854007.001]
  • [Cites] Lipids. 1999 Dec;34(12):1297-304 [10652989.001]
  • [Cites] Biochemistry. 1990 Jul 17;29(28):6626-32 [2168736.001]
  • [Cites] Lipids. 1983 Jan;18(1):42-9 [6300604.001]
  • [Cites] Biochim Biophys Acta. 1985 Sep 10;818(3):391-7 [4041445.001]
  • [Cites] J Lipid Res. 2001 Jul;42(7):1160-8 [11441145.001]
  • [Cites] J Nutr. 1999 Jan;129(1):70-6 [9915878.001]
  • [Cites] Biochim Biophys Acta. 1988 Jan 19;958(1):99-107 [2825816.001]
  • [Cites] Receptor. 1991;1(3):155-66 [1843205.001]
  • [Cites] Atherosclerosis. 1999 Nov 1;147(1):187-92 [10525140.001]
  • [Cites] Exp Gerontol. 1999 Aug;34(5):687-98 [10530793.001]
  • [Cites] Diabetes. 2004 Apr;53(4):1046-51 [15047620.001]
  • [Cites] Nature. 1962 Jun 9;194:927-9 [13871375.001]
  • [Cites] J Supramol Struct. 1978;8(4):413-30 [723275.001]
  • [Cites] J Leukoc Biol. 1993 Dec;54(6):590-8 [8245712.001]
  • [Cites] Eur Biophys J. 1991;20(1):41-52 [1935812.001]
  • [Cites] Diabetologia. 1993 Sep;36(9):850-6 [8405757.001]
  • [Cites] Hypertension. 1999 Aug;34(2):253-60 [10454450.001]
  • [Cites] Neurosci Lett. 1994 Apr 25;171(1-2):137-41 [8084475.001]
  • [Cites] Biochim Biophys Acta. 1984 Jan 27;779(1):89-137 [6229284.001]
  • [Cites] Arteriosclerosis. 1982 Mar-Apr;2(2):87-113 [7039582.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1999 May-Jun;26(5-6):426-32 [10386233.001]
  • [Cites] Lipids. 1995 Jan;30(1):35-41 [7760686.001]
  • [Cites] Am J Physiol. 1991 Feb;260(2 Pt 2):H379-85 [1899979.001]
  • [Cites] Life Sci. 1999;64(2):135-43 [10069491.001]
  • [Cites] Biochem Pharmacol. 1997 Feb 21;53(4):479-86 [9105398.001]
  • [Cites] J Lipid Res. 1986 Jan;27(1):114-20 [3958609.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Atherosclerosis. 1993 Dec;104(1-2):95-103 [8141854.001]
  • [Cites] Public Health Nutr. 2000 Mar;3(1):91-8 [10786728.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1264-9 [10982541.001]
  • [Cites] Biochemistry. 1976 Nov 2;15(22):4832-7 [990246.001]
  • [Cites] J Vasc Res. 1998 Jan-Feb;35(1):55-62 [9482696.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Sep;49(3):645-63 [8248270.001]
  • (PMID = 16933035.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cholesterol, Dietary; 1720-32-7 / Diphenylhexatriene; 25167-62-8 / Docosahexaenoic Acids; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


55. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A: Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology; 2008 Aug;48(2):646-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
  • The gene encoding the proprotein convertase subtilisin/kexin type 9 (PCSK9) is linked to familial hypercholesterolemia, as are those of the low-density lipoprotein receptor (LDLR) and apolipoprotein B.
  • PCSK9 enhances LDLR degradation, resulting in low-density lipoprotein accumulation in plasma.
  • To analyze the role of hepatic PCSK9, total and hepatocyte-specific knockout mice were generated.
  • They exhibit 42% and 27% less circulating cholesterol, respectively, showing that liver PCSK9 was responsible for two thirds of the phenotype.
  • We also demonstrated that, in liver, PCSK9 is exclusively expressed in hepatocytes, representing the main source of circulating PCSK9.
  • The data suggest that local but not circulating PCSK9 regulates cholesterol levels.
  • Although transgenic mice overexpressing high levels of liver and circulating PCSK9 led to the almost complete disappearance of the hepatic LDLR, they did not recapitulate the plasma cholesterol levels observed in LDLR-deficient mice.
  • Single LDLR or double LDLR/PCSK9 knockout mice exhibited similar cholesterol profiles, indicating that PCSK9 regulates cholesterol homeostasis exclusively through the LDLR.
  • Finally, the regenerating liver of PCSK9-deficient mice exhibited necrotic lesions, which were prevented by a high-cholesterol diet.
  • However, lipid accumulation in hepatocytes of these mice was markedly reduced under both chow and high-cholesterol diets, revealing that PCSK9 deficiency confers resistance to liver steatosis.
  • CONCLUSION: Although PCSK9 is a target for controlling hypercholesterolemia, our data indicate that upon hepatic damage, patients lacking PCSK9 could be at risk.
  • [MeSH-major] Hepatocytes / metabolism. Liver Regeneration / physiology. Receptors, LDL / metabolism. Serine Endopeptidases / metabolism
  • [MeSH-minor] Animals. Cholesterol / blood. Cholesterol, Dietary / administration & dosage. Fatty Liver / prevention & control. Hepatectomy / methods. Immunity, Innate. Lipid Metabolism / drug effects. Liver / metabolism. Liver / pathology. Mice. Mice, Knockout. Mice, Transgenic. Necrosis. Proprotein Convertases. Tissue Distribution. Up-Regulation


56. Kirvell SL, Elliott MS, Kalaria RN, Hortobágyi T, Ballard CG, Francis PT: Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study. Neurology; 2010 Nov 16;75(20):1803-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used homogenates prepared from gray matter from 2 neocortical regions (Brodmann area [BA] 9 and BA 20) and Western blotting to determine the concentrations of key components of the glutamatergic neurotransmitter system, vesicular glutamate transporter 1 (VGLUT1) and excitatory amino acid transporter EAAT2 (GLT-1), and the ubiquitous synaptic protein, synaptophysin, in 73 individuals-48 patients with cerebrovascular disease with and without dementia, 10 patients with AD, and 15 controls-in a case-control design.
  • CONCLUSIONS: These data suggest that loss of glutamatergic synapses is a feature of VaD and Alzheimer disease but the preservation of synapses, in particular glutamatergic synapses, in the frontal cortex against the temporal cortex plays a role in sustaining cognition and protecting against dementia following a stroke.
  • [MeSH-minor] Aged. Aged, 80 and over. Autopsy. Case-Control Studies. Disease Progression. Female. Frontal Lobe / metabolism. Frontal Lobe / pathology. Humans. Male. Presynaptic Terminals / metabolism. Presynaptic Terminals / pathology

  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):281-7 [10715582.001]
  • [Cites] Ann N Y Acad Sci. 2008 Nov;1144:97-112 [19076369.001]
  • [Cites] J Neurosci. 2002 Jan 1;22(1):142-55 [11756497.001]
  • [Cites] Am J Psychiatry. 2002 Jan;159(1):82-7 [11772694.001]
  • [Cites] Int J Geriatr Psychiatry. 2003 Jul;18(7):631-44 [12833308.001]
  • [Cites] Stroke. 2004 Jan;35(1):116-21 [14671247.001]
  • [Cites] J Clin Epidemiol. 1988;41(2):105-14 [3335877.001]
  • [Cites] Neurology. 1991 Apr;41(4):479-86 [2011243.001]
  • [Cites] Acta Neuropathol. 1991;82(4):239-59 [1759558.001]
  • [Cites] J Neurosci. 1998 Nov 1;18(21):8648-59 [9786972.001]
  • [Cites] J Neurol Sci. 2004 Nov 15;226(1-2):75-80 [15537525.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(2):CD003154 [15846650.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(2):CD004744 [15846730.001]
  • [Cites] Neurochem Int. 2005 Jul;47(1-2):136-42 [15936116.001]
  • [Cites] J Neurosci. 2005 Jun 29;25(26):6221-34 [15987952.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2112-7 [16360788.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Apr;32(2):103-18 [16599940.001]
  • [Cites] Neurosci Res. 2006 Aug;55(4):343-51 [16765470.001]
  • [Cites] J Neurochem. 2006 Aug;98(3):939-50 [16893425.001]
  • [Cites] Stroke. 2006 Sep;37(9):2220-41 [16917086.001]
  • [Cites] J Neurol Sci. 2007 Jun 15;257(1-2):49-55 [17306303.001]
  • [Cites] Neurobiol Aging. 2007 Nov;28(11):1664-9 [16934370.001]
  • [Cites] Ann Neurol. 2008 Jan;63(1):72-80 [18157909.001]
  • [Cites] Lancet Neurol. 2008 Mar;7(3):246-55 [18275926.001]
  • [Cites] Neurobiol Aging. 2008 Nov;29(11):1619-30 [17531353.001]
  • [Cites] Prog Neurobiol. 2001 Sep;65(1):1-105 [11369436.001]
  • (PMID = 21079182.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G0900652; United Kingdom / Medical Research Council / / G0502157; United Kingdom / Medical Research Council / / G0400074; United Kingdom / Medical Research Council / / G0500247
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SLC17A7 protein, human; 0 / Vesicular Glutamate Transport Protein 1
  • [Other-IDs] NLM/ PMC2995382
  •  go-up   go-down


57. Ballard VL, Edelberg JM: Targets for regulating angiogenesis in the ageing endothelium. Expert Opin Ther Targets; 2007 Nov;11(11):1385-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular dysfunction underlies the pathophysiology of a wide range of diseases, including atherosclerosis, diabetes and arthritis.
  • Angiogenic function is progressively impaired with increasing age and, therefore, has been linked to the increased risk of many of these diseases among older people.
  • This review examines the regulation of postnatal angiogenesis in vascular disease, the changes observed in ageing and highlights potential therapeutic targets, including endothelial progenitor cell-based strategies for the promotion of angiogenic pathways that are impaired with age.
  • [MeSH-minor] Aged. Drug Delivery Systems. Endothelium, Vascular / metabolism. Humans. Risk Factors. Up-Regulation. Vascular Diseases / drug therapy. Vascular Diseases / physiopathology

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028005.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 130
  •  go-up   go-down


58. Choi CS, Chung HK, Choi MK, Kang MH: Effects of grape pomace on the antioxidant defense system in diet-induced hypercholesterolemic rabbits. Nutr Res Pract; 2010 Apr;4(2):114-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of grape pomace on the antioxidant defense system in diet-induced hypercholesterolemic rabbits.
  • The effects of grape seeds extract and grape peels extract prepared from grape pomace on the activity of antioxidant enzymes, degree of lipid peroxidation in serum and liver tissue were investigated in rabbits fed on high cholesterol diet.
  • New Zealand white rabbits were divided as follows ;.
  • 1) NOR (normal group);.
  • 2) CHOL (cholesterol group);.
  • 3) GSH (cholesterol + grape seed extract group);.
  • 4) GPE (cholesterol + grape peel extract);.
  • 5) GSP (cholesterol + grape seed powder);.
  • 6) GPP (cholesterol + grape peel powder);.
  • 7) GE (cholesterol + grape seed and peel extract);.
  • 8) GP (cholesterol + grape seed and peel powder).
  • Eight groups of rabbits were studied for 8 weeks.
  • At the end of the experimental period, rabbits were sacrificed and the liver tissue were removed.
  • Then, GSH, GPx, GST, CAT and MDA in the liver were measured.
  • In liver tissues, total glutathione contents (GSH), glutathione peroxidase (GPx) and catalase (CAT) activity, which was significantly higher by grape seed extract supplementation.
  • The level of malondialdehyde (MDA) was lower in the serum of rabbits fed grape seed extract or grape peel powder plus cholesterol than in the serum of rabbits fed cholesterol alone.
  • It is therefore likely that grape seed extract prepared from grape pomace functioned as antioxidants in vivo, negating the effects of the oxidative stress induced by 1% cholesterol diet.
  • The grape seed extract was found effective in converting the oxidized glutathione into reduced glutathione, and in removing H(2)O(2) that is created by oxidative stress.
  • The grape peel powder was found to have small influence on reduced glutathione content, CAT and GPX activity, but it increased GST activity in liver tissues, resulting in promoting the combination of lipid peroxide and glutathione (GSH), and further, lowering the formation of lipid peroxide in the serum.
  • Therefore, grape pomace (grape seed extract and grape peel powder) supplementation is considered to activate the antioxidant enzyme system and prevent damage with hypercholesterolemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 1978 Oct 15;90(2):705-25 [31824.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Alcohol Alcohol. 1990;25(2-3):157-76 [2198032.001]
  • [Cites] Angiology. 1989 Sep;40(9):835-43 [2764311.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7725-9 [3478721.001]
  • [Cites] Lancet. 1993 Oct 23;342(8878):1007-11 [8105262.001]
  • [Cites] Biochem Pharmacol. 1993 Feb 9;45(3):753-62 [8442772.001]
  • [Cites] Biochem Pharmacol. 1996 Oct 11;52(7):1033-9 [8831722.001]
  • [Cites] Atherosclerosis. 1999 Jan;142(1):139-49 [9920515.001]
  • [Cites] J Agric Food Chem. 1999 May;47(5):1892-7 [10552467.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1090-101 [12031894.001]
  • [Cites] J Agric Food Chem. 2002 Oct 9;50(21):6217-21 [12358505.001]
  • [Cites] J Nutr. 2003 Oct;133(10):3195-9 [14519810.001]
  • [Cites] Lipids. 2006 Feb;41(2):133-9 [17707979.001]
  • [Cites] Clin Chim Acta. 1977 Oct 15;80(2):355-60 [562242.001]
  • [Cites] Biochim Biophys Acta. 1978 Mar 14;523(1):27-36 [629991.001]
  • [Cites] Methods Enzymol. 1978;52:302-10 [672633.001]
  • [Cites] Life Sci. 1977 Nov 1;21(9):1277-86 [927029.001]
  • [Cites] Methods Enzymol. 1990;186:1-85 [2172697.001]
  • [Cites] Free Radic Biol Med. 1990;9(2):155-68 [2227530.001]
  • [Cites] Free Radic Biol Med. 1988;4(2):99-106 [3278952.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Physiol Rev. 1994 Jan;74(1):139-62 [8295932.001]
  • [Cites] Am Heart J. 1993 Apr;125(4):958-73 [8465768.001]
  • [Cites] Biol Pharm Bull. 1995 Oct;18(10):1347-51 [8593434.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):139-40 [9103273.001]
  • [Cites] J Agric Food Chem. 1999 Mar;47(3):1083-91 [10552420.001]
  • [Cites] Life Sci. 2001 Nov 2;69(24):2855-66 [11720089.001]
  • [Cites] Clin Chim Acta. 2002 Mar;317(1-2):181-90 [11814474.001]
  • [Cites] J Agric Food Chem. 2002 Aug 14;50(17):4983-8 [12166994.001]
  • [Cites] Clin Chim Acta. 2003 Feb;328(1-2):155-61 [12559612.001]
  • [Cites] Atherosclerosis. 2003 Apr;167(2):347-53 [12818418.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1978;46:383-414 [345769.001]
  • (PMID = 20461199.001).
  • [ISSN] 2005-6168
  • [Journal-full-title] Nutrition research and practice
  • [ISO-abbreviation] Nutr Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2867221
  • [Keywords] NOTNLM ; Glutathione / glutathione peroxidase / grape pomace / malondialdehyde / rabbit
  •  go-up   go-down


59. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D: Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry; 2010 Feb;81(2):160-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study.
  • BACKGROUND: Cognitive decline is common in Parkinson's disease (PD).
  • [MeSH-major] Cholinergic Antagonists / therapeutic use. Cognition Disorders / epidemiology. Parkinson Disease / drug therapy. Parkinson Disease / epidemiology
  • [MeSH-minor] Aged. Antidepressive Agents / adverse effects. Brain / physiopathology. Cohort Studies. Depressive Disorder, Major / drug therapy. Depressive Disorder, Major / epidemiology. Female. Follow-Up Studies. Humans. Male. Neuropsychological Tests. Prevalence. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):129 [20145024.001]
  • (PMID = 19770163.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Cholinergic Antagonists
  •  go-up   go-down


60. Osto E, Matter CM, Kouroedov A, Malinski T, Bachschmid M, Camici GG, Kilic U, Stallmach T, Boren J, Iliceto S, Lüscher TF, Cosentino F: c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation; 2008 Nov 11;118(20):2073-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Male JNK2 knockout (JNK2(-/-)) and wild-type (WT) mice (8 weeks old) were fed either a high-cholesterol diet (HCD; 1.25% total cholesterol) or a normal diet for 14 weeks.
  • Aortic lysates of WT mice fed a HCD showed an increase in JNK phosphorylation compared with WT mice fed a normal diet (P<0.05).
  • Endothelium-dependent relaxations to acetylcholine were impaired in WT HCD mice (P<0.05 versus WT normal diet).
  • In contrast, JNK2(-/-) HCD mice did not exhibit endothelial dysfunction (96+/-5% maximal relaxation in response to acetylcholine; P<0.05 versus WT HCD).
  • In parallel, endothelial NO synthase expression was upregulated only in JNK2(-/-) HCD animals, whereas the expression of antioxidant defense systems such as extracellular superoxide dismutase and manganese superoxide dismutase was decreased in WT but not in JNK2(-/-) HCD mice.
  • In contrast to JNK2(-/-) mice, WT HCD displayed an increase in O(2)(-) and ONOO(-) concentrations as well as nitrotyrosine staining and peroxidation.
  • Thus, JNK2 may provide a novel target for prevention of vascular disease and atherosclerosis.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955669.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Grant] United States / PHS HHS / / 0418061
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Free Radical Scavengers; 0 / Lipids; 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 2.7.1.24 / Mitogen-Activated Protein Kinase 9; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


61. Berriel Díaz M, Eiden S, Daniel C, Steinbrück A, Schmidt I: Effects of periodic intake of a high-caloric diet on body mass and leptin resistance. Physiol Behav; 2006 Jun 15;88(1-2):191-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of periodic intake of a high-caloric diet on body mass and leptin resistance.
  • The effects of continuous or intermittent access to a high-caloric (HC) diet, always offered in addition to standard chow, on body mass and leptin resistance were analyzed in female C57BL/6J mice.
  • Susceptibility for diet-induced obesity (DIO) was apparent from the marked preference for the HC diet.
  • Continuous HC diet feeding of mice at 4 weeks of age induced leptin resistance within 2 weeks and massive gains in body mass, although with increasing inter-individual variability in the inbred strain considered to be isogenic.
  • In adult mice receiving HC diet for the first time, leptin treatment failed to reduce energy intake first after 11 days of HC diet feeding, but became effective again within 3 days after HC diet withdrawal.
  • In mice with a history of several preceding periods of access to the HC diet totalling >30 days, supplementary HC diet abolished the anorectic effect of leptin treatment within only 3 days and it reappeared not earlier than 11 days after HC diet withdrawal.
  • Thus, in the investigated DIO-prone mouse strain both, the loss of responsiveness to leptin under HC diet and its recovery after HC diet withdrawal strongly depended on the dietary history.
  • Recovery from leptin resistance during periods of intermittent chow feeding was associated with losses of body mass that did not completely compensate for the obesity-inducing effect of the preceding HC diet.
  • [MeSH-major] Dietary Fats / administration & dosage. Eating / physiology. Leptin / administration & dosage. Periodicity
  • [MeSH-minor] Age Factors. Animals. Behavior, Animal. Body Mass Index. Body Weight / physiology. Drug Resistance. Energy Intake / physiology. Female. Mice. Mice, Inbred C57BL

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687158.001).
  • [ISSN] 0031-9384
  • [Journal-full-title] Physiology & behavior
  • [ISO-abbreviation] Physiol. Behav.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin
  •  go-up   go-down


62. Suanarunsawat T, Devakul Na Ayutthaya W, Songsak T, Thirawarapan S, Poungshompoo S: Antioxidant Activity and Lipid-Lowering Effect of Essential Oils Extracted from Ocimum sanctum L. Leaves in Rats Fed with a High Cholesterol Diet. J Clin Biochem Nutr; 2010 Jan;46(1):52-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidant Activity and Lipid-Lowering Effect of Essential Oils Extracted from Ocimum sanctum L. Leaves in Rats Fed with a High Cholesterol Diet.
  • It has been reported that Ocimum sanctum L. (OS) leaves decrease serum lipid profile in normal and diabetic animals.
  • No experimental evidences support the anti-hyperlipidemic and antioxidative actions against hypercholesterolemia.
  • Moreover the identity of the specific chemical ingredients in OS leaves responsible for these pharmacological effects are unknown.
  • Since OS leaves are rich in essential oil (EO).
  • Therefore the present study was conducted to investigate the anti-hyperlipidemic and antioxidative activities of EO extracted from OS leaves in rats fed with high cholesterol (HC) diet.
  • EO was extracted by the hydrodistillation method and the chemical constituents were then identified by Gas Chromatography-Mass Spectrometry.
  • The experiment was performed in Male Wistar rats fed with 2.5 g%(w/w) of cholesterol diet for seven weeks.
  • During the last 3 weeks, rats were daily fed with EO.
  • The results showed that phenyl propanoid compounds including eugenol and methyl eugenol were the major constituents of EO.
  • EO suppressed the high serum lipid profile and atherogenic index as well as serum lactate dehydrogenase and creatine kinase MB subunit without significant effect on high serum levels of aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase in rats fed with HC diet.
  • In addition, EO was found to decrease the high levels of thiobarbituric acid reactive substances (TBARS), glutathione peroxidase (GPx) and superoxide dismutase (SOD) without impacting catalase (CAT) in the cardiac tissue while in the liver, it decreased high level of TBARS without significantly effecting GPx, SOD and CAT.
  • Histopathological results confirmed that EO preserved the myocardial tissue.
  • It can be concluded that EO extracted from OS leaves has lipid-lowering and antioxidative effects that protect the heart against hypercholesterolemia.
  • Eugenol that is contained in EO likely contribute to these pharmacological effects.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Biochem Nutr. 2007 Jul;41(1):27-31 [18392104.001]
  • [Cites] J Agric Food Chem. 2006 Jun 14;54(12):4378-82 [16756370.001]
  • [Cites] Mol Cell Biochem. 2006 Feb;283(1-2):115-22 [16444593.001]
  • [Cites] Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S [15640486.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Circulation. 1999 Feb 2;99(4):591-5 [9927409.001]
  • [Cites] J Agric Food Chem. 2000 Sep;48(9):3801-5 [10995274.001]
  • [Cites] Adv Exp Med Biol. 1995;369:39-48 [7598015.001]
  • [Cites] Lancet. 1987 Apr 11;1(8537):821-4 [2882231.001]
  • [Cites] Med Hypotheses. 1985 Jan;16(1):7-15 [4000000.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] J Lab Clin Med. 1975 Feb;85(2):337-41 [803541.001]
  • [Cites] Redox Rep. 2004;9(2):105-10 [15231065.001]
  • [Cites] J Am Diet Assoc. 1997 Jul;97(7 Suppl):S31-41 [9216565.001]
  • (PMID = 20104265.001).
  • [ISSN] 1880-5086
  • [Journal-full-title] Journal of clinical biochemistry and nutrition
  • [ISO-abbreviation] J Clin Biochem Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2803133
  • [Keywords] NOTNLM ; Ocimum sanctum L. / antioxidant / cardiac function / high fat diet / liver function
  •  go-up   go-down


63. Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D: Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord; 2008;25(6):559-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
  • BACKGROUND: The aim of this study was to explore the relationship between cerebrospinal fluid biomarkers and neuropsychiatric symptoms in people with Alzheimer's disease.
  • Psychosis, agitation, apathy and depression were assessed using standardised measures in 32 patients with mild Alzheimer's disease.
  • CONCLUSION: Our finding suggests that apathy is associated with the level of neurofibrillary tangles in people with mild Alzheimer's disease.
  • [MeSH-major] Alzheimer Disease / cerebrospinal fluid. Biomarkers / cerebrospinal fluid. Depression / cerebrospinal fluid. Psychotic Disorders / cerebrospinal fluid. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [ErratumIn] Dement Geriatr Cogn Disord. 2008;26(3):290. Jones, Emma [added]
  • (PMID = 18536520.001).
  • [ISSN] 1421-9824
  • [Journal-full-title] Dementia and geriatric cognitive disorders
  • [ISO-abbreviation] Dement Geriatr Cogn Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Biomarkers; 0 / Peptide Fragments; 0 / amyloid beta-protein (1-42); 0 / tau Proteins
  •  go-up   go-down


64. Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M: Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol; 2005 Sep-Oct;23(5):724
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Dermatomyositis / complications. Immunosuppressive Agents / administration & dosage. Lung Diseases, Interstitial / drug therapy. Polymyositis / complications


65. Chen CL, Huang SS, Huang JS: Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors. J Cell Physiol; 2008 Apr;215(1):223-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results indicate that high plasma cholesterol levels may contribute to the pathogenesis of certain diseases (e.g., atherosclerosis) by suppressing TGF-beta responsiveness.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. LOVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17972267.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R41 DK078438; United States / NHLBI NIH HHS / HL / R41 HL087463; United States / NIAMS NIH HHS / AR / AR052578; United States / NCI NIH HHS / CA / CA38808
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Iodine Radioisotopes; 0 / Lipoproteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta; 97C5T2UQ7J / Cholesterol; 9LHU78OQFD / Lovastatin; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


66. Anderson DR, Tsutsui JM, Xie F, Radio SJ, Porter TR: The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque. Cardiovasc Res; 2007 Feb 1;73(3):597-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque.
  • OBJECTIVE: To determine whether serum complement C3 mediates adherence of albumin-encapsulated microbubbles to vascular endothelium in the development of atherosclerotic plaques.
  • METHODS: Adherence of microbubbles to aortic endothelium was examined with scanning electron microscopy following intravenous injection of 20% intralipid in wild-type mice, genetic complement-deficient mice (C3-/-), and in pharmacologic C3-depleted wild-type mice.
  • In a second experimental model, atherosclerostic plaque was induced in apolipoprotein E-deficient mice (apoE-/-), and adherence of microbubbles to atherosclerotic plaques was evaluated using fluorescent microscopy of fluorescein isothiocynate-conjugated microbubbles.
  • Finally, imaging of aortas was performed in eight rats (four JCR:LA-cp atherosclerosis-prone rats on high cholesterol diets; four controls) following intravenous albumin microbubble injections (PESDA) to determine whether microbubble adherence to the endothelium could be detected with low mechanical index pulse sequence schemes.
  • RESULTS: Scanning electron microscopy confirmed the adherence of microbubbles to the endothelial cells of the aorta in wild-type mice following induction of hypertriglyceridemia but not in C3-depleted mice.
  • Microbubble adherence to the endothelial surface of atherosclerotic plaque was confirmed in all apoE-/- mice (median 172 microbubbles/field; compared to a median of 3 microbubbles/field in cobra venom factor-treated apoE-/- mice; p < 0.001).
  • Low mechanical index ultrasound imaging detected microbubble adherence in all JCR atherosclerosis prone rats even in the absence of vasomotor or phenotypical evidence of endothelial dysfunction.
  • The numbers of adherent microbubbles correlated with serum triglyceride levels, and were seen in conjunction with increased endothelial nitric oxide synthase activity.
  • CONCLUSIONS: Complement C3 binds to albumin-encapsulated microbubbles and mediates microbubble adherence to vascular endothelium both early and late in the atherosclerotic process.
  • [MeSH-major] Albumins / metabolism. Atherosclerosis / metabolism. Complement C3 / metabolism. Endothelium, Vascular / metabolism. Hypertriglyceridemia / metabolism
  • [MeSH-minor] Animals. Aorta. Apolipoproteins E / deficiency. Cobra Venoms / pharmacology. Female. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Mice. Mice, Inbred C57BL. Mice, Knockout. Microbubbles. Microscopy, Confocal. Microscopy, Electron, Scanning. Rats. Tissue Adhesions. Triglycerides / blood


67. van der Veen JN, Havinga R, Bloks VW, Groen AK, Kuipers F: Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha. J Lipid Res; 2007 Feb;48(2):337-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha.
  • The oxysterol-activated nuclear receptor liver X receptor alpha (LXRalpha) has been implicated in the control of both cholesterol and fatty acid metabolism.
  • In this study, we have evaluated the effects of excess dietary cholesterol on hepatic cholesterol metabolism, lipogenesis, and VLDL production in homozygous (Lxralpha(-/-)), heterozygous (Lxralpha(+/-)), and wild-type mice.
  • Mice were fed either chow or a cholesterol-enriched diet (1%, w/w) for 2 weeks.
  • On the high-cholesterol diet, fractional cholesterol absorption was higher in Lxralpha(-/-) mice than in controls, leading to delivery of more dietary cholesterol to the liver.
  • Lxralpha(-/-) mice were not able to induce expression of hepatic Abcg5/Abcg8, and massive accumulation of free cholesterol and cholesteryl esters (CEs) occurred.
  • Interestingly, despite the inability to upregulate Abcg5/Abcg8, the highly increased hepatic free cholesterol content did stimulate biliary cholesterol output in Lxralpha(-/-) mice.
  • Hepatic cholesterol accumulation was accompanied by decreased hepatic expression of lipogenic genes, probably caused by impaired sterol-regulatory element binding protein 1c processing, lower hepatic triglyceride (TG) contents, strongly reduced plasma TG concentrations (-90%), and reduced VLDL-TG production rates (-60%) in Lxralpha(-/-) mice.
  • VLDL particles were smaller and CE-enriched under these conditions.
  • Lxralpha deficiency did not affect VLDL formation under chow-fed conditions.
  • Hepatic stearyl coenzyme A desaturase 1 expression was decreased dramatically in Lxralpha(-/-) mice and did not respond to cholesterol feeding, but fatty acid profiles of liver and VLDL were only slightly different between Lxralpha(-/-) and wild-type mice.
  • Our data indicate that displacement of TGs by CEs during the VLDL assembly process underlies hypotriglyceridemia in cholesterol-fed Lxralpha(-/-) mice.
  • [MeSH-major] Cholesterol, Dietary / pharmacology. DNA-Binding Proteins / deficiency. Lipoproteins, VLDL / biosynthesis. Liver / drug effects. Liver / metabolism. Receptors, Cytoplasmic and Nuclear / deficiency. Triglycerides / biosynthesis
  • [MeSH-minor] Animals. Bile Acids and Salts / biosynthesis. Fatty Acids / metabolism. Female. Male. Mice. Mice, Knockout. Orphan Nuclear Receptors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088263.001).
  • [ISSN] 0022-2275
  • [Journal-full-title] Journal of lipid research
  • [ISO-abbreviation] J. Lipid Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Cholesterol, Dietary; 0 / DNA-Binding Proteins; 0 / Fatty Acids; 0 / Lipoproteins, VLDL; 0 / Orphan Nuclear Receptors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Triglycerides; 0 / liver X receptor; 0 / very low density lipoprotein triglyceride
  •  go-up   go-down


68. Ballard PL, Truog WE, Merrill JD, Gow A, Posencheg M, Golombek SG, Parton LA, Luan X, Cnaan A, Ballard RA: Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants. Pediatrics; 2008 Mar;121(3):555-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants.
  • PATIENTS AND METHODS: As part of the Nitric Oxide Chronic Lung Disease Trial, we collected blood samples at specified intervals from a subpopulation of 100 infants of <1250 g birth weight who received inhaled nitric oxide (20 ppm, weaned to 2 ppm) or placebo gas for 24 days.
  • RESULTS: The demographic characteristics and primary outcome for the infants were representative of the entire group of infants who were in the Nitric Oxide Chronic Lung Disease Trial.
  • For all infants at baseline, before receiving study gas, the concentration of total protein was inversely correlated with the respiratory severity score, and plasma carbonyl was positively correlated with severity score, supporting an association between oxidative stress and severity of lung disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310205.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00064; United States / NCRR NIH HHS / RR / M01 RR00080; United States / NCRR NIH HHS / RR / M01 RR00084; United States / NCRR NIH HHS / RR / M01 RR001271; United States / NCRR NIH HHS / RR / M01 RR00240; United States / NCRR NIH HHS / RR / M01 RR00425; United States / NICHD NIH HHS / HD / P30 HD26979; United States / NHLBI NIH HHS / HL / P50 HL56401; United States / NHLBI NIH HHS / HL / U01 HL62514
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine
  •  go-up   go-down


69. Huang H, Liu T, Rose JL, Stevens RL, Hoyt DG: Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet. J Inflamm (Lond); 2007;4:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It was hypothesized that a pro-atherogenic, high saturated fat and cholesterol diet (HCD) would increase the inflammatory response to E. coli endotoxin (LPS) and increase its concentration in plasma after administration to mice.
  • METHODS: C57Bl/6 mice were fed a HCD or a control diet (CD) for 4 weeks, and then treated with saline, 0.5, 1 or 2 mg LPS/kg, ip.
  • Liver injury (alanine:2-oxoglutarate aminotransferase and aspartate aminotransferase, collagen staining), circulating cytokines (tumor necrosis factor-alpha, interleukin-6 and interferon-gamma), factors that can bind LPS (serum amyloid A, apolipoprotein A1, LPS binding protein, and CD14), and plasma levels of LPS were measured.
  • RESULTS: Two mg LPS/kg killed 100% of mice fed HCD within 5 d, while no mice fed CD died.
  • HCD increased plasma alanine:2-oxoglutarate aminotransferase and aspartate aminotransferase, and the enzymes were increased more by LPS in HCD than CD mice.
  • Induction of plasma tumor necrosis factor-alpha, interleukin-6, and interferon-gamma by LPS was greater with HCD than CD.
  • Hepatic VCAM-1 and iNOS protein and mRNA were induced by LPS more in mice fed HCD than CD.
  • Tyrosine phosphorylation of signal transducer and activator of transcription-1 caused by LPS was prolonged in HCD compared with CD mice.
  • Despite the hepatic effects of HCD, diet had no effect on the LPS plasma concentration-time profile.
  • HCD alone did not affect circulating levels of plasma apolipoprotein A1 or LPS binding protein.
  • However, plasma concentrations of serum amyloid A and CD14, and hepatic toll-like receptor-4 mRNA were increased in mice fed HCD.
  • CONCLUSION: HCD increased the sensitivity of mice to LPS without affecting its plasma level.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2004 Sep 29;340(1):99-109 [15556298.001]
  • [Cites] Am J Clin Pathol. 1960 Oct;34:381-98 [13713438.001]
  • [Cites] Shock. 2006 Sep;26(3):311-5 [16912658.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):342-74 [16968945.001]
  • [Cites] Intensive Care Med. 2007 Jan;33(1):13-24 [17093985.001]
  • [Cites] J Med. 1979;10(1-2):35-48 [290725.001]
  • [Cites] Infect Immun. 1978 Aug;21(2):448-57 [689731.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Shock. 2001 Jul;16(1):44-50 [11442315.001]
  • [Cites] Trends Cell Biol. 2001 Sep;11(9):372-7 [11514191.001]
  • [Cites] Circulation. 2002 Mar 12;105(10):1158-61 [11889007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8043-7 [12060750.001]
  • [Cites] J Endotoxin Res. 2003;9(2):113-8 [12803885.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42774-84 [12923166.001]
  • [Cites] Proteomics. 2004 Feb;4(2):514-23 [14760724.001]
  • [Cites] Mol Pharmacol. 2004 Aug;66(2):302-11 [15266021.001]
  • [Cites] J Endotoxin Res. 2005;11(4):225-9 [16176659.001]
  • [Cites] J Interferon Cytokine Res. 2006 Feb;26(2):101-7 [16487030.001]
  • [Cites] FASEB J. 2006 Oct;20(12):2162-4 [16935938.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4880-7 [16982930.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):971-80 [17096066.001]
  • [Cites] Circ Res. 2007 Jun 8;100(11):1589-96 [17478729.001]
  • [Cites] J Med. 1979;10(1-2):49-64 [314965.001]
  • [Cites] Infect Immun. 1979 Nov;26(2):658-67 [317596.001]
  • [Cites] J Nutr. 1977 Jul;107(7):1340-8 [874577.001]
  • [Cites] J Nutr. 1992 Feb;122(2):294-305 [1732470.001]
  • [Cites] Infect Immun. 1990 Apr;58(4):935-7 [2180825.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):696-702 [2394827.001]
  • [Cites] Ann N Y Acad Sci. 1989;557:310-5; discussion 315-6 [2472091.001]
  • [Cites] Prog Clin Biol Res. 1985;189:181-96 [4048203.001]
  • [Cites] Infect Immun. 1973 Jul;8(1):105-9 [4198100.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1779-84 [7684434.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Feb;272(2):604-11 [7853173.001]
  • [Cites] Immunol Today. 1994 Feb;15(2):81-8 [8155266.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12040-4 [8265667.001]
  • [Cites] J Leukoc Biol. 1996 Apr;59(4):489-93 [8613694.001]
  • [Cites] Circ Res. 1997 Aug;81(2):274-81 [9242189.001]
  • [Cites] Am J Reprod Immunol. 1997 Jul;38(1):46-54 [9266010.001]
  • [Cites] Circ Res. 1997 Dec;81(6):911-21 [9400371.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Jun;161(6):1781-5 [10852744.001]
  • [Cites] Atherosclerosis. 2001 Jan;154(1):113-21 [11137089.001]
  • [Cites] Pathobiology. 1991;59(6):378-83 [1930690.001]
  • [Cites] Adv Surg. 1990;23:21-56 [2403458.001]
  • [Cites] Immunobiology. 1987 May;174(3):253-65 [3623605.001]
  • [Cites] Clin Exp Immunol. 1995 Aug;101(2):357-61 [7648721.001]
  • [Cites] Infect Immun. 1995 May;63(5):2041-6 [7729918.001]
  • [Cites] Eur Heart J. 1993 Dec;14 Suppl K:125-9 [8131781.001]
  • [Cites] Arch Surg. 1994 Feb;129(2):193-7 [8304830.001]
  • [Cites] J Exp Med. 1996 Nov 1;184(5):1601-8 [8920850.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):C1506-15 [9374635.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2776-81 [10559025.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1819-24 [11106554.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):485-93 [11489942.001]
  • [Cites] Circulation. 2001 Dec 18;104(25):3103-8 [11748108.001]
  • [Cites] J Surg Res. 2002 Jul;106(1):188-95 [12127825.001]
  • [Cites] Clin Microbiol Rev. 2003 Jul;16(3):379-414 [12857774.001]
  • [Cites] J Endotoxin Res. 2005;11(2):97-103 [15949136.001]
  • (PMID = 17997851.001).
  • [ISSN] 1476-9255
  • [Journal-full-title] Journal of inflammation (London, England)
  • [ISO-abbreviation] J Inflamm (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2186306
  •  go-up   go-down


70. Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, Anderson RF, Shinde SS, Wilson WR, Denny WA: Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. J Med Chem; 2008 Nov 13;51(21):6853-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUC req) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pharm (Weinheim). 2007 May;340(5):258-63 [17464965.001]
  • [Cites] Bioorg Med Chem. 2006 Oct 15;14(20):6917-23 [16843668.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S61-3 [17848298.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):560-71 [17869669.001]
  • [Cites] J Am Chem Soc. 2007 Oct 24;129(42):12870-7 [17900117.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):231-4 [17551816.001]
  • [Cites] J Med Chem. 2007 Dec 13;50(25):6392-404 [18001018.001]
  • [Cites] J Med Chem. 2007 Dec 27;50(26):6654-64 [18052317.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):257-65 [18172318.001]
  • [Cites] Curr Clin Pharmacol. 2006 Jan;1(1):71-9 [18666379.001]
  • [Cites] J Clin Oncol. 2010 Jun 20;28(18):2989-95 [20479425.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(3):213-20 [9923551.001]
  • [Cites] Protein Sci. 1999 Feb;8(2):298-306 [10048323.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):79-87 [15625362.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 1;60(7):969-78 [10974206.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Dec;9(12):2889-901 [11093359.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5248-53 [12234992.001]
  • [Cites] J Med Chem. 2003 Jan 2;46(1):169-82 [12502371.001]
  • [Cites] J Am Chem Soc. 2003 Jan 22;125(3):748-56 [12526674.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5970-7 [14522924.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2054-61 [15026343.001]
  • [Cites] Arch Pharm (Weinheim). 2004 May;337(5):247-58 [15095418.001]
  • [Cites] Arch Pharm (Weinheim). 2004 May;337(5):271-80 [15095420.001]
  • [Cites] Radiat Res. 2004 Jun;161(6):656-66 [15161354.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):437-47 [15170446.001]
  • [Cites] J Am Chem Soc. 2004 Jun 30;126(25):7865-74 [15212534.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):977-81 [2703405.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7745-9 [2253217.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):457-61 [1995531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(4):689-92 [1544838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(4):701-5 [1544841.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4473-7 [1643639.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1163-70 [8512801.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4633-6 [8402639.001]
  • [Cites] In Vivo. 1994 Nov-Dec;8(5):691-702 [7727714.001]
  • [Cites] J Med Chem. 1995 May 12;38(10):1786-92 [7752202.001]
  • [Cites] J Med Chem. 1995 Oct 27;38(22):4488-94 [7473576.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):952-60 [8611431.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S32-8 [8763842.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(4):361-6 [9025778.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2922-8 [9230202.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8411-6 [9237990.001]
  • [Cites] Radiat Oncol Investig. 1997;5(5):213-9 [9372543.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Lancet. 1998 May;351 Suppl 2:SII9-16 [9606361.001]
  • [Cites] Anticancer Drug Des. 1998 Sep;13(6):541-73 [9755718.001]
  • [Cites] Anticancer Drug Des. 1998 Sep;13(6):575-92 [9755719.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):149-56 [9783886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):641-9 [9806526.001]
  • [Cites] J Med Chem. 2005 Feb 24;48(4):1079-87 [15715475.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2098-104 [16648512.001]
  • [Cites] Bioorg Med Chem Lett. 2006 Aug 15;16(16):4209-13 [16777409.001]
  • [Cites] J Org Chem. 2006 Aug 18;71(17):6530-5 [16901140.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1118-28 [16912264.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1358-66 [17499003.001]
  • (PMID = 18847185.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082566-080001; United States / NCI NIH HHS / CA / P01 CA082566; United States / NCI NIH HHS / CA / P01 CA082566-080001
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Heterocyclic Compounds, 3-Ring; 0 / Oxides; 0 / Triazines
  • [Other-IDs] NLM/ NIHMS91083; NLM/ PMC2690574
  •  go-up   go-down


71. Uchida M, Ishii I, Inoue C, Akisato Y, Watanabe K, Hosoyama S, Toida T, Ariyoshi N, Kitada M: Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet. J Atheroscler Thromb; 2010 Sep 30;17(9):980-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet.
  • AIM: Kefiran is an exopolysaccharide produced by Lactobacillus kefiranofaciens, and has been proposed to have many health-promoting properties.
  • We investigated the antiatherogenic effect of kefiran on rabbits fed a high-cholesterol diet.
  • METHODS: Male New Zealand White rabbits were fed a 0.5% cholesterol diet without (control group, n = 7) or with kefiran (kefiran group, n = 8) for eight weeks.
  • The aorta was analyzed by histochemistry and atherosclerotic lesions were quantified.
  • Lipids and sugars in serum were measured.
  • Foam cell formation of RAW264.7 by βVLDL derived from both groups of rabbits was also investigated.
  • RESULTS: Cholesterol, triglyceride and phospholipids levels of serum and lipoprotein fractions were not significantly different between these groups.
  • Atherosclerotic lesions of the aorta in the kefiran group were statistically lower than those of the control group, with marked differences in the abdominal aorta.
  • T-lymphocytes were not detectable in the aorta of the kefiran group.
  • Cholesterol contents in stools were almost identical in both groups.
  • Cholesterol content in the liver of the kefiran group was statistically lower than in the control group.
  • Galactose content of βVLDL derived from the kefiran group was higher, and the lipid peroxidation level was much lower than in the control group.
  • RAW264.7 macrophages treated with βVLDL from the kefiran group showed a more spherical shape and accumulated statistically lower cholesterol than macrophages treated with βVLDL from the control group.
  • CONCLUSION: Orally derived kefiran is absorbed in the blood.
  • Kefiran prevents the onset and development of atherosclerosis in hypercholesterolemic rabbits by anti-inflammatory and anti-oxidant actions.
  • [MeSH-major] Atherosclerosis / prevention & control. Polysaccharides / pharmacology
  • [MeSH-minor] Administration, Oral. Animals. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anticholesteremic Agents / pharmacology. Antioxidants / pharmacology. Aorta, Thoracic / pathology. Cell Line. Cholesterol / blood. Cholesterol / metabolism. Cholesterol, Dietary / administration & dosage. Diet, Atherogenic. Feces / chemistry. Galactose / metabolism. Lipid Peroxides / metabolism. Lipoproteins, IDL / metabolism. Lipoproteins, IDL / pharmacology. Liver / metabolism. Macrophages / cytology. Macrophages / drug effects. Macrophages / metabolism. Male. Mice. Rabbits

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20543518.001).
  • [ISSN] 1880-3873
  • [Journal-full-title] Journal of atherosclerosis and thrombosis
  • [ISO-abbreviation] J. Atheroscler. Thromb.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticholesteremic Agents; 0 / Antioxidants; 0 / Cholesterol, Dietary; 0 / Lipid Peroxides; 0 / Lipoproteins, IDL; 0 / Polysaccharides; 0 / kefir grain polysaccharide; 97C5T2UQ7J / Cholesterol; X2RN3Q8DNE / Galactose
  •  go-up   go-down


72. Johansson ME, Wickman A, Fitzgerald SM, Gan LM, Bergström G: Angiotensin II, type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoE-/- mice. J Hypertens; 2005 Aug;23(8):1541-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AT1 and AT2 receptor expression were analysed using real-time polymerase chain reaction (PCR) and the localization of the AT2 receptor protein confirmed with immunohistochemistry.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hypertens. 2005 Aug;23(8):1469-70 [16003170.001]
  • (PMID = 16003181.001).
  • [ISSN] 0263-6352
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Cholesterol, Dietary; 0 / Imidazoles; 0 / Pyridines; 0 / Receptor, Angiotensin, Type 2; 0 / Vasoconstrictor Agents; 11128-99-7 / Angiotensin II; 130663-39-7 / PD 123319
  •  go-up   go-down


73. Domeika M, Unemo M, Ballard RC, Eastern European Network for Sexual and Reproductive Health (EE SRH Network): Laboratory support for the diagnosis and surveillance of sexually transmitted infections (STIs) in Eastern Europe. Euro Surveill; 2009;14(39)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory support for the diagnosis and surveillance of sexually transmitted infections (STIs) in Eastern Europe.
  • [MeSH-major] Clinical Laboratory Techniques / standards. Population Surveillance / methods. Practice Guidelines as Topic. Sexually Transmitted Diseases / diagnosis. Sexually Transmitted Diseases / epidemiology

  • MedlinePlus Health Information. consumer health - Laboratory Tests.
  • MedlinePlus Health Information. consumer health - Sexually Transmitted Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19814962.001).
  • [ISSN] 1560-7917
  • [Journal-full-title] Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
  • [ISO-abbreviation] Euro Surveill.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


74. Dutta K, Nandi D, Bishayi B: Repeated systemic Escherichia coli infection enhances anti-oxidant response in hypercholesterolemic mice inducing cardiovascular inflammation. Inflammation; 2009 Apr;32(2):89-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been well established that diet high in cholesterol and saturated fatty acids could significantly elevate plasma cholesterol levels and also increase the risk of cardiovascular diseases.
  • Swiss albino mice (4 weeks old) were randomly assigned to high cholesterol diet (HCD) or normal laboratory diet (NLD) groups.
  • Serum cholesterol levels were elevated in HCD-fed mice, compared to NLD.
  • Our study suggests that during hypercholesterolemia, repeated systemic E. coli infection induces an endogenous antioxidant response that serves to modulate vascular inflammation leading to cardiovascular diseases.
  • [MeSH-major] Cardiovascular Diseases / etiology. Escherichia coli Infections / complications. Escherichia coli Infections / metabolism. Hypercholesterolemia / complications. Inflammation / etiology. Oxidative Stress. Peroxidase / analysis

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 1997 Sep;65(9):3889-95 [9284168.001]
  • [Cites] J Clin Invest. 1996 Sep 1;98(5):1253-60 [8787689.001]
  • [Cites] Hypertension. 2003 Dec;42(6):1075-81 [14581295.001]
  • [Cites] Arch Med Res. 2006 May;37(4):436-48 [16624640.001]
  • [Cites] J Lipid Res. 1993 Dec;34(12):2147-58 [8301233.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(14):1744-8 [14594625.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4520-4 [8890201.001]
  • [Cites] Cell. 1992 Oct 16;71(2):343-53 [1423598.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Hypertension. 2004 May;43(5):983-7 [15037563.001]
  • [Cites] Methods Enzymol. 1984;105:121-6 [6727660.001]
  • [Cites] J Biol Chem. 1952 Mar;195(1):161-6 [14938365.001]
  • [Cites] Atherosclerosis. 1993 Jul;101(2):135-44 [8379958.001]
  • [Cites] Ann Nutr Metab. 2003;47(3-4):144-51 [12743466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Oct;73(10):3723-5 [824648.001]
  • [Cites] Methods Mol Biol. 2003;225:343-52 [12769501.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Hypertension. 2004 Oct;44(4):381-6 [15337734.001]
  • [Cites] J Appl Physiol (1985). 2002 May;92(5):1995-2004 [11960950.001]
  • (PMID = 19221870.001).
  • [ISSN] 1573-2576
  • [Journal-full-title] Inflammation
  • [ISO-abbreviation] Inflammation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Lipids; 9007-41-4 / C-Reactive Protein; 97C5T2UQ7J / Cholesterol; EC 1.- / Oxidoreductases; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


75. White J, Guerin T, Swanson H, Post S, Zhu H, Gong M, Liu J, Everson WV, Li XA, Graf GA, Ballard HO, Ross SA, Smart EJ: Diabetic HDL-associated myristic acid inhibits acetylcholine-induced nitric oxide generation by preventing the association of endothelial nitric oxide synthase with calmodulin. Am J Physiol Cell Physiol; 2008 Jan;294(1):C295-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analyses of both the human and mouse diabetic HDL particles showed that the HDLs contained increased levels of myristic acid.
  • These findings have important implications regarding cardiovascular disease in diabetic patients.

  • MedlinePlus Health Information. consumer health - Diabetes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. MYRISTIC ACID .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] NIH Guide Grants Contracts. 2012 Dec 14;:NOT-OD-13-014 [23248821.001]
  • [RetractionIn] Am J Physiol Cell Physiol. 2013 Apr 15;304(8):C812 [23588580.001]
  • [CommentIn] Fed Regist. 2012 Nov 20;77(224):69627-69628 [27737224.001]
  • (PMID = 17977947.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-63025; United States / NHLBI NIH HHS / HL / HL-68509; United States / NCRR NIH HHS / RR / P20-RR-105592
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calmodulin; 0 / Estrogens; 0 / Ionophores; 0 / Lipoproteins, HDL; 0 / Receptors, Cholinergic; 0 / Receptors, Leptin; 0 / leptin receptor, mouse; 0I3V7S25AW / Myristic Acid; 31C4KY9ESH / Nitric Oxide; 56092-81-0 / Ionomycin; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase Type III; N9YNS0M02X / Acetylcholine; SY7Q814VUP / Calcium
  •  go-up   go-down


76. Ghadami M, El-Demerdash E, Salama SA, Binhazim AA, Archibong AE, Chen X, Ballard BR, Sairam MR, Al-Hendy A: Toward gene therapy of premature ovarian failure: intraovarian injection of adenovirus expressing human FSH receptor restores folliculogenesis in FSHR(-/-) FORKO mice. Mol Hum Reprod; 2010 Apr;16(4):241-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward gene therapy of premature ovarian failure: intraovarian injection of adenovirus expressing human FSH receptor restores folliculogenesis in FSHR(-/-) FORKO mice.
  • The disease leads to infertility in a normal karyotype female with an elevated follicle stimulating hormone (FSH) and decreased serum estrogen level.
  • We investigated the effects of bilateral intra-ovarian injection of an adenovirus expressing a normal copy of human FSHR on the reproductive system of 6-10 weeks female FORKO mice.
  • In conclusion, intra-ovarian injection of an adenovirus expressing human FSHR gene is able to restore FSH responsiveness and reinitiate ovarian folliculogenesis as well as resume estrogen production in female FORKO mice.

  • Genetic Alliance. consumer health - premature ovarian failure.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Endocrinol. 1999 Nov;13(11):1844-54 [10551778.001]
  • [Cites] Gynecol Obstet Invest. 2009;68(1):19-32 [19325244.001]
  • [Cites] Endocrinology. 2000 Jul;141(7):2614-23 [10875266.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4295-308 [11089565.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1151-5 [11889179.001]
  • [Cites] Hum Reprod. 2003 Feb;18(2):251-6 [12571157.001]
  • [Cites] Biol Reprod. 2003 Oct;69(4):1281-93 [12801993.001]
  • [Cites] Fed Proc. 1970 Nov-Dec;29(6):1880-7 [5529888.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 May;7(6):215-28 [5173165.001]
  • [Cites] Annu Rev Biochem. 1981;50:465-95 [6267989.001]
  • [Cites] Fertil Steril. 1984 Nov;42(5):741-4 [6092154.001]
  • [Cites] J Reprod Fertil. 1986 May;77(1):287-96 [3088270.001]
  • [Cites] Domest Anim Endocrinol. 1987 Jul;4(3):157-65 [3507889.001]
  • [Cites] Mol Endocrinol. 1990 Apr;4(4):525-30 [2126341.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Mar 29;175(3):1125-30 [1709010.001]
  • [Cites] Genomics. 1993 Jan;15(1):222-4 [8432542.001]
  • [Cites] Endocrinology. 1993 Apr;132(4):1687-91 [8462469.001]
  • [Cites] Mol Cell Endocrinol. 1993 Feb;91(1-2):119-25 [8386109.001]
  • [Cites] Mol Cell Endocrinol. 1992 Nov;89(1-2):141-51 [1301382.001]
  • [Cites] Mol Cell Endocrinol. 1993 Jun;93(2):219-26 [8394255.001]
  • [Cites] Mol Cell Endocrinol. 1994 Jun;102(1-2):93-102 [7926278.001]
  • [Cites] Biol Reprod. 1995 Jul;53(1):103-9 [7669840.001]
  • [Cites] Cell. 1995 Sep 22;82(6):959-68 [7553856.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):205-6 [9020851.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3748-51 [9360535.001]
  • [Cites] Endocr Rev. 1997 Dec;18(6):739-73 [9408742.001]
  • [Cites] J Clin Invest. 1998 Oct 1;102(7):1352-9 [9769327.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13612-7 [9811848.001]
  • [Cites] Endocrinology. 1998 Dec;139(12):5205-14 [9832461.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1621-31 [15547533.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(2):61-70 [16954695.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3949-57 [17635941.001]
  • [Cites] Mol Hum Reprod. 2008 Jan;14(1):9-15 [18084009.001]
  • [Cites] Adv Exp Med Biol. 2000;465:37-46 [10810613.001]
  • (PMID = 20086006.001).
  • [ISSN] 1460-2407
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R21HD046639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, FSH
  • [Other-IDs] NLM/ PMC2834408
  •  go-up   go-down


77. Semenova VA, Schmidt DS, Taylor TH Jr, Li H, Steward-Clark E, Soroka SD, Ballard MM, Quinn CP: Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax. Vaccine; 2007 Feb 26;25(10):1780-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
  • The anti-PA IgG1, IgG2, IgG3, and IgG4 subclass responses to clinical anthrax and to different numbers of anthrax vaccine adsorbed (AVA, BioThrax) injections were determined in a cross-sectional study of sera from 63 vaccinees and 13 clinical anthrax patients.
  • The data show that both vaccination with three AVA injections and clinical anthrax elicit anti-PA IgG1, IgG2, and IgG3 subclass responses.
  • An anti-PA IgG4 response was detected in AVA recipients after the fourth injection.
  • The anthrax lethal toxin (LTx) neutralization efficacy of sera from recipients who received 4 to > or =10 AVA injections did not vary significantly in relation to changes in distribution of anti-PA IgG1 and IgG4 subclasses.
  • [MeSH-major] Anthrax / immunology. Anthrax Vaccines / immunology. Antibodies, Bacterial / blood. Antibodies, Bacterial / classification. Antigens, Bacterial / immunology. Bacterial Toxins / immunology. Immunoglobulin G / blood. Immunoglobulin G / classification
  • [MeSH-minor] Adult. Aged. Antitoxins / blood. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Cutaneous Anthrax.
  • Genetic Alliance. consumer health - Anthrax.
  • MedlinePlus Health Information. consumer health - Anthrax.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229495.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anthrax Vaccines; 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Antitoxins; 0 / Bacterial Toxins; 0 / Immunoglobulin G; 0 / anthrax toxin
  •  go-up   go-down


78. Petnehazy T, Stokes KY, Russell JM, Granger DN: Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension; 2005 Feb;45(2):209-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukocyte and platelet adhesion and oxidative stress were quantified by intravital microscopy in cremaster muscle, and P-selectin and AT1-R expression was determined in mice placed on a normal diet (ND) or high-cholesterol diet (HCD) for 2 weeks.
  • In HCD mice receiving losartan (HCD-Los) in drinking water, platelet and leukocyte recruitment was reduced to ND levels.
  • Increased platelet adhesion was observed in HCD mice receiving platelets from HCD-Los mice, consistent with a direct beneficial action of losartan on the vessel wall.

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • Hazardous Substances Data Bank. Losartan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hypertension. 2005 Feb;45(2):185-6 [15655121.001]
  • (PMID = 15655122.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL26441
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Oxidants; 0 / P-Selectin; 0 / Receptor, Angiotensin, Type 1; JMS50MPO89 / Losartan
  •  go-up   go-down


79. Bae IY, Kim SM, Lee S, Lee HG: Effect of enzymatic hydrolysis on cholesterol-lowering activity of oat beta-glucan. N Biotechnol; 2010 Feb 28;27(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of enzymatic hydrolysis on cholesterol-lowering activity of oat beta-glucan.
  • In this study, oat beta-glucan hydrolysate, having average molecular weight of 730,000g/mol which was previously shown to have great in vitro bile acid binding capacity, was prepared by enzymatic hydrolysis.
  • Furthermore its in vivo hypocholestrolemic effects were evaluated in rats that were fed high-cholesterol diets.
  • Supplements with beta-glucan hydrolysate as well as native beta-glucan significantly reduced the levels of LDL- and VLDL-cholesterol in serum and further improved the lipid profile in liver.
  • When rats were fed high-cholesterol diets, supplemented with the beta-glucan hydrolysate, greater fecal bile acid excretion was observed, which could be favorably correlated to in vitro bile acid binding capacity.
  • In addition, the hydrolysate was more effective at increasing the excretion of fecal cholesterol and triglyceride than the native beta-glucan, showing its effectiveness in improving the lipid profile.
  • [MeSH-major] Anticholesteremic Agents / metabolism. Avena / chemistry. Cholesterol, Dietary / metabolism. Diet. beta-Glucans / metabolism
  • [MeSH-minor] Animals. Bile Acids and Salts / metabolism. Cholesterol, LDL / metabolism. Cholesterol, VLDL / metabolism. Feces / chemistry. Hydrolysis. Lipids / blood. Liver / chemistry. Molecular Weight. Rats

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19931657.001).
  • [ISSN] 1876-4347
  • [Journal-full-title] New biotechnology
  • [ISO-abbreviation] N Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Bile Acids and Salts; 0 / Cholesterol, Dietary; 0 / Cholesterol, LDL; 0 / Cholesterol, VLDL; 0 / Lipids; 0 / beta-Glucans
  •  go-up   go-down


80. Sonnesyn H, Nilsen DW, Rongve A, Nore S, Ballard C, Tysnes OB, Aarsland D: High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord; 2009;28(4):307-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Aged. Blood Pressure / physiology. Cohort Studies. Electrocardiography. Female. Humans. Lewy Body Disease / complications. Lewy Body Disease / epidemiology. Lewy Body Disease / physiopathology. Long QT Syndrome / epidemiology. Long QT Syndrome / physiopathology. Male. Neuropsychological Tests. Prospective Studies

  • MedlinePlus Health Information. consumer health - Dementia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19828952.001).
  • [ISSN] 1421-9824
  • [Journal-full-title] Dementia and geriatric cognitive disorders
  • [ISO-abbreviation] Dement Geriatr Cogn Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


81. Ballard HO, Anstead MI, Shook LA: Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res; 2007;8:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Azithromycin reduces the severity of illness in patients with inflammatory lung disease such as cystic fibrosis and diffuse panbronchiolitis.
  • Bronchopulmonary dysplasia (BPD) is a pulmonary disorder which causes significant morbidity and mortality in premature infants.

  • Genetic Alliance. consumer health - Bronchopulmonary Dysplasia.
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2004 Jul;114(1):e96-101 [15231980.001]
  • [Cites] Pediatrics. 2004 Jun;113(6):1709-14 [15173495.001]
  • [Cites] N Engl J Med. 1990 Dec 27;323(26):1793-9 [2247118.001]
  • [Cites] Antibiot Chemother (1971). 1991;44:94-8 [1801651.001]
  • [Cites] Pediatrics. 1994 May;93(5):712-8 [8165067.001]
  • [Cites] J Pediatr. 1994 Jun;124(6):956-61 [8201486.001]
  • [Cites] Pediatrics. 1996 Feb;97(2):210-5 [8584379.001]
  • [Cites] Pathology. 1996 Aug;28(3):266-9 [8912360.001]
  • [Cites] Pediatr Infect Dis J. 1997 Apr;16(4):364-9 [9109137.001]
  • [Cites] Pediatr Pulmonol. 1997 Nov;24(5):331-6 [9407566.001]
  • [Cites] J Perinatol. 1997 Nov-Dec;17(6):428-33 [9447527.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1997 Nov;77(3):F198-201 [9462189.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1998 Jan;78(1):F10-4 [9536833.001]
  • [Cites] J Antimicrob Chemother. 1998 Mar;41 Suppl B:47-50 [9579712.001]
  • [Cites] Antimicrob Agents Chemother. 1998 May;42(5):1290-2 [9593171.001]
  • [Cites] Pediatr Infect Dis J. 1998 Jul;17(7):615-20 [9686728.001]
  • [Cites] N Engl J Med. 1999 Jun 24;340(25):1962-8 [10379020.001]
  • [Cites] Thorax. 1999 Aug;54 Suppl 2:S58-62 [10451695.001]
  • [Cites] Pediatrics. 2004 Dec;114(6):1649-57 [15574629.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1179-86 [15846199.001]
  • [Cites] N Engl J Med. 2006 Jul 27;355(4):354-64 [16870914.001]
  • [Cites] Respir Res. 2006;7:134 [17064416.001]
  • [Cites] Pediatr Res. 1999 Dec;46(6):641-3 [10590017.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jan;292(1):156-63 [10604943.001]
  • [Cites] Biol Neonate. 2001;79(3-4):205-9 [11275652.001]
  • [Cites] Pediatr Pulmonol. 2001 Jun;31(6):464-73 [11389580.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9 [11401896.001]
  • [Cites] J Perinatol. 2001 Apr-May;21(3):156-60 [11503101.001]
  • [Cites] Respir Res. 2001;2(1):27-32 [11686862.001]
  • [Cites] Arch Dis Child. 2002 Jan;86(1):40-3 [11806882.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Feb;11(2):189-215 [11829712.001]
  • [Cites] Thorax. 2002 Mar;57(3):212-6 [11867823.001]
  • [Cites] Semin Neonatol. 2001 Aug;6(4):331-42 [11972434.001]
  • [Cites] Biol Neonate. 2002;82(1):22-8 [12119537.001]
  • [Cites] Eur J Pharmacol. 2002 Aug 30;450(3):277-289 [12208321.001]
  • [Cites] Pediatr Rev. 2002 Oct;23(10):349-58 [12359869.001]
  • [Cites] Semin Neonatol. 2003 Feb;8(1):63-71 [12667831.001]
  • [Cites] Chemotherapy. 2003 May;49(1-2):39-43 [12714809.001]
  • [Cites] J Perinatol. 2003 Apr-May;23(3):240-9 [12732863.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jul 1;168(1):121-5 [12672648.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2099-107 [14645637.001]
  • [Cites] J Orthop Res. 2004 Jan;22(1):21-9 [14656655.001]
  • [Cites] Chest. 2004 Feb;125(2 Suppl):41S-50S; quiz 51S [14872000.001]
  • [Cites] Thorax. 2004 Jun;59(6):540-1 [15170047.001]
  • [Cites] Agents Actions. 1988 Aug;25(1-2):124-31 [2847507.001]
  • (PMID = 17550598.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 83905-01-5 / Azithromycin
  • [Other-IDs] NLM/ PMC1896160
  •  go-up   go-down


82. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C: BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord; 2009 Feb 15;24(3):392-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease.
  • The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).
  • [MeSH-major] Apolipoprotein E4 / genetics. Butyrylcholinesterase / genetics. Cognition Disorders / epidemiology. Genotype. Hyperhomocysteinemia / epidemiology. Lewy Body Disease / epidemiology. Lewy Body Disease / genetics
  • [MeSH-minor] Aged. Female. Gene Frequency. Humans. Male. Neuroprotective Agents / therapeutic use. Neuropsychological Tests. Phenylcarbamates / therapeutic use. Psychomotor Disorders / diagnosis. Psychomotor Disorders / epidemiology. Randomized Controlled Trials as Topic. Rivastigmine. Severity of Illness Index

  • Genetic Alliance. consumer health - Dementias.
  • MedlinePlus Health Information. consumer health - Lewy Body Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Movement Disorder Society.
  • (PMID = 19006190.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400074; United Kingdom / Medical Research Council / / G0502157; United States / NIA NIH HHS / AG / P50 AG005136; United States / NIA NIH HHS / AG / P50 AG005136-25
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein E4; 0 / Neuroprotective Agents; 0 / Phenylcarbamates; EC 3.1.1.- / Butyrylcholinesterase; PKI06M3IW0 / Rivastigmine
  •  go-up   go-down


83. Connor-Ballard PA: Understanding and managing burn pain: Part 2. Am J Nurs; 2009 May;109(5):54-62; quiz 63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Analgesia. Analgesics / therapeutic use. Anti-Infective Agents, Local / therapeutic use. Carboxymethylcellulose Sodium / therapeutic use. Causality. Drug Monitoring / nursing. Drug Therapy, Combination. Humans. Mafenide / therapeutic use. Nurse's Role. Polyesters / therapeutic use. Polyethylenes / therapeutic use. Practice Guidelines as Topic. Relaxation Therapy. Silver Sulfadiazine / therapeutic use. Skin Care / methods. Skin Care / nursing. Stress Disorders, Post-Traumatic / etiology. Stress Disorders, Post-Traumatic / prevention & control

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Pain.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411907.001).
  • [ISSN] 1538-7488
  • [Journal-full-title] The American journal of nursing
  • [ISO-abbreviation] Am J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acticoat; 0 / Analgesics; 0 / Anti-Infective Agents, Local; 0 / Polyesters; 0 / Polyethylenes; 58447S8P4L / Mafenide; 9004-32-4 / Carboxymethylcellulose Sodium; W46JY43EJR / Silver Sulfadiazine
  • [Number-of-references] 36
  •  go-up   go-down


84. Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin; 2008 Sep;24(9):2561-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rivastigmine demonstrated superiority over placebo on three measures of cognitive performance (Vascular Dementia Assessment Scale, Alzheimer's Disease Assessment Scale cognitive subscale, Mini-Mental State Examination; all p< or = 0.05, intent-to-treat population [ITT]), but not other outcomes.
  • Exploratory analyses indicated that older patients (> or =75 years old), assumed more likely to also have Alzheimer's disease (AD) pathology, demonstrated significant cognitive responses to rivastigmine and a safety profile similar to that seen in AD patients.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674411.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00099216
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Phenylcarbamates; 0 / Placebos; PKI06M3IW0 / Rivastigmine
  •  go-up   go-down


85. Zhang ZS, James AE, Huang Y, Ho WK, Sahota DS, Chen ZY: Quantification and characterization of aortic cholesterol in rabbits fed a high-cholesterol diet. Int J Food Sci Nutr; 2005 Aug;56(5):359-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification and characterization of aortic cholesterol in rabbits fed a high-cholesterol diet.
  • Determination of fat percentage of aortic intimal area stained by Sudan III is useful as an index of atherosclerosis in the rabbit animal model.
  • However, the determination of sudanophilic area of the thoracic aorta is two-dimensional and does not measure the third dimension of depth.
  • The objective of the present study was to quantify and characterize aortic lipids using the gas-liquid chromatographic (GLC) technique and to determine whether elevated measurements of total cholesterol and cholesteryl esters was correlated with increased measurements of sudanophilic area staining of the thoracic aorta in rabbits given either a normal chow or a 1% cholesterol diet.
  • The GLC results showed that there was a mean accumulation of 10.9 mg of cholesterol per gram of aortic tissue in the rabbits given a cholesterol diet (mean sudanophilic area of 23.8%).
  • In contrast, rabbits on a normal chow diet had only a deposition of 0.58 mg of cholesterol per gram of the aortic tissue diet (mean sudanophilic area of 1.4%).
  • The present study suggests that quantification of the aortic lipids can be performed by using GLC techniques and that it could be used as an alternative to the measurement of sudanophilic area when assessing the severity of atherosclerosis.
  • [MeSH-major] Aorta / chemistry. Atherosclerosis / etiology. Cholesterol / analysis
  • [MeSH-minor] Animals. Cholesterol Esters / analysis. Cholesterol, Dietary / administration & dosage. Chromatography. Fatty Acids, Nonesterified / analysis. Female. Male. Models, Animal. Rabbits. Staining and Labeling. Triglycerides / analysis. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236597.001).
  • [ISSN] 0963-7486
  • [Journal-full-title] International journal of food sciences and nutrition
  • [ISO-abbreviation] Int J Food Sci Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol Esters; 0 / Cholesterol, Dietary; 0 / Fatty Acids, Nonesterified; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


86. Tomofuji T, Azuma T, Kusano H, Sanbe T, Ekuni D, Tamaki N, Yamamoto T, Watanabe T: Oxidative damage of periodontal tissue in the rat periodontitis model: effects of a high-cholesterol diet. FEBS Lett; 2006 Jun 26;580(15):3601-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animal Feed. Animals. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Disease Models, Animal. Fibroblasts. Interleukin-1 / metabolism. Male. Mitochondria / metabolism. Oxidation-Reduction / drug effects. Rats. Rats, Wistar. Triglycerides / blood. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750199.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Triglycerides; 0 / Tumor Necrosis Factor-alpha; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; 97C5T2UQ7J / Cholesterol; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


87. Paganini Stein FL, Schmidt B, Furlong EB, Souza-Soares LA, Soares MC, Vaz MR, Muccillo Baisch AL: Vascular responses to extractable fractions of Ilex paraguariensis in rats fed standard and high-cholesterol diets. Biol Res Nurs; 2005 Oct;7(2):146-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular responses to extractable fractions of Ilex paraguariensis in rats fed standard and high-cholesterol diets.
  • The authors investigated the vasorelaxant properties of the aqueous (Aq-EF) and acid n-butanolic (acn-BuOH) extractable fractions from Ilex paraguariensis leaves.
  • Perfusion pressure was evaluated using isolated and perfused mesenteric arterial beds (MABs) from rats fed hypercholesterolemic and standard diets.
  • Extract-induced vasorelaxation in the presence and absence of various inhibitors was examined following precontraction of the MABs with methoxamine (30 microM) solution.
  • In hypercholesterolemic-diet rats, relaxation in intact MABs was significantly decreased with ac-n-BuOH-EF bolus (300, 600, 900 microg) in comparison to those in standard-diet rats.
  • After the endothelium was stripped from the MABs, the vascular responses to ac-n-BuOH-EF and 900 microg bolus of Aq-EF were significantly changed.
  • Treatment of the MABs with an inhibitor of nitric oxide synthase, N(G)-nitro-L-arginine methylester hydrochloride (L-NAME, 10 mM), did not change either ac-n-BuOH-EF- or Aq-EF-induced vasodilation except for the 900 microg bolus of Aq-EF.
  • The guanilate cyclase inhibitor methylene blue (100 microM) did not affect vasodilation for either fraction in the MABs from the hypercholesterolemic-diet rats.
  • The chronic oral administration of I. paraguariensis extract in hypercholesterolemic-diet rats resulted in a significant reduction in serum levels of cholesterol and triglycerides.
  • These results suggest that I. paraguariensis ac-n-BuOH-EF and Aq-EF induce vasodilation in standard-diet rats in a dose-dependent manner and that the hypercholesterolemic diet substantially reduced the effect of ac-n-BuOH-EF on precontracted MABs.
  • [MeSH-major] Hypercholesterolemia / prevention & control. Ilex paraguariensis. Phytotherapy. Plant Extracts / pharmacology. Vasodilation / drug effects
  • [MeSH-minor] Analysis of Variance. Animals. Dose-Response Relationship, Drug. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Male. Mesenteric Arteries / drug effects. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267376.001).
  • [ISSN] 1099-8004
  • [Journal-full-title] Biological research for nursing
  • [ISO-abbreviation] Biol Res Nurs
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


88. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R: Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol; 2005 Feb 1;23(4):774-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors.
  • PURPOSE: Obese women and women who gain weight after a breast cancer diagnosis are at a greater risk for breast cancer recurrence and death compared with lean women and women who do not gain weight after diagnosis.
  • In this population-based study, we assessed weight and body fat changes from during the first year of diagnosis to during the third year after diagnosis, and whether any changes in weight and body fat varied by demographic, prognostic, and lifestyle factors in 514 women with incident Stage 0-IIIA breast cancer.
  • RESULTS: Women increased their weight and percent body fat by 1.7 +/- 4.7 kg and 2.1% +/- 3.9%, respectively, from during their first year of diagnosis to during their third year of diagnosis.
  • Greater increases in weight were observed among women diagnosed with a higher disease stage, younger age, being postmenopausal, and women who decreased their physical activity from diagnosis to up to 3 years after diagnosis (P for trend < .05).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 1999 Oct;57(3):285-90 [10617305.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):674-84 [10649263.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):635-43 [10766250.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2751-7 [10870057.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2381-9 [11331316.001]
  • [Cites] Oncol Nurs Forum. 2001 May;28(4):675-84 [11383182.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):42-51 [11773152.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1128-43 [11844838.001]
  • [Cites] Cancer Pract. 2002 Mar-Apr;10(2):66-74 [11903271.001]
  • [Cites] N Engl J Med. 1999 Oct 7;341(15):1097-105 [10511607.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3504S-3507S [12421877.001]
  • [Cites] Sao Paulo Med J. 2002 Jul 4;120(4):113-7 [12436158.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1746-57 [12655532.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1961-6 [12743149.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76 [14519753.001]
  • [Cites] Breast Cancer Res Treat. 2004 Feb;83(3):201-10 [14758090.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2248-53 [15126549.001]
  • [Cites] Med Sci Sports Exerc. 2004 Sep;36(9):1484-91 [15354027.001]
  • [Cites] J Natl Cancer Inst. 1981 Oct;67(4):785-9 [6944548.001]
  • [Cites] Breast Cancer Res Treat. 1985;5(2):195-200 [4016284.001]
  • [Cites] Am J Epidemiol. 1986 May;123(5):767-74 [3962960.001]
  • [Cites] Breast Cancer Res Treat. 1986;7(1):23-30 [3516262.001]
  • [Cites] Breast Cancer Res Treat. 1988 Apr;11(1):59-66 [3382763.001]
  • [Cites] Arch Intern Med. 1990 Mar;150(3):665-72 [2310286.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1327-34 [2199619.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1954-9 [2004310.001]
  • [Cites] Int J Epidemiol. 1991 Mar;20(1):151-6 [2066214.001]
  • [Cites] JAMA. 1995 Feb 8;273(6):461-5 [7654270.001]
  • [Cites] J Natl Cancer Inst. 1995 Mar 1;87(5):361-6 [7853417.001]
  • [Cites] J Am Diet Assoc. 1999 Oct;99(10):1212-21 [10524383.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3302-16 [12149305.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):120-9 [10458225.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] J Am Diet Assoc. 1997 May;97(5):519-26, 529; quiz 527-8 [9145091.001]
  • (PMID = 15681521.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC035138-22; United States / NCI NIH HHS / CA / T32 CA09661; United States / NCRR NIH HHS / RR / M01-RR-00037; United States / NCI NIH HHS / CN / N01-CN-75036-20; United States / NCRR NIH HHS / RR / M01 RR000037; United States / NCI NIH HHS / PC / N01 PC035138-22; United States / NCI NIH HHS / CN / N01 CN005228; United States / NCI NIH HHS / CN / N01-CN-05228; United States / NICHD NIH HHS / HD / N01-HD-3-3175; United States / NCI NIH HHS / CA / T32 CA009661
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS250940; NLM/ PMC3000612
  •  go-up   go-down


89. Li J, Zhao SP, Yang J, Dong SZ, Zhou HN: [Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Jun;32(3):480-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits].
  • OBJECTIVE: To explore the effect of niacin on the serum adiponectin concentration in hypercholesterolemia rabbit and the adiponectin concentration secreted by adipocytes in normal rabbits.
  • METHODS: Ten male New Zealand white rabbits fed with high cholesterol diet for 8 weeks were randomly divided into 2 groups:.
  • (1) The high cholesterol group maintained a high cholesterol diet for 8 weeks. (2) The same cholesterol diet plus niacin (0.4g/kg*d ) were administrated for 6 weeks in the niacin group.
  • A control group was fed with normal diet for 14 weeks.
  • Subcutaneous adipose from the control group was collected for adipocyte culture.
  • Matured adipocytes were incubated with various concentrations of niacin (0, 0.25, 0.5, 1.0, and 2.0micromol/L).
  • Adiponectin concentrations in the serum and adipocyte culture supernatant were measured by enzyme-linked-immunosorbent assay.
  • RESULTS: Compared with the control group, rabbits in the high cholesterol group showed higher serum levels of total cholesterol, and low density lipoprotein cholesterol (LDL-C), all of which were significantly reduced by niacin treatment (P<0.01),and serum high density lipoprotein-cholesterol (HDL-C) significantly increased (P<0.01).
  • At 8th week, the mean adiponectin concentration of rabbits fed with high cholesterol diet was significantly lower than that of the control group[(1.268+/-0.039)mg/L vs.(1.449+/-0.107)mg/L,P<0.01].
  • Niacin treatment significantly elevated the serum adiponectin level which was positively related to HDL-C,and negatively related to TC and LDL-C.
  • Cell experiment in vitro indicated that niacin could significantly induce the adiponectin secretion of adipocytes in a dose-dependent manner.
  • CONCLUSION: Niacin can significantly promote the adiponectin secretion of adipocytes, suggesting that niacin probably has an ability of elevating the serum adiponectin level in addition to lipid-lowering effect.
  • [MeSH-major] Adipocytes / drug effects. Adiponectin / secretion. Niacin / pharmacology
  • [MeSH-minor] Animals. Cholesterol / blood. Cholesterol, Dietary / administration & dosage. Cholesterol, Dietary / toxicity. Cholesterol, HDL / blood. Cholesterol, LDL / blood. Dose-Response Relationship, Drug. Hypercholesterolemia / blood. Hypercholesterolemia / etiology. Hypercholesterolemia / prevention & control. Hypolipidemic Agents / pharmacology. Male. Rabbits. Random Allocation

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611329.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Cholesterol, Dietary; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Hypolipidemic Agents; 2679MF687A / Niacin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


90. Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE: Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res; 2005 May 31;1045(1-2):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since H3 receptor (H3R) antagonists/inverse agonists can improve cognitive function in animal models, they may have the potential to be used as add-on therapy in the treatment of schizophrenia, a disease with significant cognitive deficits.
  • In order to clarify the basis of this finding, we replicated this result and extended the work with another imidazole and two non-imidazole H3R antagonists.

  • MedlinePlus Health Information. consumer health - Cold and Cough Medicines.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910772.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Benzofurans; 0 / Drug Combinations; 0 / Histamine Antagonists; 0 / Imidazoles; 0 / Piperidines; 0 / Pyrrolidines; 0 / Receptors, Histamine H3; 0 / ciproxifan; 106243-16-7 / thioperamide; 820484N8I3 / Histamine; 86H6B395PI / benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-; 9035-51-2 / Cytochrome P-450 Enzyme System; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone; R9400W927I / Ketoconazole
  •  go-up   go-down


91. Stachon P, Missiou A, Walter C, Varo N, Colberg C, Wolf D, Buchner M, von Zur Mühlen C, Zirlik K, Bode C, Zirlik A: Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. PLoS One; 2010;5(7):e11589
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several lines of evidence identified TRAF6 as a pro-inflammatory signaling molecule in vitro and we previously demonstrated overexpression of TRAF6 in human and Murine atherosclerotic plaques.
  • This study investigated the role of TRAF6-deficiency in mice developing atherosclerosis, a chronic inflammatory disease.
  • In accord, in a small clinical study TRAF6/GAPDH total blood RNA ratios did not differ between groups of patients with stable coronary heart disease (0.034+/-0.0021, N = 178), acute coronary heart disease (0.029+/-0.0027, N = 70), and those without coronary heart disease (0.032+/-0.0016, N = 77) as assessed by angiography.
  • CONCLUSION: Our study demonstrates that TRAF6 is not required for atherogenesis in mice and does not associate with clinical disease in humans.
  • [MeSH-minor] Animals. Aorta, Abdominal / metabolism. Cells, Cultured. Cholesterol / adverse effects. Cholesterol / blood. Collagen Type I / genetics. Collagen Type I / metabolism. Dietary Fats / adverse effects. Female. Flow Cytometry. Hematopoiesis / genetics. Hematopoiesis / physiology. Humans. Immunohistochemistry. Liver Transplantation. Mice. Mice, Mutant Strains. Polymerase Chain Reaction. Pregnancy. Receptors, LDL / genetics. Receptors, LDL / physiology. Weight Gain / drug effects

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1674-80 [11597944.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1271-80 [11250893.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):443-7 [12140561.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):868-74 [12490960.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):656-60 [12615675.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17278-82 [15001576.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10679-84 [15249654.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):2913-7 [15322147.001]
  • [Cites] Cardiovasc Res. 2004 Oct 1;64(1):154-64 [15364623.001]
  • [Cites] J Lipid Res. 1995 Nov;36(11):2320-8 [8656070.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):443-6 [8837778.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):28745-8 [8910514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9792-6 [9275204.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2097-101 [9625770.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1015-24 [10215628.001]
  • [Cites] J Biol Chem. 1999 May 14;274(20):14246-54 [10318845.001]
  • [Cites] Genes Cells. 1999 Jun;4(6):353-62 [10421844.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42 [15345516.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):1081-90 [15634933.001]
  • [Cites] Science. 2005 Apr 8;308(5719):248-51 [15705807.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1244-9 [15746436.001]
  • [Cites] Circulation. 2007 Mar 27;115(12):1571-80 [17372166.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 May;27(5):1101-7 [17332487.001]
  • [Cites] Adv Exp Med Biol. 2007;597:131-51 [17633023.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):339-46 [18268038.001]
  • [Cites] Blood. 2008 May 1;111(9):4596-604 [18195092.001]
  • [Cites] Cell Signal. 2008 Sep;20(9):1679-86 [18603409.001]
  • [Cites] N Engl J Med. 2008 Nov 20;359(21):2195-207 [18997196.001]
  • [Cites] J Exp Med. 2010 Feb 15;207(2):391-404 [20100871.001]
  • [Cites] Circulation. 2010 Feb 23;121(7):e46-e215 [20019324.001]
  • [Cites] Science. 2010 Apr 9;328(5975):228-31 [20203013.001]
  • [Cites] Circulation. 2010 May 11;121(18):2033-44 [20421522.001]
  • [Cites] Nat Med. 2000 Feb;6(2):114 [10655072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7458-63 [10861012.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6482-91 [11607847.001]
  • (PMID = 20644648.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Dietary Fats; 0 / Receptors, LDL; 0 / TNF Receptor-Associated Factor 6; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC2904388
  •  go-up   go-down


92. Yamamoto T, Tomofuji T, Tamaki N, Ekuni D, Azuma T, Sanbe T: Effects of topical application of lipopolysaccharide and proteases on hepatic injury induced by high-cholesterol diet in rats. J Periodontal Res; 2010 Feb;45(1):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bacterial Proteins / adverse effects. Cholesterol, Dietary / adverse effects. Escherichia coli. Lipopolysaccharides / adverse effects. Liver / drug effects. Liver Diseases / etiology. Peptide Hydrolases / adverse effects. Periodontitis / etiology